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SUMMARY
Blood and urine gold levels were monitored in patients with rheumatoid 
arthritis treated with sodium aurothiomalate (Myochrysin). The results 
failed to demonstrate any association between the measured parameters 
and patient response. It was concluded that routine determinations of 
gold concentrations could not be used to predict which patients would 
fail to respond to treatment or would develop gold toxicity and the 
concept of therapeutic blood gold concentrations was shown to be invalid. 
The results were inconsistent with a previously proposed hypothesis that 
blood gold concentrations are inversely proportional to urinary gold 
excretion. Concentrations of gold in tissues removed from patients 
receiving Myochrysin showed that the metal was deposited in synovial 
tissue during chrysotherapy but that when treatment stopped, this gold 
was relocated elsewhere.
14 14
(1,4- Othiomalic acid and sodium(l,4~ C)aurothiomalate were prepared
for experimental studies using rats. It.was shown that a large proportion 
of the thiomalic acid remained at the site of intramuscular injection but 
sodium aurothiomalate was completely absorbed. Excretion and tissue 
retention of absorbed radioactivity showed that there was similar meta­
bolism of the thiomalate moiety of both compounds suggesting a rapid 
removal of the gold from aurothiomalate. However, some differences in 
the urinary radioactive metabolites and tissue distribution pattern 
indicated that removal of gold was not complete and that some intact 
aurothiomalate remained. This inference was consistent with the results 
from :in vvtvo albumin binding experiments which demonstrated the presence 
of protein bound and non-bound aurothiomalate representing approximately 
30% of the initial material. Subcellular distribution and biliary 
excretion experiments showed that the gold and carbon-14 followed quite 
separate pathways intracellularly. Gold became concentrated in lysosomes 
whereas the major organelle which accumulated carbon-14 was the mito­
chondrion.
A wide range of interactions between gold and essential trace metals was
e*
demonstrated in a further series of experiments using rats. Accumulation 
of trace metals in the kidney was accompanied by the induction of a 
cytosolic gold-binding protein which also contained copper and zinc. 
Microscopic examination of renal tissue also showed that gold (and 
possibly copper) was also present within lysosomes of proximal tubular
cells. These animals also had evidence of renal tubular dysfunction. 
The results suggested that interactions between gold and trace metals, 
particularly copper, could be important in successful chrysotherapy 
and in gold toxicity. A mechanism for gold toxicity involving copper 
and metallothionein metabolism is proposed.
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C H A P T E R  O N E
GENERAL INTRODUCTION
1.1 INTRODUCTION
Gold has captivated the interest of man for thousands of years. 
References to economic, decorative and artistic uses can be found in 
the oral, written and archeological histories of most ancient civilis­
ations. From examples such as the treasures taken from the tomb of 
Tutankhamun and books of the Old Testament it is evident that gold has 
long had an important role in the ceremonies of many religious groups. 
From Greek literature, e.g. the story of Jason and the Golden Fleece, 
and from more recent history, e.g. the alchemists of the Middle Ages 
and the Spanish in Central America, it is seen that the desire to obtain 
the metal, powerfully influences attitudes and ambitions of men. These 
traditions can be followed through to the present day where frantic 
speculations seen on the world's gold exchanges testify to the allure 
and power which is embodied within the metal.
In addition to this universal attraction to gold for its aesthetic 
properties and intrinsic value, a history of biological use exists which 
can be traced back to the Chinese civilisations of 2500 BC. (1,2)
1.2 BIOLOGICAL CHEMISTRY OF GOLD
The position of gold in the Periodic Table (Table 1.1) places the metal 
between the transition elements and the B-series of metals. Metallic 
gold, Au(0), is an extremely stable form but will react in aqueous 
solution with the thiol-containing compounds L-cysteine ([) and 
D-penicillamine (li) (3) Certain plants will accumulate gold from gold- 
rich soils and solubilisation of the metal in these situations may be 
effected by plant root micro-organisms able to secrete aminoacids. (4)
SHCH0-CHNH C00H 
L-cysteine (|)
Table 1.1 POSITION AND FEATURES OF GOLD
Position in Periodic Table and electronic configurations of the metal 
and important ions.
VIII
Group
IB 11B
Electronic Configuration
Ni Cu Zn Au(0) 5s2 5P6 5 d 10 6 s 1’
Pd Ag Cd Au (1) 5s2 5p6 5 d 1 0
Pt Au Hg -Au(lll) 5s2 5p6 5d8
SH (CII ) CCHNH C00H 
D-penicillamine(H)
Of the higher oxidation states, compounds of Au(ll) and Au(V) are very 
unstable in aqueous solution and are unlikely to be of biological 
importance although a potential role for Au(ll) as an intermediate in 
redox reactions of Au(l) and Au(lll) has been speculated upon. (4)
Reactions with Au(l) and Au(lll) have been much more fully investigated. 
From the position in the Periodic Table and from the electronic configur­
ations, it could be anticipated that gold would exhibit the properties 
both of the transition and the B-group metals. Au(l) would resemble the 
B-metals which have a closed d-shell and demonstrate covalent bonding 
while Au(lll), with the unfilled d~shell, would form the ionic-ligand 
bonds typical of the transition metals.
1.2.1 Au(l), Aurous Compounds
The gold(l) cation does not exist in water, therefore while a wide range 
of aurous compounds have been formed, only complex compounds are stable 
in the presence of water. Gold(l) usually exhibits linear, twofold co­
ordination due to the small energy difference between the filled 5d 
orbital and the unfilled 6s orbital which allows considerable hybridiz­
ation of these orbitals. Examples of higher co-ordination numbers with 
trigonal planar and tetrahedral complexes have also been described. 
Soluble aurous complexes have been extensively investigated, particularly 
mercaptides, phosphines and cyanides which, have greatest relevance to 
biological systems.
Gold(1)-thiol complexes: Au-S-R
Stable 1:1 thiol complexes readily form when gold(l) halide or cyanide is
added to cysteine, penicillamine or glutathione(III) Analogous complexes
will also form between cysteine or penicillamine and compounds of the
type R PAuCl. Triethyl phosphine gold cysteine slowly breaks down to 
o
give gold(l) cysteine, whereas the triethyl phosphine gold penicillamine
    \
complex is stable to further substitution-. (3) Paradoxically, the 
triphenyl phosphine gold complexes of cysteine and penicillamine are 
both stable.
CGOHNH CHCH CHoC0NHCHCH„SHC0NHCHoC00H 7£ £ £ £ £
glutathione (III)
Penicillamine and AuCl^ react to give Au(l) penicillamine in nitrogen 
or Au(lll) penicillamine in air while cysteine forms only the Au(l) 
cysteine complex. (5)
These reactions suggest that in the presence of thiol ligands the 
Au(l) £  Au(lll) system may be very active and -in V'i'OO therefore, where 
several thiol compounds exist, gold(lll) thiol complexes may be derived 
from an Au(l) precursor.
The structures of gold(l) complexes with other thiol compounds are less 
well defined. It has been suggested that sodium gold(l) thiomalatedV) 
will form a stable species with thiomalic acid (V) until a gold: thio-
malate ratio in excess of 1:1.75 is attained at which point free thio-
1 3malate is observed in a "C nuclear magnetic resonance spectrum. (6) It
3 —
is proposed that this stable complex has the formula Auj+(tm-s) 7. which, 
by analogy with observations on crystalline copper(1) thiolates, could 
represent a tetrahedron of trigonally planar co-ordinated aurous ions 
located at the centres of opposite faces of (p2tm~S>6 octahedron with 
one additional (fluxional) terminal tm-S . (6) The thiomalate ligand 
can be replaced from sodium gold thiomalate by strong sulphur donors 
such as cysteine. (7)
Reactions with the free thiol group on albumin have been investigated 
particularly with sodium gold thiomalate.” The gold ion binds strongly 
to albumin-SH but the evidence for displacement of the thiomalate is 
contradictory. (7,8) Other thiol-binding species, e.g. drugs such as 
phenylbutazone, will in turn influence the reaction of albumin with gold.
Total or partial displacement of the ligand on the addition of other 
thiol compounds indicates the formation of mixed species. Isab and
i 3
Sadler detected thiol exchange by ‘ C nuclear magnetic resonance when 
N-acetyl-L-cysteine, mercaptoacetic acid, L-cysteine methyl ester, amino- 
ethane thiol, penicillamine or glutathione were added to sodium gold(l) 
thiomalate. (6) Sattari also prepared mixed thiol-gold complexes which 
he characterised by infra-red spectroscopy and elemental analysis. (9) 
Equimolar additions of cysteine to gold(l) thiomalate released half the 
thiomalate with the formation of cysteinatothioraalatodigold(l). Similarly,
COONaCHSAuCH COONa 
£
(IV )
COOHCHSHCH. COOH 
£
(V)
glutathione displaced two thirds of the thiomalate and formed bis(gluta- 
thionato)inono(thiomalate)trigold(l). Sodium diethyldithiocarbamate 
however released all the thiomalate to give diethyldithiocarbamatogold(l). 
Sattari also noted that a thioether (methionine) did not react with gold(l) 
thiomalate.
Because of the widespread vn VVOO distribution'of many of the compounds 
described in these experiments, it is probable that these gold thiol 
complexes and the mixed thiol-gold species will form and be of importance 
in the biochemistry of gold. Gold(l) thioglucose is extensively used in 
biological systems but the chemistry has not been examined as thoroughly 
as has that of gold(l) thiomalate.
Gold(l)-phosphine complexes: Au--P-R_
Oral administration of gold(l) thiol compounds has proven to be unsuitable 
for achieving useful clinical or experimental levels -in V'lVO. (10) Both
absorption and excretion are rapid, and accumulation to effective con­
centrations therefore fails to occur. Slow release from a parenteral 
injection is the usual mode of presentation. Gold phosphine compounds 
however are usually soluble in organic solvents and will therefore inter­
act with lipid media such as cell membranes. Thus gold, phosphine complexes 
which do not require to be injected have recently been investigated as 
alternatives to gold thiol compounds. (11)
Bromo(triethylphosphine)gold reacts with a range of compounds but 
particularly with thiols, to form a mixed complex (Et PAuSR) by substitu-
O
tion of the bromide. Reaction with thiol's occur readily in alkaline 
solution to form a monomeric product although, as noted above, some will 
slowly decompose to give triethylphosphine and an insoluble polymer of 
the gold thiol, e.g. gold(l) cysteine.
Triethylphosphine gold X (X = Cl or Br) compounds do not readily dissolve 
in water but do become soluble upon addition of sodium thiosulphate due 
to the formation of EtgPAuS.SO^. These compounds are readily oxidized 
with a further molecule of halogen to give the auric species Et^PAuX^. (12)
Triethylphosphine gold chloride is one gold phosphine compound which has 
been used i-n V'lVO but it is triethylphosphinegold-2,3,4,6-tetra-0-acetyl- 
l-thio-$-D-glucopyranoside that has been particularly investigated. (11)
Gold(l)-cyanide complexes
The most stable aurous complexes are those which involve the cyanide 
ligand. Gold(l) cyanide is soluble in cyanide solution to give the 
anion (Au(CN)p) , a reaction which is exploited in the commercial 
extraction and recovery of gold. Fourfold co-ordination is observed 
when the potassium salt chelates with nitrogen ligands such as 2,2/- 
bipyridyl with the formation of complexes of the type K(Au(CN)2 (bipy)). (12)
The use of aurous cyanide Au(l)CN as an in vitro anti-bacterial agent 
marked the initiation of modern gold therapeutics. (13) It was the less 
than total success in vivo and the accompanying toxicity which prompted 
a search for alternative gold drugs among the thiol and phosphine complexes.
While gold cyanide complexes were quite soon superseded as pharmacological 
compounds, most of the very few studies of gold(l) binding sites on
—  *f-
proteins have involved (Au(CN)p) . Gold inhibits the binding of NAD to 
the lives: enzyme, alcohol dehydrogenase; (Au(CN)2) competes with the 
phosphate group on the co-enzyme thus preventing access to the binding 
site. (4) The gold does not appear to bind to available thiol groups on 
the enzyme, nor does it bind to the free-SII group of carbonic anydrase.
The link to this enzyme is thought to involve hydrogen bonding between a 
cyanide group and a zinc-co-ordinated 'water molecule held between histidine 
residues. (4)
The aurous complexes discussed are all stable in aqueous media. It is 
this property which has allowed them to be introduced into biological 
systems for a variety of purposes. Examples of reactions which may take 
place within such environments have been described and it is apparent that 
ligand exchange and the formation of mixed ligand clusters probably occur. 
Such exchanges may extend between the groups, e.g. phosphine-thiol, as well 
as within a group. Because of the extensive range of thiol compounds found 
within the body and their important biochemical roles, these molecules will 
be of considerable significance in the in vivo fate of gold compounds.
1.2.2 Au(lll), Auric Compounds
Gold(lll) compounds are generally much more stable than corresponding 
aurous compounds. As with Au(l) there is one predominant co-ordination 
number, i.e. four, although a few compounds with five and six co-ordination 
have been described.
Compared with aurous compounds, auric compounds have been less extensively- 
used in biological systems. Often it has been assumed that a similar 
biochemistry would obtain and the application of neutral solution of auric 
chloride was once proposed as an antiseptic eye-wash. (14) This assumption 
however is unlikely to be valid; auric compounds are strong oxidising 
agents and may be rapidly reduced to aurous gold to which any subsequent 
reaction would be attributed. However, stability is increased by the 
presence of nitrogen ligands and therefore some Au(lll) compounds within 
biological systems (which are normally mildly reducing) need not necessarily 
go to Au(l).
As with gold(l), an extensive range of compounds have been prepared but 
very few are of relevance to the biological chemistry of gold(ill). (12)
Both cysteine and glutathione will reduce gold(111) compounds to form 
the appropriate aurous thiolate. Likewise gold(lll) thiomalate will not 
stabilise in aqueous solution but reduces to the gold(l) complex. With 
2,3-dimercaptopropanol (British Anti-Lewisite, BAL)(VI), a range of 
insoluble compounds, indicative of Au(I) and Au(lll) polymeric sj>ecies 
are formed in association with (AuCl ) . By' contrast, gold(l) penicillamine 
formed under aerobic conditions readily oxidises to produce the gold(111) 
penicillamine complex. ^
/( C—  ~ P-h 'D !‘
CH SHCHSHCH„OH (VI) . ^  V V'v * ;
2* £
Tetrachloraurate will cause precipitation of albumin if present in 
sufficient concentration while at lower concentrations reduction of the 
gold(lll) takes place.
Since there is some stability in biological systems of gold(111) complexes 
and since the auric species may even be favoured in some situations, it 
is important to consider possible ligand exchange. Such reactions have 
not been well studied in aqueous media but from the data available it is 
evident that exchange on Au(lll) is very slow in comparison with A u (l). 
Hydrolysis of (AuCl^) proceeds stepwise -*• AuOHCl^ -*• Au (0H)2C12 ■-»- 
Au(OH)gCl -*• Au(OH)^ . The first hydrolysis is complete within 1 minute, 
the second within 1 hour while the last two require several hours. (15)
Other examples include substitutions which readily occur with aurous 
compounds but fail to take place at all with the corresponding auric' 
complex. (4) These examples illustrate the greater strength of an.
Au(lll)-X bond compared with Au(l)~X.
1.2.3 Au(lll), Protein Labelling
In the determination of protein structure by X-ray crystallography, gold 
has been used as a marker in order to label and identify areas of the 
molecules. Thus there are considerable data available on gold binding 
sites for several proteins including Bence-Jones protein, (16) chymo- 
trypsin, (17) yeast phosphoglycerate kinase, (18) and lactate dehydro­
genase. (19) The nature of the binding is very dependent upon the 
experimental conditions. With excess Cl , (AuCl^) binds to positively
charged arginine residues on lysozyme, (20) while with sperm whale
3+
myoglobin in an ammonia buffer, complexes such as Au(NH ) and 
2+ 4
Au(NH ) NH are presumed to form, which then bind to carbonyl groups. (21)
O o a
As with Au(l), binding to the thiol groups of cysteine residues is a 
possibility but reduction to aurous gold is likely to occur.
Insoluble complexes are formed between (AuCl ) and purines such as 
adenine. (22) Tetrachloraurate and adenosine nucleotide however produces 
a soluble complex. (23) Although ribose, deoxyribose-5-phosphate, sucrose 
or dextrose all promote the reduction of Au(lll) to Au(0) this is not 
achieved by the nucleotide. Pyrimidine complexes with gold(111) have 
also been prepared and gold 5-diazoura.cil, (Au(5du)2Cl2 )Cl .HC1 has ant'i- 
tumour activity in mice. (24)
' >
Therefore, from the chemistry of auric compounds it would be anticipated | 
that in most situations Au(lll) introduced into a physiological milleau j
would soon be reduced to aurous gold or even to the metal. However, the j 
stability of a few compounds such as gold'(Hl) penicillamine suggest that 
where appropriate conditions exist, auric compounds may be localised or 
even be formed. Where present these compounds are stable to substitution I 
or exchange. However, it is the gold(l) complexes which in general will j 
probably be of major biological importance. >
1.2.4 Compounds with Gold-Metal Bonds
A number of compounds containing gold-metal bonds have recently been 
prepared and can be classified into two groups:
(a) Compounds in which several gold atoms are clustered in discrete
3-
organisations. The (Au^(tm-s)^) species referred to above is an 
example although clusters containing as many as eleven gold atoms 
have been described with even larger organisations predicted. (25)
(b) Compounds containing direct Au-M bonds. Simple dimers, e.g. Au-Au, 
Au-Ag, Au-Cu are observed in gaseous phases but complexes of the 
type LAuMnCCO)^ or LAuMn(CO) l/ are much more common. (12) In these
O i:
prepared compounds, L, and l/ are usually triphenylphosphine or a
simple derivative. The reactions of these compounds are similar to
those of carbonyl halides, Mn(CO)rX, suggesting that the LAu group
o
behaves in an analogous fashion, to a pseudo halogen. Whether such 
compounds could form in vivo has not been suggested.
1.2.5 Summary
Of the various gold oxidation states, Au(l) and Au(lll) are essentially 
the only two which could exist within an aqueous physiological environment. 
While in general terms Au(lll) compounds are more stable than those of 
Au(l), it is the aurous complexes which are most likely to exist in bio­
logical systems, the auric gold being reduced to aurous. By virtue of 
their natural abundance, thiol complexes with gold(l) are the most 
important, although phosphine and cyanide compounds, when introduced, can 
be expected to react with physiological ligands such as protein, to induce 
biochemical effects. Gold(lll) ligand bonds are very stable and these 
complexes therefore probably give rise to less dramatic responses.
Substitution and exchange of ligands associated with aurous complexes have 
been shown to occur very readily in vitro3 and it is likely that similar 
reactions will occur in vivo where a variety of intra- and extracellular 
ligands exist. Gold clusters which have been demonstrated in aqueous 
solution may also form in vivo3 although these have not been sought. The 
possible existence of other direct gold-metal interactions has similarly 
so far been overlooked.
1 * 3 CHEMOTHERAPEUTICS OF GOLD
Gold, and gold compounds have retained a favoured place in the pharmacopea 
of "physicians" since at least the beginnings of recorded history. A 
formulation of auric chloride, prepared by dissolving gold in aqua regia 
and neutralised with chalk, was recommended by Roger Bacon in the thirteenth 
century as a treatment for leprosy. (2) At various times since, gold 
therapy has been claimed to be a "miracle cure", effective for virtually 
every disorder. However, since large numbers of the populations continued 
to suffer v/ith painful disease and to be vulnerable to infection, presumably 
the treatment was not available other than to an influential minority or
else such assertions were not taken entirely seriously except perhaps by 
the proponents who no doubt had a commercial interest in their acceptance. 
During the last century gold compounds have been used on a more rational 
and scientific basis with particular emphasis in recent years upon 
conditions with an auto-immune element. (Fig. 1.1)
1.3.1 Gold Therapy; Antibacterial Activity
Antibacterial effects of gold were first demonstrated ninety years ago. (13) 
Koch showed in 1890 that potassium auricyanide inhibits the growth of 
Mycobacterium tuberculosis when added to culture medium at a concentration 
of one part in two million. This was followed by a report that intravenously 
administered sodium aurichloride had antibacterial effects in experimental 
tuberculosis. (26) The associated toxicity prohibited immediate thoughts 
of clinical use. However, by the second decade of the twentieth century 
attempts were being made and despite the hazards, compounds such as 
potassium auricyanide were reported to have therapeutic activity in cases 
of tubex*culosis and also in syphillis. (27)
The encouraging response prompted the development of more than twenty new 
gold complexes in a search for compounds which would provide efficacy but 
have lower toxicity. An immediate example, reported in 1914, was TAuro~ 
cantan’. (Table 1.2) This compound was given by sub-cutaneous injection 
but was of limited value causing tissue necrosis after repeated admin­
istration. (10)
Those compounds which demonstrated favourable anti-tubercular and anti­
syphilitic activity were rapidly introduced for the treatment of disease 
with minimal pre-clinical and clinical trials. Qrgano-gold complexes were 
first introduced at this stage v/ith the synthesis of 2-aurothio-4-amino- 
benzoic acid ('Krysolgan’). (28) It was claimed that this compound was as 
effective as the toxic inorganic gold compounds. Other workers confirmed 
this view but found it to be equally as toxic also. (10) Several other 
gold-sulphur complexes and one gold-nitrogen complex were prepared during 
this period and were all administered intravenously. (Table 1.2)
Sodium aurothiosulphate, first investigated in 1913 received considerable 
interest and was introduced for the treatment, by intravenous injection, 
of tuberculosis in 1924. (29) It remained the drug of choice until anti­
tuberculosis therapy entered a new phase with the development of the 
modern drugs isoniazid, para-amino salicylic acid and rifamficin.
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FIGURE 1.1 LANDMARKS IN GOLD CHEMOTHERAPY
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Table 1.2 SOME GOLD COMPOUNDS USED FOR GOLD-CHEMOTHERAPY
Compound and Trade Name Formula
Cantharidylethylenediamine 
aurocyanide (Aurocantan)
CH
CXI,
CH
CH
COOH
0
C — CONHCH CH NH
CH
CH
Sodium aurothiosulphate 
(Sanochrysin)
Ha3A" < W 2
2- aurothio-4-amino- benzoic 
acid (Krysolgan)
Gold keratinate (Auro- 
Detoxin)
H N COOH
SAu
-CO-NH-CH-CO-NH-CH-
CH SAu CH SAu
Sodium 3-aurothio-2,-propanol- 
1-sulphonate (Alloehrysin)
Au-S-CH2-CHOH-CH2-SO Na
Aurothioglucose (Solganal B 
Oleosum)
Sodium aurothiomalate 
(Myochrysin)
3-triethylphosphinegold(1) 
2,3,4,6-tetra-O-acetyl-l-
f*
thio-$~D-glucopyranoside 
(Auranofin (SK and F D- 
39162))
CH OH 
2
C
OH II
I
C
OH SAu
H
CH -COO Na
t A
OH
AuS-CH-COO Na
R
Et -P-Au-S
R
Au(CN)2
R = CH3C02
1.3.2 Gold Therapy; Rheumatoid Arthritis - Introduction
While these gold compounds were being developed for the treatment of 
diseases associated with micro-organisms they were not used exclusively 
for such purposes. Fifty to sixty years ago it was (erroneously) believed 
that what are now recognised to be completely separate conditions, were 
manifestations of tuberculosis. Therefore, patients with lupus erythe­
matosus (LE) were treated with various gold compounds by Martenstein. (30) 
With a similar rationale, Forestier (31) adopted gold therapy (chryso- 
therapy) for rheumatoid arthritis using the newly developed gold compound 
sodium 3-aurothio-2-propanol-l“Sulphonate (’Alloehrysin1) and later, 
sodium aurothicmalate ('Myochrysin’). (Table 1.2) Lack of success in 
the first disorder led to the immediate demise of gold treatment in LE. 
However, the considerable success achieved with what was hitherto a 
completely intractable disease, quickly established gold therapy as a 
valuable weapon against rheumatoid arthritis.
Chrysotherapy for rheumatoid arthritis, however, was no less free from 
the problems of associated toxicity than in tuberculosis and in efforts 
to minimise the side-effects further gold preparations (Table 1.2) continued 
to be introduced. Experience during the succeeding years confirmed sodium 
aurothiomalate and aurothioglucose as the two compounds which were most 
effective and had an acceptable level of toxicity so that by 1950 no other 
preparations were in routine use. Both were administered by intra-muscular 
injection.
,c*/\ T u ' 1
Forestier's initial observations concerning the effects of gold on 
rheumatoid arthritis were substantiated in" many other reports (32-34) but 
some doubts on the value of chrysotherapy were later expressed when it 
was pointed out that with one exception (35) studies had omitted to include 
control series of patients. There arose therefore considerable doubt and 
confusion surrounding a treatment which had been in use for thirty years. 
Such a situation could not be allowed to continue and the Empire Rheumatism 
Council (ERC) organised a multi-centre, double-blind controlled trial to 
determine; Does gold have a beneficial action on rheumatoid arthritis?
Patients with active rheumatoid arthritis of 1 to 5 years' duration were 
included in the trial. The test group received 20 injections of 50 mg 
sodium aurothiomalate (total dose - 1.0 g) and the control group z’eceived 
20 injections containing 0.5 jig (total dose - 0.01 g ) . The group treated
withygold showed improvement of their disease when judged by clinical 
and laboratory criteria, which was greater than that observed in the 
controls. (36,37) The question was therefore answered and the drug 
continues still to be widely used. Since the final report of the ERC 
multi-centre trial the one significant development in gold therapy for 
rheumatoid arthritis has been the introduction of a gold complex which 
can be administered orally. This has the advantages of reducing patient 
discomfort and easing administration.
Following trials in adjuvent arthritic rats, initially with triethyl- 
phosphinegold chloride and subsequently with other trialkylphosphinegold  ^
complexes, 3-triethylphosphinegold - 2,3,4,6“tetra-Q-acetyl~l-thiG-3-D- 
glucopy r anoside (SK & F D-39162, 'Aurartof in') was used to treat patients 
with rheumatoid arthritis. (11) The first report appeared in 1976 and in 
8 patients who were treated and studied for only six months, improvement 
of the disease was confirmed by clinical and laboratory assessment. Reports 
of larger and longer trials, including control series of patients, and 
documentation of side-effects are still awaited but the initial evidence 
is that oral chrysotherapy is as effective as the conventional treatment.
Therefore, chrysotherapy for the treatment of refractory rheumatoid 
arthritis has a well established role which shows no sign of being 
displaced by alternative drugs of more recent development. Gold therapy 
for tuberculosis has been abandoned but there are a number of other 
conditions in which gold or gold compounds are used. Such cases are fewer 
than those of rheumatoid arthritis but nonetheless they help to emphasise 
the considerable value of chrysotherapy. -
1.3.3 Gold Therapy; Non-Rheumatoid Arthritis 
Psoriatic Arthritis
Psoriasis is a fluctuating disease which affects the skin and nails. A 
dry, scaling rash is found, often on extensor surfaces but sometimes also 
on the scalp, in the axillae, under the breasts or in the genito-anal 
region. The nails have a characteristic "thimble pitting” and, in severe 
forms, subungual^separation. (38) In about 10% of patients a seronegative, 
anodular, erosive arthritis occurs, generally in association with a relapse 
of the dermatological symptoms. In a small proportion of patients, however, 
the arthritis can develop before the eventual appearance of skin lesions.
Chrysotherapy for psoriatic arthritis was first suggested in 1959 and 
sporadic reports since'.then have' advocated its use. (39) From a large
retrospective study of the treatments employed in 98 patients with the 
disease it was concluded that chrysotherapy has a definite place in the 
management of severe psoriatic arthropathy and that the incidence of 
severe toxic reaction is low. (40)
Sodium aurothiomalate is no more toxic in children than in adults and 
chrysotherapy is therefore appropriate in Still’s Disease (Juvenile 
Chronic Polyarthritis). (41) Gold treatment has also been used in a 
limited series of patients with Palindromic arthritis.
Other conditions which have been successfully treated with sodium auro- 
thiomalate also have an immunological involvement. Pemphigus is a chronic 
disease in which patients have intra-epidermal acantholytic bullae and 
produce an anti-epithelial antibody. A high mortality rate is found in 
untreated disease and prolonged use of systemic corticosteroids causes 
undesirable morbidity. Chrysotherapy was introduced in 1973 and 
subsequent experience suggests that with careful supervision a good 
response rate with a very low incidence of gold toxicity can be achieved. 
(42) There are also reports from Japan of chrysotherapy used to treat 
bronchial asthma. (43)
1.3.4 Gold Therapy; Miscellaneous Uses
Extensive joint inflammation and effusion which is unresponsive to the 
usual methods of control may be treated by surgical removal of synovial 
tissue. As an alternative, synovectomy can be accomplished by intra- 
articular injection of radioactive (198Au) colloidal gold. (44) (198Au)
colloidal gold has also been used as an i-n si-tu cancer chemotherapeutic 
agent by instillation into body cavities where it limits spread of meta­
static disease. (45)
As with gold salts a history of medical use of metallic gold can be traced 
over many centuries, principally in dentistry.
1.4 RHEUMATOID ARTHRITIS
1.4.1 Introduction
It has been seen that gold has been and continues to be applied to a wide 
spectrum of clinical problems ranging from those associated with experi­
mental physiology to the control of various unrelated diseases.
Despite being employed for these multi-various purposes it is the treat­
ment of rheumatoid arthritis which presents the primary target upon which 
chrysotherapy is concentrated. Work described in later chapters concerns 
studies in patients with rheumatoid arthritis treated with gold - which 
also provided the stimulus for the experimental investigations included. 
Thus it is relevant to provide a brief description of this disease.
Rheumatoid arthritis is an inflammatory disease of synovial tissue which 
leads to destructive changes in the underlying joints. Arthritis (joint 
inflammation) is the most obvious and frequent manifestation but many 
other systems may also be involved in what is essentially a generalised 
disease. Abnormal antibodies (rheumatoid factors) are present in the 
blood of affected subjects. It is an extremely painful and crippling 
disease for which the cause remains unknown and which can be very difficult 
to control and treat. Lansbury has written that rheumatoid arthritis 
"may be likened to a smouldering fire which slowly consumes the b o d y ’s 
supporting structures and ultimately leaves behind a mass of twisted 
wreckage” . (46)
1.4.2 Clinical and Pathological Features
The fundamental feature of rheumatoid arthritis is synovitis involving the 
joints, bursea and tendon sheaths. The synovium becomes oedematous with 
infiltration by lymphocytes and plasma cells aggregated into follicles. 
Erosions to both the cartilage and underlying bone at the cartilage/ 
synovial junction occur to leave large cystic areas which can be seen 
radiologically within a year of onset. (47)
Rheumatoid arthritis has many systemic features in addition to those 
associated with the inflammation and damage to joints and bone. Sub­
cutaneous nodules are one such feature which is almost pathognomonic of 
rheumatoid arthritis (occasionally observed also in systemic lupus 
erythematosus). The nodules are small masses, 2 mm - 3 cm in diameter, 
located at pressure points such as the elbows and Achilles tendon and 
sometimes over joints of the fingers and toes. They are found in 25% of 
patients with rheumatoid arthritis, are non-tender or painful and 
histologically form a non-encapsulated zonal granuloma.
Arteritis is an important development in the disease. Inflammation causing 
arterial occlusion occurs only in those patients who are strongly sero­
positive and usualI37 also have subcutaneous nodules.
Patients with, rheumatoid arthritis have a higher incidence of previous 
chest disease than the general population but may also suffer from various 
lesions to which no cause can be attributed and are therefore collectively 
described as rheumatoid lungo These lesions include:
- pleural effusion; sterile pleural fluid produced in association with 
chronic inflammatory changes in pleural biopsy tissue,, Occurs in a 
small proportion of male patients„
- fibrosing alveolitis; impaired pulmonary function.
- rheumatoid nodules - of t h e .same histological appearance as sub­
cutaneous nodules but found in lung parenchymal tissue.
- pneumoconiosis; a radiological picture of reticular shadowing and 
peripheral opacities.
Rheumatoid arthritis is invariably accompanied by an anaemia due to iron 
and folic acid deficiency. Anaemia may also form part of F e l t y ’s Syndrome 
which is the combination of rheumatoid arthritis, splenomegaly and 
neutropenia. Associated features include low resistance to infection, 
weight loss, lymph node enlargement, skin pigmentation and leg ulceration.
The natural history of the disease does not follow a predictable pattern 
but develops along a course typical only to the individual. The course 
may be punctuated by spontaneous improvement or exacerbation and permanent 
remission may occur at any stage. In only a small number of patients does 
the disease produce extensive disability and an inevitable progression to 
overwhelming crippling is not the usual prospect.
The signs which are predictive of a poor prognosis include: insidious onset 
of the disease, failure to go into remission during the first year, early 
appearance of radiological erosions and of nodules, high levels and early 
appearance of the laboratory monitors of disease activity. As active 
progressive disease continues for longer periods, the final outcome can 
be predicted to be proportionately more severe.
Three times as many women are affected with rheumatoid arthritis as are 
men. The disease may develop at any age although numbers increase with a
peak age of onset during the fifth decade. Within the aged population 
(over 65 years) the incidence of the disease is three times greater than 
within the general population.
From studies with families it appears probable that a small genetic 
component to the disease exists. The incidence of rheumatoid arthritis 
and the prevalence of serum rheumatoid factors are slightly greater in 
close relatives than in controls. However, any genetic influence which 
operates is very Y/eak in comparison with other components. (48)
Rheumatoid arthritis affects populations in all parts of the world 
irrespective of climatic conditions or ethnic origins. The incidence in 
underdeveloped countries is lower than is found in the more advanced 
countries but this probably reflects the reduced life expectancy of the 
population, especially the women.
1.4.3 Aetiology of Rheumatoid Arthr itis
The aetiology of rheumatoid arthritis remains one of the greatest enigmas 
in modern medicine. Despite the considerable research extending for more 
than fifty years and the embarrassing excess of clinical material for study, 
the origins of the disease are as yet unknown. In the context of a 
discussion on dermatology, Shuster remarked "facts are as common as beard 
hairs and by themselves are as useless". He could, just as appropriately, 
have been thinking of what v/e know of rheumatoid arthritis where observa­
tions are legion and almost overwhelm attempts to define the cause of the 
disease. "
Despite this perhaps pessimistic introduction, hypotheses have been 
assembled into which much of the evidence can be slotted to give reasonable 
working models, albeit ones that are incomplete. Although the cause is 
obscure, it is believed that development of the disease begins with an 
initiating factor which sets up an immune reaction, and also involves one 
or more perpetuating factors.
A number of initiating factors have been proposed but the participation 
of any of them has never been clearly demonostrated. The possible role of 
an infective agent is suggested by the evidence that rheumatoid arthritis 
is a comparatively recent disease of mankind. At the same time (a)
Arthritis is frequently associated with viral infections such as rubella
(although the arthritis rarely persists); (b) Serum rheumatoid factors 
(see below) are found during many infective illnesses (see Table 1-3) 
and in animals treated with repeated injection of killed bacteria; (c)
Many of the systemic features of rheumatoid arthritis, e.g. fever, 
lyinphadenopathy and splenomegaly, are similar to those of infection and 
in many patients the onset of their illness is accompanied by an infection 
of the upper respiratory tract; (d) Rheumatoid-like diseases can be 
produced in animals by injection with micro-organisms.
Despite this suggestive data that an infection may precipitate the 
disease', it has not proved possible to isolate a causative agent from an 
affected joint. Warren et at. prepared a saline extract of synovial tissue 
from patients with rheumatoid arthritis. (49) The offspring of mice 
injected with the extract developed arthritis as did the next generation, 
suggesting that some transmissible agent was present. Mycoplasma fermentans, 
diphtheroids and Listeria have reportedly been isolated from rheumatoid 
joints but attempts to isolate viruses have been unsuccessful. (50-52)
Gerber has proposed an alternative hypothesis which is consistent with many 
of the biochemical changes observed in the serum and synovial fluid of 
patients with rheumatoid arthritis. (53) He suggests that abnormal 
aggregations of gammaglobulin within the synovial fluid precipitates an 
antigenic reaction with the appearance of rheumatoid factors and joint 
inflammation. The argument upon which the hypothesis (which is shown in 
Fig. 1.2) is developed, is as follows:-
Table 1.3 —
CAUSES OF POSITIVE RHEUMATOID FACTOR TESTS 
CONDITION COMMENTS
Rheumatoid arthritis Especially those with nodules and erosions.
Normal persons Approximately 4% of the population.
Relatives of rheumatoid Slightly higher incidence, but low titres.
arthritis patients
SLE Up to 40%
Progressive systemic Up to 40%
sclerosis
Subacute bacterial Up to 25%. Negative following antibiotic
endocarditis therapy.
Table 1.3 (contd)
CONDITION COMMENTS
Liver diseases Especially infective hepatitis, chronic 
active hepatitis and cirrhosis.
Pulmonary fibrosis Not necessarily associated with rheumatoid
arthritis.
Leprosy Up to 50%
Chronic pulmonary tuber­
culosis
5-20%
Conditions with raised e.g. sarcoidosis, multiple myeloma, 
macroglohulinaemia.gammaglobulin level
Sicca syndrome Almost 100%
Protein aggregation in vitro is promoted by copper and by hyaluronic 
acid but is inhibited by histidine. (53) The in vitro depolymerization 
of hyaluronic acid by ascorbic acid is inhibited by caeruloplasmin. (54) 
Abnormal aggregates of immunoglobulin are found in the synovial fluid of 
patients with rheumatoid arthritis. (55) Also in patients with rheumatoid 
arthritis the concentration of thiol groups (e.g. protein) in serum is 
reduced while the concentrations of copper and caeruloplasmin in both 
serum and synovial fluid are increased. (56-58) The serum free histidine 
concentration is decreased, (59) and there are increased amounts of 
hyaluronic acid at the joint (the concentration is reduced but fluid 
volume is much greater). (60) Thus the conditions which are favourable 
for protein aggregation may well exist in the synovial fluid of these 
patients.
Further evidence to support the hypothesis is found from:
1. experiments where copper was added to plasma and abnormal, heavy, 
sedimenting protein fractions were observed on ultracentrifugation (53),
2. the urinary excretion of a copper-ligand was determined in rheumatoid 
arthritis patients. The ligand was not positively characterised but 
it was not a sulphur donor and similar behaviour v/as noted with 
histidine and 3-methyl-histidine. (61)
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These data implicate copper and its carrier protein caeruloplasmin at 
several sites in the hypothesis with the inference that copper metabolism 
is particularly important in the aetiology of rheumatoid arthritis.
Myoehrisin and penicillamine are reported to inhibit protein aggregation.
(53) The hypothesis would predict an easing of the antigenic reaction 
with a subsequent decline in the production of rheumatoid factors and 
subsidence of the inflammation. This is the response which is observed 
in the majority of patients treated with these drugs.
The biochemical hypothesis offers no explanation of the disorder in 
copper metabolism and there is no attempt to apply the theory to the 
systemic symptoms. Less attention has been paid than has been given to 
the proposal of an. infective agent as initiator.
Transition from the initial response to the chronic disease with inflam­
mation and joint destruction is marked by increased immune activity. 
According to the supposed initiating factor, this overactivity may be 
driven on by persistent exposure to the infective organism or the continuing 
alteration in protein structure. This immunological activity may become 
self-perpetuating as an auto-immune disease is generated in response to a 
change in the antigenic specificity of some component within the joint.
The immunological features of the disease are revealed by the presence of 
plasma cells and lymphocytes within the joint, the formation of rheumatoid 
factors and immune complexes with their appearance in serum and reduced 
complement activity in synovial fluid.
Rheumatoid factors are antibodies directed against antigenic determinants 
on the Fc fragment of the gammaglobulin, IgG. In most cases the antibody 
is of the type IgM, and it is this immunoglobulin which is determined in 
conventional laboratory tests (see Section 1.4.4). The presence of IgM 
rheumatoid factors defines a patient as having seropositive disease. More 
recently it has been shown that some patients will have IgG or IgA type 
rheumatoid factors. Rheumatoid factors circulate as soluble complexes, 
one molecule of IgM combined with five or six molecules of IgG. Rheumatoid 
factor in the serum of a patient represents a series of different anti­
bodies, each of which will react specifically with a different mammalian IgG.
The rheumatoid factors are produced in lymph nodes and locally in the 
synovium fay plasma cells. Since rheumatoid factors are found in the 
serum of some healthy persons and of patients with other diseases, and 
since animals immunised with their own IgG (in Freunds adjuvent) will 
produce rheumatoid factor but do not develop arthritis, it is probable 
that rheumatoid factors do not themselves cause the rheumatoid arthritis 
but are associated with it. (62) The immune complexes however may be 
more involved with the pathological lesions. They are believed to 
activate complement and become phagocytosed fay granulocytes in the 
synovial fluid. This process may precipitate a release of lysosomal 
enzymes from the granulocyte which, with the activated complement, may 
then stimulate an inflammatory response on the synovium. Fluid from 
inflamed joints is known to contain lysosomal enzymes and has a reduced 
total haemolytic complement level. (63)
Despite this rather simplified description it is evident that a major 
feature of rheumatoid arthritis is the activity of the immune mechanism 
and response. There is good evidence to indicate that a considerable 
portion of this activity is of an auto-immune nature and that rheumatoid 
factors and immune complexes at least reflect disease activity and are 
probably involved in stimulating inflammation. None of the theories 
adequately explain all the changes in biochemistry and serology which are 
detected in patients with this disease.
1.4.4 Special Investigations
A considerable number of laboratory and other investigative procedures 
have been described which may be informative in the differential diagnosis 
of connective tissue disorders and in establishing the severity of the 
disease. Some of these tests are regularly repeated in order to follow 
the development of the condition and to assess the response to treatment. 
There is a second group of investigations in which abnormal results have 
been found in patients with rheumatoid arthritis but the significance of 
which is uncertain. These tests have not found a place in the routine 
assessment of patients although most have ardent proponents who regularly 
proclaim their virtue.
Routine Investigations
1. Radiology. Early radiological signs reflect only the inflammation, 
showing soft shadows around swollen joints, osteoporosis and narrow­
ing of joint space. These changes are typically observed at the small 
joints of the hands and feet although other joints e.g. the hip are 
subsequently affected in a similar way. With the progression of the 
disease more pronounced erosive changes are seen. Collapse and mal­
alignment of joints may be the eventual outcome of bone erosion which 
is seen but other, stable deformities can be produced.
2. . Erythrocyte Sedimentation Rate (ESR). The sedimentation rate reflects
inflammatory activity and is an indispensible investigation. While 
the inter-individual variation is considerable, repeated measurements 
on the same person provide an extremely useful guide to the state of 
the disease.
3. Tests for Rheumatoid Factors. Rheumatoid factor is detected by its 
effect upon an IgG (human or rabbit)/particle complex. In the 
presence of rheumatoid factor these particles will agglutinate to 
give a visible flocculate or precipitate. Two basic procedures have 
been described for measurements of rheumatoid factor - (a) Latex 
flocculation and (b) Rose-Waaler (Sheep cell) tests. The latter test 
has been refined into the sheep cell agglutination test (SCAT) and 
the differential agglutination test (DAT).
The two tests are often used to complement each other. Because human 
IgG is present in the latex test, this is a more sensitive procedure 
but has poor specificity for rheumatoid arthritis. The sheep cell 
methods are more elaborate to perform.but are less subject to inter­
ference. The former is therefore a convenient, rapid screening test 
with the latter used for confirmation of positive results.
4. Haematological Status. Because of the anaemia consequent upon the 
chronic inflammatory nature of the disease it is important to monitor 
iron and folate status of the patients. Routine haematological tests 
are therefore undertaken at the same time as the erythrocyte sedimenta­
tion rate is measured.
Non-Routine Investigations
There have been a limited number of studies to assess the effect of 
rheumatoid disease upon the chemical composition of serum. The systemic 
disease affects several organs and it would be expected therefore that 
serum chemistry would be altered in response to this involvement.
Wilding ei at. measured thirteen parameters of serum chemistry, ESR, 
haemoglobin and white cell count, in patients with arthritis in order to 
determine which of the tests routinely performed in hospital laboratories 
best represent the biochemical and haematological profile of rheumatoid 
arthritis. (64) More than half the biochemical and all three haematological 
tests were significantly different in the patients with rheumatoid arthritis 
compared with the reference population. Albumin and bilirubin showed 
greatest shifts away from the reference values. The most important finding 
from this and similar studies was the demonstration of a reduced concentra­
tion of serum albumin which was found to be as good as the ESR as an index 
of rheumatoid inflaminatory activity. Impaired hepatic synthesis may be 
responsible for this (cliolesterol concentrations were also reduced) but 
there are studies which suggest that in rheumatoid arthritis the rate of 
catabolism is increased. (65)
McConkey et at. have argued that as a guide to the eventual structural 
damage wrought by the disease, the intensity and duration of inflammatory 
activity serves as a good index. (6 6 ) In addition to the ESR they 
demonstrated that acute phase reactants (the proteins produced in response 
to a non-specific tissue injury and inflammation), measured in the serum, 
are reliable markers of control over inflaramatory and rheumatoid disease 
activity.
The biochemical hypothesis for the aetiology of rheumatoid arthritis was 
elaborated by Gerber (see Section 1.4.3) to include observed changes in 
the concentrations of components in the synovial fluid. Measurements of 
copper, caeruloplasmin and histidine etc. .which have been made in synovial 
fluid from patients and controls have shown that concentrations of these 
elements in the synovial fluid of subjects with rheumatoid arthritis are 
consistent with the hypothesis. Collection of synovial fluid however is 
not a procedure which is readily carried out and therefore measurements of 
the serum concentrations have been performed to provide an assessment of 
fluid content.
Many reports have shown that in patients with rheumatoid arthritis the 
concentration of free histidine in serum is significantly decreased compared 
with the histidinaemia of normal subjects and patients with non-rheumatoid 
diseases. (67,68) This hypohistidinaemia was profound in both men and 
women and correlated with the severity of disease as demonstrated by a 
range of parameters. (59)
The serum concentration of copper and its carrier protein caeruloplasmin 
were shown to be increased in patients with, rheumatoid arthritis as long 
ago as 1958 and there have been many subsequent reports confirming this 
observation. (57,58,69,70,71) The increased serum copper concentration 
could be a non-specific effect as caeruloplasmin (an acute phase reactant) 
is released in response to the disease. However several studies have 
demonstrated an increase in non-caeruloplasmin bound copper suggesting 
that additional mechanisms are operating. (58,71) At the same time as 
the serum copper increases the concentration of zinc falls. (72) Therefore 
the copper/zinc ratio provides a further parameter which can be used to 
assess disease activity together with ESR, rheumatoid factor, acute phase 
reactants and histidine. (73)
Examination of synovial fluid. Synovial fluid may occasionally be 
aspirated from an inflamed joint to relieve pressure or to assist with a 
diagnosis when a patient is first seen. Unlike the viscous, straw-coloured 
synovial fluid from a normal joint the aspirate from an inflamed joint is 
opaque, less viscous and of a much greater volume. A grey, turbid fluid 
is indicative of septic arthritis. Fluid can be examined for cells and 
micro-organisms and if the diagnosis is uncertain, measurement of rheumatoid 
factor may be helpful.
Other investigations are possible but are usually of academic rather than 
clinical relevance. Thus, as has been noted earlier, copper, caeruloplasmin, 
hyaluronic acid and histidine concentrations have been measured in fluid 
and the activities of various enzymes also measured, particularly the 
hydrolases released from lysozomes. *
1.4.5 Treatment
Treatment of rheumatoid arthritis is multi-faceted and affords an example 
of the value of multidisciplinary teams focussing a range.of medical 
expertise upon the problems presented by a patient with a serious disease.
For the patient with rheumatoid arthritis the following therapeutic and 
social options are available, although not all may necessarily have to be 
used; rest, provision of supportive appliances, physiotherapy, occupational 
therapy, provision of appropriate housing aids etc., drugs and surgery.
While all are important in the management of the patient, consideration in 
this discussion will be given only to drug therapy.
Rheumatoid arthritis causes a patient a number of problems which can be 
treated with drugs. These include pain and the associated difficulty with 
sleeping, depression, inflammation and joint stiffness, dysfunction to 
associated systemic organs and the active, erosive disease itself. The 
simple classification of treatment with drugs recognises (a) non-specific 
or symptomatic therapy and (b) specific therapy which acts slowly upon the 
rheumatic disease process to alter the course of a progressive disease. 
Included in the first group are the so-called "first-line drugs" which are 
analgesics, and the "second-line drugs" which are represented by non­
steroidal anti-inflammatory drugs (NSAID’s). The specific agents form the 
"third-line drugs", and very occasionally it may also be necessary to make 
limited use of steroids either locally or sysiemically. Thus a stepwise 
pharmacological approach to the disease is evident, the patient initially 
receiving pain relief and as necessary progressing to more aggressive forms 
of treatment.
Analgesics
Not all patients will require any other treatment than simple pain relief. 
Aspirin is the traditional drug of choice, but cannot be used without a 
certain risk. (41) In very severe disease where pain is considered 
unbearable and the prognosis very poor, addictive analgesics such as 
morphine may be prescribed.
Non-Steroidal Anti-Inflammatory Drugs
By reducing swelling and pain, and by allowing improved joint function, 
these drugs considerably help the clinical condition. They represent the 
major form of drug treatment for rheumatoid arthritis, and a large number 
of such compounds are now available.
Specific Drugs
These agents must be taken for several weeks before evidence of improvement 
becomes apparent. If therapy is ceased prematurely the subsequent relapse 
is also delayed. Patients for whom specific therapy is appropriate are 
those with acute inflammatory rheumatoid changes with active and progressive 
disease and in whom NSAID’s have proved ineffective. Their introduction 
should not be considered unless the disease has been active for at least 
six months since spontaneous remission may occur. If remission is induced 
by one of these agents, it is necessary to continue maintenance suppressive 
therapy In order to ensure that the improvement continues.
All drugs in this group are potentially toxic, some extremely so, and 
therapy should not be embarked upon unless it is evident that all other 
treatment is ineffective.
Gold - The gold drugs were the earliest of this group to be introduced, 
and will be discussed in detail in the next section.
D-Penici11amine - Penicillamine is often the first choice drug in this 
group because it has a greater effect upon the progression of the disease 
as shown by X-ray changes. It also has a high incidence of side-effects 
and about 40% of patients have to cease treatment either because of lack 
of effect or because of toxicity. The incidence of toxic reactions is 
increased if patients have been previously treated with gold. (74)
Azothioprine - Azothioprine is an anti-metabolite, interfering with purine . 
metabolism, and is thought to have an immunosuppressive effect. It can 
cause depression of bone marrow activity and have gastro-intestinal 
intolerance.
Other powerful dxmgs may be considered but have a high incidence of serious 
side-effects and are not therefore used unless the disease is very 
advanced, likely to be fatal and has failed to respond to other treatment. 
(41)
Steroids
Steroids used systemically in doses necessary to control the inflammation, 
will inevitably cause Cushing's syndrome and at the same time have no 
effect upon the eventual outcome. Steroid therapy has no real place in 
the treatment of rheumatoid arthritis therefore, although prednisolone is 
occasionally used to provide relief of night pain and morning stiffness. 
Small doses of prednisolone can also be used in the explosive rheumatoid 
arthritis which suddenly develops in the elderly. If a response is not 
observed within a few days of commencing, the treatment should be terminated 
to avoid steroid dependency.
Local injections of steroids to achieve pain relief in a stiff or deformed 
joint, or to suppress inflammation in a tendon or ligament, will eliminate 
the undesirable systemic effects. Subsequent injections are less effective, 
and a course of more than one or two doses is of no benefit.
1.5 CHRYSOTHERAPY FOR RHEUMATOID ARTHRITIS
1.5.1 Introduction
As was earlier suggested, it was the introduction of gold salts which 
provided the first sign that rheumatoid arthritis was susceptible to 
control by drugs. Although the rationale for this step was based upon 
false assumptions and an associated toxicity has always been recognised, 
chrysotherapy continues to occupy a significant place in the suppression 
of the disease.
Notwithstanding a history of more than fifty yearsf use of gold salts, 
and recent intensive investigation, our appreciation of their fate in 
vi-VO and our understanding of how they exert their anti-rheumatoid action 
is still incomplete. This section will describe what is known to occur 
during chrysotherapy using sodium aurothiomalate and also show some of 
the outstanding problems in order to p?’ovide' an introduction to the work 
reported in subsequent chapters.
Y/ith the exception of the recently introduced gold pliosphine complexes 
which are orally administered, gold salts are given by intramuscular 
injection. In adults the dose is not adjusted to the body weight of the 
patient nor, with few exceptions, has the blood gold concentration been 
measured to allow modulation of the regime.
During the period prior to the Empire Rheumatism Council (ERC) multi-centre 
trial, a common system of chrysotherapy evolved among clinicians using 
sodium aurothiomalate. This system, based upon empirical experience, was 
adopted for the ERC trial and with certain modifications remains in use 
today. (36,37).
The concept adopted for the standard regime is that of supplying a total 
dose of 1,0 g sodium aurothiomalate. A test ^ dose of 10 mg is first given 
in order to eliminate patients who are particularly sensitive to gold and 
readily experience toxicity. Subsequent doses are of 50 mg given at weekly 
intervals until the patient has received the total of 1.0 g.
In the assessment of patients included in the ERC trial which was performed 
18 months after the start of the trial, those treated with gold fared better 
than the controls. (36) At this point some of the gold-treated group, whose 
improvement was less remarkable, received a second course of injections. In
the final assessment at thirty months, it was noted that much of the 
initial improvement had disappeared and that the second course of injections 
(given to the poor responders) did not affect this reversal. (37)
The trial unambiguously showed that gold was effective in controlling 
rheumatoid arthritis but that a proportion, of patients show poor or no 
response and that eventually active disease reasserts itself. As a 
consequence therefore it is recognised that maintenance doses of gold 
must be supplied after the 1.0 g has been given and that a certain flexi­
bility in administration can be introduced. A regime typical of current 
practice is to give the 10 mg test dose followed by weekly injections of 
50 mg. (41) When a favourable response is obtained, the interval between 
injections is gradually altered to two and then four or six weeks and is 
continued for an indefinite period. Should a relapse occur while maintenance 
therapy is being applied, the inter-dose interval is reduced until control 
is re-established. Non-responders are identified after 1.0 g has been given. 
If a larger dose, e.g. 100 mg per week for a few weeks still has no effect, 
chrysotherapy should be discontinued and another drug used.
Blood counts and urinary protein determinations (to identify bone-marrow 
suppression and kidney damage) should be regularly carried out. Rashes are 
the most frequent side-effect. Resolution is usually rapid upon temporary 
cessation of treatment but if the rash reappears when treatment is restarted,
it is unwise to continue with chrysotherapy.
1.5.2 Physiology of Gold
Early work using radioactively labelled compounds showed that the absorption 
of soluble gold complexes by the intestine is very rapid but that plasma 
concentrations are not comparable with the high levels found following intra­
muscular injection. This was confirmed by much later work with guinea pigs 
where the serum gold concentration following oral administration was one- 
third of that attained by intramuscular injection twenty-four hours after 
the dose. (75) Urinary excretion is rapid and the gold therefore fails to 
accumulate and is presumed to be therapeutically ineffective. Therefore, 
with the exception of the orally administered gold phosphine complexes, 
gold drugs have been given by intramuscular injection.
Absorption from the injection site into the blood has been frequently
measured in patients with rheumatoid arthritis, in healthy volunteers and
in animals, using radioactive and stable gold. Following injection of 
50 mg aurothiomalate the peak plasma gold concentrations are reached 
within six hours. (75-81) The peak is seen somewhat earlier if a smaller 
injection is given. The increment in plasma gold concentration is extremely 
variable between individuals, thus although the mean increase is consistently 
reported as approximately 20 ymol/& (400 yg/100 m l ) , the range may be as 
great as 10-30 ymol/& (200-600 yg/lGQ m l ) . Some of this variation can be 
attributed to the different body sizes of the patients. Palmer and Dunkley 
demonstrated a close relationship between serum gold concentration and body 
weight in fifteen patients. (82)
The concentration of gold in blood declines from the peak level following 
an exponential course with a rapid element for thirty hours and a slower 
fall during the subsequent five days. (77-79,83,84) The mean half life for 
gold in serum has been calculated and. the results are in reasonable agreement 
at 4.5 to 5.5 days. (77,83,84) A consequence of this rate of decline is 
that when weekly injections are being given the underlying blood concentra­
tion will gradually rise. This trend is illustrated in Fig. 1.3 which shows 
the rapid increase in concentration immediately after an injection with the 
fall prior to the next dose. (80,81,85) The underlying concentration 
eventually stabilises at a level which varies with the individual patient 
within a range of approximately 5.0 to 17.8 ]imol/£ (100 to 350 yg/100 ml).
19 7 19 5Studies using both Au- and Au-labelled aurothiomalate showed that a 
pre-existing gold burden does not influence the way in which injected gold 
is handled by the body. (77) . .
The concept of a therapeutic blood concentration is widely applied to
pharmacology and was thought to be relevant to chrysotherapy by Lorber. (8 6 )
Because of the extreme individual variation in response (i.e. blood gold
levels), he suggested that some patients were not getting sufficient gold
to the tissues where the disease was active and therefore showed a restrained
response to treatment. Likewise, others accumulated an excess of gold and
these were the patients in whom gold proved to be toxic. This concept, if
demonstrated to be appropriate, provides a place for routine determination 
/*
of blood gold concentrations and modulation of the dose regime in order to 
maintain the ’therapeutic level1.
Although no scientific evidence was available to support or refute the 
idea, many other rheumatologists, on the basis of their clinical experience,
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were unconvinced of the validity of the concept in chrysotherapy. In the 
next chapter data will be presented from trials which were designed to 
provide firm evidence as to the relevance of the concept. At about the 
same time, other workers were carrying out similar exercises.
Distribution of Gold in Blood
During the last decade techniques which make possible a sophisticated 
separation of blood into component fractions have been developed and 
applied to the question of how gold is distributed within the blood. At 
the same time, analysis for gold has become simpler and affords greater 
sensitivity, making it possible to measure the metal in the minor 
components of blood.
Early experiments to examine gold distribution were carried out using 
radioactively labelled colloidal gold, but the first attempt to look at 
sodium aurothiomalate was made by Lawrence. (87) He concluded that 
plasma gold is exclusively protein-bound, that two-thirds is associated 
with fibrinogen and that 2 0% of the total blood gold is within the erythro­
cytes. However, while the degree of protein binding was found to be high 
he (and others) inferred that since there is a considerable excretion of 
gold into the urine following injection, an appreciable fraction must 
exist for a short time at least, in a small molecular weight form.
Most of Lawrence’s conclusions have not been substantiated by subsequent 
work which has shown that the methods used to investigate gold binding 
will themselves affect the distribution in blood samples. Relocation of 
gold has been demonstrated to occur in vi~6ro when samples are left to 
stand or are subject to a prolonged separation procedure. Furthermore, it 
is now realised that gold may bind to the membranes used in separation 
techniques such as dialj'sis and ultrafiltration v/ith the production of 
erroneous results. Despite reservations with some experimental data, 
there are many points where consistent results have been obtained from a 
variety of techniques.
Contrary to the results obtained by Lawrence, it is no longer believed 
that gold is found v/ithin or attached to erythrocytes and neither is it 
accepted that there is any difference between the serum and plasma concentra­
tions of gold. (88,89) Lawrence further concluded that gold was firmly 
bound to plasma protein but this finding also is not entirely correct.
Examination of samples by gel filtration, paper and cellulose acetate 
electrophoresis, acrylamide gel electrophoresis, immunoelectrophoresis 
and radial immunodiffusion all show that most of the gold binds firmly 
to albumin. Depending upon the technique, the proportion of the total 
gold which is bound to albumin is reported as between 60 (exceptionally) 
and 99% with most finding 90-95%. (76,90,91)
Again depending upon the procedure and the sensitivity of the technique 
available to measure gold, the non-albumin component has been found 
associated with gammaglobulins and with low molecular weight (less than 
1000) compounds. (92)
As the total gold concentration is increased, either experimentally in 
vitro or from patients receiving larger doses of aurothiomalate, so the 
non-albumin bound proportion also increases. (76,90,93) Because of the 
considerable technical problems involved in analysing large numbers of 
samples no study has included more than four patients and there are no 
results which can be used to attempt to relate non-albumin bound gold to 
clinical response or toxicity. The most extensive work is that of 
Danpure et at. (76) where plasma samples were separated into .albumin, 
globulins and unbound fractions. Samples were collected from just three 
patients at intervals after an injection of aurothiomalate for up to one 
week. The rapid rise and slow decline in total gold concentration 
described in the previous section was seen and this was paralleled by. 
the concentration of gold bound to albumin. 1 0 -20% of gold was bound to 
high molecular weight components and this fraction followed the opposite 
pattern to albumin with the lowest proportion found after administration. 
The greatest fluctuation was observed in the non-protein bound gold where 
the concentration rapidly rose 2 to 5 times within 10-30 minutes of the 
injection.
Lorber et at. (94) attempted to characterise the high molecular weight 
components using immunological techniques. They found gold associated 
with IgG, IgA, IgM, immunec.omplexes and complement proteins and that the 
gold:protein ratio increased linearly with the total serum gold concentra- 
tion.
Gold in blood therefore is confined exclusively to the plasma. The 
majority is bound to albumin with about 10% associated with globulins and
a very small fraction found with, low molecular weight compounds. Follow­
ing an intramuscular injection there is an increase in the unbound and 
albumin-bound gold with a relative decrease in the proportion of globulin 
gold. The total gold concentration then decreases exponentially, some 
gold is excreted, some enters body tissues, and some is redistributed 
(possibly via other compartments) to the high molecular weight proteins.
Distribution of Gold to Tissues
Tissue distribution of gold following exposure to various gold compounds 
has been determined in animals and, less extensively, in man. Block et 
at. (95) gave six different gold compounds as a series of intramuscular 
injections to rats and measured the concentration of gold in kidney, liver, 
spleen, heart and lungs at intervals for up to 12 weeks. With the exception 
of colloidal gold sulphate, the pattern of gold distribution and the change 
with time was qualitatively similar for each of the gold complexes. One 
day after the last injection the highest concentration was found in the 
kidney with substantial amounts also in the liver and spleen. Only trace 
amounts were found in the other organs examined. The gold concentration 
in each of the tissxies decreased steadily throughout the twelve weeks 
although the initial pattern of distribution was retained. The quantitative 
results were quite different for the various compounds with most gold being 
retained from gold sodium thiosulphate and the least found in animals given 
sodium succinimidoaurate. With colloidal gold sulphate, the gold went 
initially tc the liver but was gradually transferred to the kidney.
Similar results were obtained by Bertrand et at. (96) who also used gold 
sodium thiosulphate but in both rat and rabbit. These authors examined an 
increased number of tissues including synovium, tendon and bone and found 
that connective and non-connective tissues contained gold in similar 
concentrations. In guinea pigs, rats and rabbits, gold from aurothiomalate 
was distributed with a similar pattern to that described above. (75,92,97). 
Most gold went to the kidney with the spleen also having large amounts. 
Organs of the reticuloendothelial system - liver and lymph glands - bad 
significant concentrations of gold as did the adrenal and reproductive 
organs. Small amdunts were found in all other tissues indicating that 
absorbed gold becomes very widely distributed. Concentrations were very 
much lower 24 weeks after the administration.
McQueen and Dykes (92) also administered aurothiomalate to rabbits but 
differentiated the kidneys into cortex and medulla prior to analysis for
gold. The concentration of the metal in the kidney medulla was equivalent 
to that measured in liver, adrenal and lung and was between 10 and 20% of 
that found in the cortex.
In two of these studies artificial inflammation was induced in animals and 
the amount of gold taken up by the affected tissue was consistently much 
greater than that taken into normal tissue. (96,97) Other organs, kidney, 
spleen, liver and heart also had increased concentrations of gold (although 
not as marked), when compared with normal animals.
This series of reports showed that the tissue distribution of gold from 
different gold complexes is remarkably similar in different species of 
animal. The opportunity to conduct similar studies of the distribution 
of gold in human tissues is unlikely to become readily available. Clearly 
it is unusual for many patients who have received gold to die and have a 
full post-mortem with removal of tissue suitable for gold analysis.
Gottlieb et at. (98) wei'e able to measure the concentration of gold in the 
tissues from one patient, a lady who died from an overdose of barbiturate.
The patient had an 11-year history of rheumatoid arthritis and had been 
treated by chrysotherapy for the previous four years. Therapy had been 
continued uninterrupted, the last dose was given 8 weeks prior to her 
death and she had received a total of 2.53 g gold. Nineteen tissues 
(grouped as reticuloendothelial, musculoskeletal and other) v/ere taken 
for analysis for gold together with post-mortem blood, urine, plasma, 
pericardial and synovial fluids. Gold v/as -detected in all samples. The 
highest measured concentration was in the para-aortic lymphnode with the 
liver and adrenal also having high concentrations of gold (greater than 
100 jJg/g). Gold in the kidney cortex was at the same level as the liver 
and was double that measured in the renal medulla. Low concentrations were 
found in muscle (except for the site of injection), synovium, cartilage and 
bone. The authors concluded that gold concentrates in those tissues contain­
ing an abundance of reticuloendothelial cells.
This exceptionally extensive work and the authors’ conclusions have been
e*
referred to repeatedly although there are certain features which should 
indicate caution in accepting all the data.
1. Six of the tissues were analysed in duplicate and the agreement in 
results for most of the pairs is so poor as to be beyond acceptance 
e.g. Results of 396 and 211 JJg/g were given for the lymphoid tissue.
2. The plasma concentration (8 weeks, after the last injection) was
reported as 48.2 }imol/il (950 pg/100 ml) which is in excess of the 
peak levels usually found a few hours post administration.
3. The urine sample similarly had an impossibly high gold concentration
These inconsistencies must raise doubts either to the accuracy of the 
analytical technique (neutron activation analysis) or to the validity of 
taking samples after an unspecified delay, post-mortem.
A smaller range of tissues from seven patients were obtained for similar 
analysis by Vernon Roberts et at. (99) Unlike Gottlieb et at. they found 
the highest concentrations not in reticuloendothelial tissues but in the 
kidney, adrenal, lyraphnode and diseased synovial tissue (i.e. with a 
similar distribution to that found in experimental animals).
Other opportunities to examine a limited number of tissues are presented 
when patients undergo surgical operations (e.g. for hip-joint replacement) 
or from biopsy samples. In one patient so examined the concentration of 
gold in rheumatoid synovium was at least ten times that in adjacent muscle 
and skin. (96) A more comprehensive study of gold concentrations in human 
tissue will be presented in the next chapter.
-Excr€HriGn~cT^Geid_-____
Given the very high proportion of protein-bound gold found in most studies, 
urinary excretion of the metal should be trivial. That gold can be 
measured in the urine during chrysotherapy is however a point used in the 
argument that, despite the experimental results, some is not tightly 
protein-bound, particularly soon after an injection.
The urinary excretion increases abruptly during the first day post-injection 
and thereafter falls steadily during subsequent days (80,100) demonstrating 
a similar pattern to that seen for plasma concentrations (Fig. 1.3). With 
the standard weekly dose of 50 mg sodium aurothiomalate, between 10% and 
20% of the injected gold is excreted in the urine during the next seven 
days. When maintenance therapy is being given the proportion excreted 
progressively falls through the second and following weeks. (80) In 
general, the greater the amount injected, the greater the percentage of the 
dose that is excreted.
recoi'ded
Monitoring urinary excretion has been suggested as a valuable technique 
to predict, response to chrysotherapy. Smith et at. (101) proposed that 
patients could be divided into three groups, i.e. normo-, hypo- and hyper- 
excretors of gold. It was suggested that hyperexcretors remove gold from 
the body too rapidly or before sufficient has concentrated in tissues to 
be effective. Conversely hypoexcretors retain excessive gold and toxic 
side-effects are produced.
This proposal has not been supported by data from other investigators and 
while the relationship is not strong hyperexcretion is more likely to be 
associated with high plasma gold concentrations (79,80,83) and not with 
the low levels as predicted by the hypothesis of Smith et at. (1 0 1 )
Removal of gold via the faeces is even more variable. Mascarenhas et 
at. (80) performed gold balance studies with three patients receiving 
conventional chrysotherapy and with patients on maintenance therapy.
With a single exception, removal of gold in the urine was always greater 
than that through the faeces (an observation confirmed by other reports). 
Nevertheless the gold excreted in the faeces formed a significant proportion 
of the total eliminated (between 10% and 55%). One preliminary study with 
two patients attempted to determine the amount of biliary excretion of gold. 
It was shown that this accounted for less than 50% of faecal gold. (102).
Thus in the seven post-injection days somewhere between 14% and 40% of the 
gold is excreted in the urine and faeces. Measurements of gold in hair, 
skin and nails indicate that insignif icant'* amounts are lost into these 
tissues. (103) Therefore the body retains"in excess of 60% of the injected 
gold and as has been seen above while uptake into the kidney, spleen and I 
liver accounts for most of this, some gold is retained in all body tissues.]
i
From metabolic balance studies and the use of whole body radiation counting, 
Gerber et at. (84) followed i95Au sodium aurothiomalate in patients with 
rheumatoid arthritis. From their data they formulated a linear two- 
compartment model. They described a "superficial1* compartment which 
includes serum, synovial fluid and possibly other body fluids also and 
a "deep" compartment. This so-called deep compartment was recognised to 
be an undoubted over-simplification of the real situation particularly since 
the distribution of gold in different organs is not homogeneous. However, 
the rates of movement of gold into and out of serum can be represented in
this model to show the avidity with which the metal is retained within 
the body.
1.5.3 Effects of Gold
Toxic responses. The major limiting factor in the use of chrysotherapy 
is the significant incidence of side-effects. The number of patients 
reporting undesirable responses to gold is given in the major trials (37, 
104,105) at 30-35% (Table 1.4). These effects range from relatively 
trivial, tolerable reactions to marrow aplasia which can be fatal. A wide 
range of iatrogenic effects have been attributed to chrysotherapy and these 
are described below. It is however important to note that the incidence 
of some of the reactions e.g. skin rashes may not be as high as first 
appears. In the well-designed trials the number of patients in whom skin 
eruptions and proteinuria developed was almost as high in the control 
patients given an innocuous placebo as in the gold treated subjects. (32)
Table 1.4
TOXIC EFFECTS OF GOLD
Description Incidence in patients
Mucocutaneous reactions. Effects upon the skin and raucous membranes of 
the mouth are the most frequently reported toxic reaction to gold.
Pruritis is the commonest manifestation followed by non-specific dermatitis. 
Further lesions which have been described include lichen planus, pityriasis 
rosea and exfoliative dermatitis. (106) These reactions are found to be 
mild and self-limiting and upon cessation of gold therapy healing occurs 
either with topical steroids or more usually without any additional treat­
ments. In most cases the skin reaction first develops early on in a course
receiving gold
Mucocutaneous reactions
Proteinuria and nephrotic syndrome 
Thrombocytopenia 
Marrow Aplasia 
Miscellaneous reactions
)
)
)
)
)
)
)
)
)
)
cholestatic hepatitis 
enterocolitis
Probably less than 
1%
pulmonary infiltration 
occular chrysiasis 
metallic taste
of chrysotherapy. When a good response to the removal of gold is obtained 
careful therapy can be successfully reintroduced without any further 
problems.
Proteinuria and nephrotic syndrome. Mild, intermittent albuminuria can be 
expected to occur in young or middle-aged women from miscellaneous causes 
such as urinary tract infection and the incidence of proteinuria found in 
controlled trials is almost as great in controls as in gold treated patients 
Patients are usually asymptomatic and the proteinuria detected only by 
regular monitoring of the urine. Renal damage as a consequence of gold 
therapy is usually a membranous glomerulonephritis and is much more 
infrequent than the intermittent albuminuria. (107) Progressive renal 
impairment and renal failure is avoided by withdrawal of chrysotherapy and 
an excellent prognosis is possible.
Thrombocytopenia and Marrow Aplasia. The thrombocytopenia associated with 
chrysotherapy is of two types:
1 . an isolated haematological phenomenon with an incidence of about 
3% and less serious than,
2 . a manifestation of generalised marrow aplasia.
The appearance of isolated thrombocytopenia is unpredictable and regular 
platelet counts will not necessarily predict thrombocytopenia. Life 
threatening haemorrhages have not occurred but immediate withdrawal of 
gold and commencement of steroid therapy is required. (108)
Marrow aplasia is potentially the most serious side-effect. (109) The 
frequency with which it occurs is not clear. From a review of reported 
cases it has been suggested that in. the United Kingdom, 16 deaths occurred 
during seven years (110) while other studies examined 50 cases from which 
the mortality was 66%. (106) A drop in indices of marrow activity is an 
alarm to cease chrysotherapy and investigate the problem.
Bone marrow examination allows differentiation between isolated thrombo­
cytopenia and aplastic anaemia. In the former condition a cellular marrow 
with active megakaryocytes is found while in aplasia the picture is of a. 
hypocellular condition with suppression of blast cells and maturation arrest 
The number of cases has been too few to allow the preparation of adequate 
treatment. Chelating agents, steroids and marrow transplantation have been
used but the appreciable number of deaths (from haemorrhage and/or 
infection) shows that these are far from successful.
Miscellaneous Reactions. Less frequently occurring side-effects have been 
reported to develop in patients receiving chrysotherapy. Improvement upon 
removal of the gold and reappearance if therapy is re-instated are the 
signs which indicate that these effects are associated with gold.
Cholestatic Jaundice. Obstructive jaundice has been described in three 
middle-aged women patients. (Ill) A typical clinical picture with jaundice, 
malaise, pruritis etc. developed after two or three injections with sodium 
aurothiomalate. Drug-induced jaundice was considered after laparotomy or 
liver biopsy revealed no specific causes. Spontaneous recovery occurred 
in all three cases.
Enterocolitis. This too is an uncommon reaction occurring in middle-aged 
women who have received low doses of gold. Symptoms include fever, nausea, 
vomiting, abdominal pain and diarrhoea. The colon becomes inflamed and 
has superficial erosions but rapidly heals with withdrawal of gold and 
the use of steroid enemas. (1 1 2 ).
Diffuse Interstitial Lung Disease. Pulmonary injury producing symptoms of 
cough and dyspnoea, and having radiological signs of bilateral pulmonary 
infiltration has been described in several reports during the last five 
years. Lymphocytes and plasma cells are seen in lung biopsies to infil­
trate the alveolar septa and interstitial-'fibrotic tissue. (113) In eighteen 
of the twenty patients reviewed by Scott et al. (114) the lung dysfunction 
improved or resolved completely.
Foetotoxicity. Foetotoxicity and teratogenicity of gold have not been 
examined although the advisability of continuing with chrysotherapy during 
pregnancy has been questioned. (115)
1.5.4 Effects of Gold Upon Immune and Inflammatory Responses.
Possible Mechanisms of Action
The immune response and the inflammatory response represent major components 
in rheumatoid disease activity. It is, therefore, from the effects of gold 
upon the many facets of these processes that an appreciation of the mode or 
modes of action of gold drugs can be gathered. The first studies to answer'
usome of these questions were unfruitful and failed to demonstrate effects 
of gold upon humoral or cell-mediated immunity. However more recently, 
elegant experiments have shown that gold has important modulating activity 
upon immune and inflammatory responses. (116)
A gradual decrease in the circulating concentration of immunoglobulins 
and rheumatoid factor in patients treated with gold has been successfully 
demonstrated on a number of occasions. (94,117) The fall in concentration 
of these anti-bodies does not begin until treatment has progressed for 
about six months and then plateaus after one to three years. The decrease 
compared with pretreatment concentrations was shown to average 53%, 37% 
and 34% for IgM, IgG and IgA respectively by Lorber et at. (94) who also 
showed a 27% decrease in the number of circulating lymphocytes and a fall 
in the rheumatoid factor titre (sometimes to zero).
Concurrent with the decline in immunoglobulin concentration there is an 
increase in serum albumin levels suggesting that a generalised suppression 
of protein synthesis is not responsible for this effect of gold salts. (94) 
Therefore a restriction on the number of cells responsible for synthesis 
of immunoglobulin and/or actual inhibition of protein synthesis within the 
cells, could be effecting the gradual decreases observed. From a variety 
of experimental approaches it is evident that mitogen- and antigen- 
stimulated lymphocyte cell proliferation is inhibited by sodium auro­
thiomalate 'in vitro. (118) By acting upon the T lymphocyte proliferation, 
activity of the immunoglobulin-producing B lymphocytes (which require T 
cells as helpers) will be suppressed. Other, functions of the lymphocytes 
e.g. cellular cytotoxicity, migration, phagocytosis, chemotaxis and digest­
ion are also inhibited by gold. (116)
\
Activation of complement via both the classical and alternative pathways 
has a profound stimulatory effect upon the inflammatory processes. Sodium 
aurothiomalate inhibits in vitro activation of Cls and Factor D (both of 
which act as serine esterases) to shut down the classical pathway and to 
interrupt the amplification loop of the alternative pathway respectively. 
(119,120)
The phagocytic activity of inflammatory cells from patients with rheumatoid 
arthritis is enhanced with controls but is suppressed in those treated with 
sodium aurothiomalate. (121) Suppression develops progressively throughout
the period of treatment and persists beyond cessation of chrysotherapy.
The mechanism of suppression is unknown but it is suggested that there may 
be (i) inhibition of cellular migration from germinal sites and (ii) 
membrane stabilisation so that release of lytic enzymes into synovial 
fluid is prevented.
One of the earliest attempts to determine a mechanism of action for gold 
in rheumatoid arthritis was described by Persellin and Ziff. (122) They 
measured the activity of lysosomal enzymes from peritoneal macrophages of 
guinea pigs and noted that inhibition occurred when gold was added at 
concentrations of 2.5-5.0 mM which is a 200-500 fold excess compared with 
expected therapeutic concentrations in'synovial fluid but might be achieved 
as gold is actively sequestered into the lysosome. This inhibition is of 
considerable importance since the activity of these enzymes, released from 
macrophages in the joint tissue, is believed to be responsible for the 
destruction of synovium which in turn presents structurally altered protein 
capable of reinforcing the immune response. (123) Lysosomal enzymes from I
other animals and from man which have subsequently been shown to be 
inhibited by gold are listed in Table 1.5. Included also are the enzymes 
from serum which have been similarly investigated and it is intriguing 
to note that gold apparently has no inhibitory action on these enzymes. (124)
Reference to proteolysis causing damage to synovial tissue was made above 
and there is some evidence that gold salts have an effect upon the synovium 
itself. In addition to the enzymes concerned with tissue destruction those 
involved with connective tissue metabolism"may be inhibited by gold. (125, 
126) The activities of fibroblast glucosamine-6-phosphate synthetase, malic 
dehydrogenase and enzymes of the nucleic acid synthesis pathways are 
inhibited by gold as are those of amino acids and carbohydrate metabolism 
taken from blood cells. Proliferation of cultured synovial cells and the 
synthesis of collagen by the fibroblasts in culture are altered in the 
presence of sodium aurothiomalate. Dose dependent inhibition of cell growth 
and type III collagen synthesis was produced by the gold compound but not 
by sodium thiomalate. Synovial proliferation and pannus growth are damaging
features to joints in rheumatoid arthritis as infiltration of cartilage 
occurs and mobility becomes impaired and painful. Restriction of synovial 
cell metabolism and invasive proliferation would therefore provide relief 
from the disease.
Table 1.5 EFFECT OF GOLD UPON ENZYMES
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Some of the evidence -which demonstrates that gold will affect many 
parameters of immune and inflammatory responses has been listed. Other 
actions of gold have been earlier referred e.g. inhibition of protein 
denaturation and there is continued speculation that involvement with 
additional metabolic processes may occur thus widening even further the 
sphere of operation of this anti-rheumatic drug.
It is however important to note that most of the actions of gold described 
have been demonstrated only in in V'itro systems or in artificially induced 
models of inflammation and the relevance and relative importance of each of 
these observations.to the in VVOO disease is very much uncertain. However 
in these experimental systems the effects (when tested) were shown to be 
dose-dependent and to be caused by the gold and not by thiomalate. A 
schematic representation of the possible actions of gold in rheumatoid 
arthritis is shown in Fig. 1.4 which brings together theories of the 
aetiology of the disease, the immune mechanisms and the pathological 
lesions i.e. the gross, chronic, inflammatory response.
1.6 AIMS AND OBJECTIVES
The incidence of gold toxicity together with those patients who fail to 
show a therapeutic response presents a vexing problem during chrysotherapy. 
The work reported in subsequent chapters describes investigations carried 
out to examine features which were considered to be of possible importance 
in patient response to chrysotherapy. These features included the 
concentrations of gold in body fluids and tissues, the role of the carrier 
molecule (thiomalate) upon uptake, disposition and elimination of gold and 
trace-metal interrelationships and possible mechanisms of gold toxicity.
1. A spectrum of clinical response, related to rates of absorption, 
metabolism, excretion etc. is not uncommon in pharmacology. 
Consequently the importance of regular measurements of biologically 
active compounds, e.g. lithium, or some closely related metabolite, 
is well recognised and therapeutic drug monitoring is now standard 
practice. Clinical investigations were therefore planned to determine 
whether regular measurements of the gold concentrations in body fluids 
would assist in the management of chrysotherapy for rheumatoid 
arthritis.
2. Passage of the injected drug from the site of injection to the site 
of action has not been thoroughly elucidated. Relevance of the 
thiomalate (or other carrier) moiety and the tissue or plasma 
concentration of thiol-containing compounds upon reactivity, rate 
of transfer etc. are unknown. Experiments to determine movement of 
gold and thiomalate in experimental animals were conducted and the 
concentration of gold in major organs measured in gold treated animals 
and in patients receiving chrysotherapy.
3. Essential metals, particularly copper, are important in the aetiology 
of rheumatoid arthritis (Fig. 1.2) and chrysotherapy provokes changes 
in serum metal concentrations. As fluctuations in trace metal 
dispositions are associated with the toxicity of other metals the 
effect of chrysotherapy upon the metal content of tissues and body 
fluids of experimental animals was assessed.
C H A P T E R  T W O
SODIUM AURQTHIOMALATE AND 
CLINICAL STUDIES
2.1 INTRODUCTION
2„lol Routine Monitoring of Blood and Urine Gold Concentrations 
During Chrysotherapy
The extended background to the development of chrysotherapy as an 
acknowledged treatment for tuberculosis, rheumatoid arthritis and 
later for other conditions was discussed in the previous chapter. 
Phases such as the introduction of different gold drugs, evolution 
of therapeutic regimes, conduct of organised trials each extended 
over many years.
Because of this background of more than fifty years’ use, rhe quanti­
tative and qualitative incidence of therapeutic failure has become 
assimilated into the tradition of chrysotherapy and is accepted almost 
as an inevitable feature of treatment by gold. Teaching practices 
devote as much time to the recognition of, and response to, toxic 
manifestations as is given to the methods of assessment of effects 
upon the actual disease. Furthermore, the incidence of toxicity means 
that chrysotherapy is accepted almost as a treatment of last resort 
when all else has failed. Patients in whom gold fails to elicit any 
beneficial response are left with little alternative other than power­
ful analgesics.
The overall effect is that for these different reasons between one- 
fifth and one-third of patients whose condition is deemed appropriate 
for chrysotherapy are eventually denied the considerable therapeutic 
benefit which may be derived from treatment with gold.
The gross manifestations of toxicity, dermatitis, proteinuria, throm­
bocytopenia etc. are well recognised and v/ere described in the first 
chapter. However, what causes some patients to react to gold in a 
particular way that is not seen in others is not at all understood. 
Similarly the lack of clinical response to gold cannot be explained 
when it appears that other patients in whom the disease (as judged by 
clinical examination, radiological assessment and laboratory investi­
gations) is very similar, demonstrate dramatic improvement in their 
besetting condition.
This was the problem that obtained for many years in the field of 
chrysotherapy for rheumatoid arthritis and was addressed first by
Smith et at. (101) then subsequently by a few others but in particular 
Jsy'JLorber. The hypothesis proposed in these early investigations was 
that the serum total gold concentration was fundamental to the response 
obtained. Toxicity would be associated with high serum gold concen­
trations while a lack of response would be found when low serum gold 
concentrations were achieved. Central to this concept was the assumpt­
ion that given a standard administration of gold it is the rate of
urinary excretion which has the major influence upon the concentration
/ of gold in the serum. It was suggested therefore that the difference \/1'
■ X ,
| between patients which was responsible for the variation in response
\ Cf(.
\during chrysotherapy was the renal handling of gold. ^ , <'■
' - L'u Ct.
To differentiate between the patients who might demonstrate toxicity,
might not respond or might benefit from chrysotherapy, Smith et at. 
proposed that urinary gold excretion in samples collected over twenty- 
four hours, on seven successive days, should be monitored in order to 
select the hypo-, hyper- and norrao-excretors of gold. (101) However, 
the collection of twenty-four hour urine samples is notoriously 
difficult and to anticipate many patients properly doing so for 
extended periods is extremely optimistic. At the same time, the 
problems of accurate analysis for low concentrations of gold meant 
that adoption of the proposals of Smith et at. by any other than a 
limited number of specialist centres v/as not practically possible.
A somewhat more sophisticated procedure v/as advocated twelve years 
later by Kralik. (127) Because of the improvements in analytical 
techniques it became possible to measure gold relatively simply in 
serum and in urine. Kralik proposed that the ratio, concentration of 
gold in urine/concentration of gold in serum, would provide a valuable 
indicator for the prediction of complications in chrysotherapy. He 
suggested that a low ratio (less than 1.0) was indicative of hypo- 
excretion and an accumulation of gold in the serum. Where patients 
were found to have a ratio of less than 1.0 he advocated appropriate 
modification to the course of treatment. At about the same time Lorber 
first suggested adjustment of treatment in order to maintain the gold 
concentration above a certain (unspecified) level and thereby attain a 
therapeutic response. (128)
Of these original reports it was only that of Smith et at, which 
included results of continual observations on patients receiving 
adjusted-dose therapy (101) but for the reasons discussed above this 
type of work was never followed up or repeated elsewhere. With the 
development of atomic absorption spectrophotometry as a reliable 
analytical procedure for accurately measuring gold, and with the 
suggestion by Lorber that measurements of serum gold concentrations 
could also be of value in the management of rheumatoid arthritis 
patients treated with chrysotherapy, it was decided to carry out a 
study to assess the value of undertaking routine determinations of 
blood and urine gold concentrations.
2.1.2 Maintenance Chrysotherapy in Rheumatoid Arthritis
The conventional regime for the administration of gold salts is to 
give weekly injections of 50 mg sodium aurothiomalate (25 rag gold), or 
a similar dose of aurotliioglucose, until a total dose of 1.0 g (500 mg 
gold) has been provided. Thereafter the patient is transferred to 
maintenance therapy and the interval between injections is increased, 
usually to four weeks or a little longer. (129) This regime is still 
widely used by many rheumatologists but there are those for whom the 
concept of a 1.0 g initial course is a little too inflexible and who 
prefer at times to adopt either a gentler or a more aggressive approach 
depending upon the response by the patient. (41)
Similarly the management of the maintenance period has been questioned 
and reconsidered with conflicting results obtained from a wide range 
of different schedules. Although there is a well-recognised time-lag 
between treatment and response - both at commencement and termination 
of chrysotherapy, the results reported by Cats would suggest that 
maintenance therapy is unnecessary. (130) From the results of this 
study it was inferred that remission is maintained for at least a year 
after the loading dose of 1.0 g has been received. While this conclusion 
is consistent with the findings of the Empire Rheumatism Council (ERC) 
trial (36) , the author apparently overlooks the observations in the final 
ERC report where,virtually all the advantages accrued from gold treatment 
had been lost at the end of two years. (37) While a number of studies 
have been conducted where a more active course of therapy has been applied 
(41,81,85,131,132) few have actually been designed or have presented their 
results in such a way as to allow comparison with the standard, four­
weekly regime.
Of those where such a comparison is possible completely contradictory 
results were obtained. Thus Mascarenhas et at. grouped patients into 
those with substantial therapeutic response, those who improved but 
also developed toxic manifestations and those without therapeutic 
response. (80) Within each group there were a similar number of 
subjects on weekly, bi-weekly and 4-weekly maintenance therapy and an 
appropriate range of plasma gold concentrations.
On the other hand, Lorber et at. who specifically modulated maintenance 
therapy in order to keep serum gold concentrations in excess of 15.2 
ymol/Jl (300 ]ig/100 ml) claimed not to have an increased incidence of 
adverse reactions coupled with significant clinical benefits recorded 
in those patients comjpared with the control ga/oup receiving the 
conventional dosage schedule. (85)
Because these studies produced such disparate results and. recommend- ^ 
ations it was considered appropriate to critically compare maintenance / 
dose schedules. A study was therefore undertaken to determine the
response to gold in patients given injections at two-weekly intervals j
and at four-weekly intervals with particular attention given to !
progression of the disease, the incidence of toxicity and the relation­
ship of serum gold concentrations to relapse and side-effects. !
2.1.3 Tissue Gold Levels After Chrysotherapy
From the work in animals given soluble gold salts, it is apparent that 
following injection the gold is rapidly dispersed throughout all the 
body. (92,95-97) Certain tissues however accumulate gold to greater 
concentrations than others and this particularly applies to the kidney 
cortex, the liver, spleen and possibly the adrenal gland. Disposition 
of gold has been followed at various time intervals up to twenty-four 
weeks after injection but in most cases animals have been examined after 
just a few days.
Progressive loss of gold from all tissues occurs with time and at the 
completion of the prolonged (24 week) study only about 1% remained 
compared v/ith the amount present at tv/o weeks. (9 7) The exception to 
this v/as the gold content in the lymph glands v/hich was 20% of the 
earlier level.
The data available from human tissues is far less extensive, only the 
report from Gottlieb et at. attempted to provide a picture of the 
total body distribution. (98) This however referred to just one 
patient and contained certain analytical anomalies which were discussed 
in the preceding chapter. In this report the lowest concentrations of 
gold were found in the tissues of the skeleto-muscular system - bone, 
synovium, muscle and cartilage.
From patients undergoing surgery it is possible to obtain and take for 
analysis, samples of tissue which are exposed or excised during the 
operative procedure. While this will not necessarily provide data for 
a wide range of tissues, the opportunity is presented to assemble 
relevant data from a reasonable number of patients.
It was felt important to know something more of the gold content of 
articular tissue in order to help appraise the role of gold salts in 
the treatment of rheumatoid arthritis. The animal studies are not 
informative on this aspect and the data of Gottlieb et at. (98) remain 
somewhat unreliable. Therefore in a series of rheumatoid arthritis 
patients for whom surgical hip joint replacement was provided as part 
of the management of their condition, samples of bone, synovium, 
striated muscle and fat were analysed for the gold concentrations.
2.1.4 Additional Studies
Opportunities arose during the course of this work to examine briefly 
two other problems associated with chrysotherapy:
1. Possible foetotoxicity of gold therapy during pregnancy.
2. Application of laboratory investigations to the treatment of gold- 
induced thrombocytopenia.
Possible Foetotoxicity of Gold
Teratogenic effects have been demonstrated experimentally following 
exposure to very large concentrations of gold. (133) Little data are 
available concerning the effects in man of gold administered thera- 
peutically during pregnancy. Two cases relevant to this question 
required the measurement of gold in body tissues and fluids thus adding 
to the available information.
Laboratory Investigations in Gold-Induced Thrombocytopenia
| Cases of marrow aplasia manifesting as a thrombocytopenia are a rare j 
I complication of chrysotherapy but while aplasia is uncommon, mortality | ^
occurs with a probable incidence of at least 50% in such cases. (106) '
; \
In a statistical study of drug associated deaths compared with the 
number of prescriptions written, fatal gold-induced thrombocytopenia 
was cited as having the greatest frequency of occurrence. (110)
To reverse the thrombocytopenia, the use of chelating agents or 
peritoneal dialysis have been advocated in order to remove the offending 
gold. However, the elimination of gold may (134) or may not (135) be 
effective. Similarly a place for marrow transplantation has been 
considered but has not been successfully demonstrated. (136) The 
severity and danger of thrombocytopenia therefore makes not only careful 
supervision mandatory for all patients treated with gold but also requires 
continued investigation of methods which might improve understanding of 
this toxic response and allow more effective treatment.
Two cases of ladies who developed refractory thrombocytopenia after 
receiving short courses of gold provided for the monitoring of serum 
and urine gold concentrations, and other parameters throughout the 
period of chelation therapy.
2.2 CLINICAL M ETHODS
2.2.1 Introduction f . .
The clinical studies were carried out in association with the Depart­
ment of Rheumatology, G u y ’s Hospital, Norfolk and Norwich Hospital,
St. Richard’s Hospital, Chichester, The Poisons Unit, New Cross 
Hospital and the United States Air Force Hospital, Lakenheath, (USAFE), 
Suffolk. The staff at these centres contributed considerably to these 
studies in the organisation and management of the clinical programmes, 
evaluation of patients’ progress and collation of data from various 
sources.
2.2.2 Routine Monitoring of Blood and Urine Gold Concentrations 
During Chrysotherapy
The study was designed to determine which, if any of a variety of 
clinical and laboratory parameters, including gold levels, were associated
with a favourable response to chrysotherapy. Patients included in the 
study were grouped into two separate categories:
1. Retrospective Group.
All patients (total number = 86) who attended the G u y ’s Hospital 
Department of Rheumatology Gold Clinic during a period of one and a 
half years were included in this study. Fortj/ patients were also 
included in a separate study which examined the incidence of skin 
reactions and their association with serum gold concentrations.
2. Prospective Group.
New patients to the Clinic (total number = 2 2 ) , who had never 
previously been treated with gold, were followed throughout the initial 
one gram course with sodium aurothiomalate.
As each patient entered the studies the following information was 
obtained: age, sex, duration of disease and the presence or absence 
of: nodules, erosions on X-ray examination and rheumatoid factor in 
serum.
At each visit to the clinic the patient v/as examined by the physician 
and samples of blood and urine (random sample of mid-stream urine) were 
collected. Gold injections were given at the clinic after blood and 
urine samples had been taken. .
Treatment of Samples:- ■
Two samples of blood were collected - anticoagulated (using dipotassium 
ethylene-diametetra-acetic acid) and clotted blood. The clotted blood 
samples were centrifuged and the serum transferred to a clean tube.
Analysis:-
Yftiole blood. The following haematological parameters were measured 
red cell count, white cell count, haemoglobin, mean corpuscular volume, 
mean corpuscular haemoglobin, mean corpuscular haematocrit, platelet 
count and erythrocyte sedimentation rate.
■
Serum. The gold concentration was measured. t
Urine. Qualitative analysis for protein, glucose, ketones, bilirubin, 
blood and pH. Quantitative determination of gold and creatinine.
At the end of the one-gram course, patients in the Prospective group 
were graded according to their clinical response as - much worse, 
worse, unchanged, improved, much improved.
2.2.3 Maintenance Chrysotherapy in Rheumatoid Arthritis
This study was designed to compare the response to maintenance gold 
injections given at two-week intervals and at four-week intervals by 
monitoring progress of the disease and incidence of toxicity and to 
examine the relationship between response and serum gold concentrations.
Stage 1. Patients receiving their first course of chrysotherapy were 
admitted to the preliminary phase of the study which consisted of a 
test dose of 10 rag sodium aurothiomalate followed by weeklj^ injections 
of 50 mg to a total of one gram. Non-steroidal, anti-inflammatory 
agents were continued throughout the study and alterations, other than 
reduction of dose on remission, were avoided v/hen possible.
At the commencement of the study, patients were randomly allocated to 
proceed during stage 2 to either the 2-week or 4~week maintenance 
schedule. Each group was matched for age, sex and X-ray score.
Stage 2. Those patients who had shown definite clinical improvement 
by the third month of stage 1, and had developed no evidence of gold 
toxicity, progressed to the second stage of the study which then 
continued for a further twelve months.
Patients were examined after 3, 4 and 5 months of weekly gold injections 
(Stage 1.) and at three-monthly intervals during maintenance therapy i.e. 
at 8, 11, 14 and 17 months from the commencement of the study. Observa­
tions made at each examination were:-
duration of morning stiffness, joint tenderness, grip strength 
and proximal interphalanged joint circumference. X-ray 
examination for erosions in the hands and feet were made at 
5, 11 and 17 months.
Blood samples were collected at each assessment point. Haemoglobin 
and ESR were measured on whole blood while serum samples were analysed - 
for sheep cell agglutination titre and gold concentration.
2.2.4 Tissue Gold Levels After Chrysotherapy
Sixteen patients with rheumatoid arthritis who had previously received 
gold injections were included in this study. The subjects were under­
going surgical replacement of the hip-joint to relieve pain and 
improve mobility. During the course of the operation tissue samples 
were removed into clean plastic containers. The full list of tissues 
taken from the patients v/as:- bone (acetabulum), skeletal muscle, 
synovium, fat, skin, joint capsule, bone marrow and tendon. Specimens 
of all these tissues were not obtained from every patient.
2.2.5 Additional Studies 
Possible Foetotoxicity of Gold
Case 1. A 28 year old woman received four injections of gold, for 
the treatment of psoriatic arthropathy, during the first part of her 
second pregnancy. Spontaneous onset of labour occurred at 36 weeks 
and a baby boy (weighing 2160 g) was delivered by elective Caesarian 
Section because the mother had had a previous section. There were no 
other complications and the infant’s condition at birth v/as good without 
inquiring resuscitation.
Case 2. A woman in whom rheumatoid arthritis had been diagnosed when 
she was aged 17 years, commenced gold therapy tv/o years later and 
was receiving 100 mg sodium aurothiomalate monthly. At the age of 21 
she became pregnant but against the advice of her clinician decided to 
continue with the chrysotherapy throughout the pregnancy. The last 
injection of gold given while she was pregnant v/as at three days prior 
to delivery.
Laboratory Investigations in Gold-Induced Thrombocytopenia
Case 1. A lady (EA) aged 60 years had rheumatoid arthritis diagnosed 
three years previously and was treated with analgesics. Chrysotherapy 
was considered suitable and was commenced in April 1979. After three 
months, by which time she had received 670 mg sodium aurothiomalate she 
suddenly developed a widespread petechial rash, a burning feeling in 
hands and feet, haematuria and her urine contained traces of protein. 
Gold treatment was stopped and she was admitted to hospital where gold 
toxicity v/as considered. Haematological examinations of the blood and 
bone marrow confirmed a thrombocytopenia and absence of marrow mega-
Case 2. A 49 year old lady (J.G.) had an eighteen month history of 
rheumatoid arthritis. She was originally treated with physiotherapy 
and Ibuprofen but at the assessment one year after diagnosis, radio­
logical deterioration of the disease was apparent and it v/as decided 
to institute chrysotherapy. An improvement in her condition was noted 
but after two months she complained of blisters on her hands. This 
was thought not to be associated with gold but a reduced dose was 
prescribed. One month later however she required admission to 
hospital for treatment of a generalised rash., pruritis and mouth ulcers, 
diagnosed as probably gold induced. A thrombocytopenia was discovered 
when investigated on admission.
2.3 ANALYTICAL METHODS
2.3.1 Gold
The concentrations of gold in serum, 'urine and tissue samples were 
determined by atomic absorption spectrophotometry. Two atomic 
absorption spectrophotometers were used for the measurement of gold.
The instrumental conditions used are shown in Table 2.1. Hollow cathode 
lamps obtained from S. & J. Juniper, Harlow, were used in both instru­
ments. A stoichiometric, air/acetylene flame was appropriate for the 
gold determinations.
Table 2.1 Instrumental Operating Conditions Used For The Analysis 
of Gold By Atomic Absorption Spectroscopy
Perkin Elmer" Instrumentation Laboratories 
Model 303 Model 353
Lamp current (mA) 10 7
Wavelength (nm) 242.8 242.8
Slit width 7 A 320 ym
Photomultiplier
Voltage (V) - 530
Scale expansion - serum x3 x2.5
- urine x3 x2.5
- tissues xl xl
Serum
A modification of the method described by Lorber et at. was used. (128) 
The technique of internal standardisation was adopted to calculate the 
concentration of gold and a detergent solution was added to the serum 
in order to reduce viscosity and facilitate sample aspiration through 
the nebuliser and preraix chamber. Methodological details are:~
Reagents: Stock gold chloride standard, Img Au/ml. The atomic
absorption standard solution from BDH Chemicals Ltd. 
was obtained.
Working gold standard 5 yg/ml. 0,5 ml of the stock gold 
solution was diluted to 100 ml with distilled water.
Triton X-100, 5% v/v. 25 ral Triton X-100 (Sigma Chemicals 
Limited) was added to 200 ml distilled water. The mixture 
was warmed to effect solution and the volume made up to 
500 ml with distilled water.
Two tubes (A and B) were set up for each specimen.
Tube A Tube B 
Serum 1.0 ml 1.0 ml
Working gold standard ~ 0.5 ml
Distilled water 0.5 ml -
5% Triton X-100 0.5 ml 0.5 ml
The contents of each tube were thoroughly mixed, the solutions aspirated 
in turn into the atomic absorption spectrophotometer and the absorbance 
noted.
Calculation of concentration of gold, ymol/£ - 250 x A x  10 where
(B - A) x 197
A = absorbance for Tube A 
B = absorbance for Tube B
Urine '
J
The internal standardisation procedure used for serum was modified to 
determine gold "in urine. Addition of the detergent solution to reduce 
viscosity was not necessary but because of the lower concentration of 
gold within the urine, a greater sample to diluent ratio was provided. -
Two tubes (A and B) were set up for each specimen.
Tube A Tube B
Urine 1.5 ml 1.5 ml
Working gold standard 
Distilled water 0.5 ml
0.5 ml
The contents of each tube were thoroughly mixed, the solutions aspirated
in turn into the atomic absorption spectrophotometer and the absorbance
noted.
Calculation of concentration of gold, ]irnol/£ - 4 x 125 x A x 10
~  ~  _ __ whe:
3 x (B - A) x 197
A = absorbance for Tube A
B = absorbance for Tube B
To ensure that reliable, accurate results were obtained, an internal 
quality control (QC) programme was devised for this laboratory and an 
external quality assessment (QA) scheme was established with the 
participation of six other laboratories.
Internal quality control : 500 ml donor horse serum was obtained from 
SeraLab Limited. 200 ml were dispensed into two clean 250 ml volumetric 
flasks and an appropriate volume of diluted gold standard solution added
to give concentrations of 7.6 ymol/J& (150 yg/100 ml) and 17.8 ymol/£
(350 yg/103 nil). The volumes were made up to 250 ml, dispensed into
o ‘ -] „ f -
clean, glass 5 ml tubes and stored at -20 C. /
Whenever clinical specimens were analysed, one each of the two internal 
QC samples were allowed to thaw, were mixed and also analysed for the 
concentrations of gold. Results were reported only if the values 
obtained on the internal QC samples fell within specified ranges (± 7.5% 
at 7.6 ]imol/& and ±5.0% at 17.8 ymol/&).
External quality assessment: Samples were similarly prepared from donor
horse serum but with a wider range of gold concentrations. Each month,
<■«
three samples were sent to the participating laboratories and their 
results returned to the organising centre (University of Surrey). From 
this data the mean, standard deviation and coefficient of variation were 
calculated. Although the number of participants „was small making the 
calculated mean somewhat suspect this programme aids rapid detection and
/
quality assessment scheme for gold formed part of a larger prograir 
which included the analysis of copper, zinc and aluminium in serum
rectification of ^curacy of analysis. (This
cadmium and lead in blood and cadmium and mercury in urine.)
Tissue Samples
Two sample preparation procedures were used during the period that this 
work was in progress. The samples obtained from the study reported in 
section 2.4.3 were subjected to ashing in a muffle furnace while the 
later samples, section 2.4.4, were treated with strong oxidising acids.
/'
Dry ashing; Tissue samples weighing about p.5 g were added into tared v
v_
silica crucibles and -accurate^ weighed. To obtain representative 
specimens, small tissue snips from several sites within the material 
removed at operation were taken to give the total weight of about 0.5 g. 
Segments of bone were obtained by sectioning the acetabulum in the 
longitudinal plane to expose the spongy interior tissue. Small sections 
were removed from across the face of the cut surface and from the outer 
edges, thus providing samples from several areas of the bone. Duplicate 
samples were taken from all specimens.
The crucibles containing the tissue samples were placed inside a cold 
muffle furnace and then heated to 450-500°C for at least 16 hours. The 
heat was turned off and the furnace allowed to cool to enable remova.1 of 
the crucibles. A white powdery ash remained although with bone some of 
the original architecture of the inorganic matrix could still be seen. 
These residues, including that of the bone, were readily dissolved in
1.0 ml of 0.1 M nitric acid.
Standard gold solutions: The stock standard solution was diluted 1,0 ml
to 100 ml with 0.1 M nitric acid to provide a gold solution of 10 yg/ml.
A further series of dilutions were made to give standard gold solutions j 
of 1.0, 2.5, 5.0 and 7.5 yg/ml. j
The standard and sample solutions were sequentially aspirated into the 
atomic absorption spectrophotometer and the absorbances noted.
Standard curves v/ere constructed from the readings and the concentrations 
of gold in the sample solutions determined. The amount of gold in the
where x = tissue gold concentration in yg/g wet weight
c = concentration of gold in sample solution in yg/ml 
w = weight of tissue sample taken for analysis in grams.
Acid digestion. Tissue samples weighing 0.5 to 1.0 gram were transferred 
to tared, acid-washed, 100 ml conical flasks and accurately weighed. As 
for dry ashing, small pieces of tissue were taken from various sites to 
obtain representative specimens. Duplicate samples were weighed out for 
all specimens.
Concentrated nitric acid (5.0 ml) and 60% perchloric acid (1.0 ml) were
added to the samples using automatic dispensers (all acids were Analar
Grade). The flasks were maintained at room temperature for at least 30
minutes to allow any initial reaction and frothing to subside and v/ere
then transferred to a hot plate placed within a wash-down fume cupboard.
The surface temperature of the hot plate v/as set to 100°C and the flasks
gently heated for about one hour. After all the tissue samples had
o
dissolved the temperature was gradually increased to about 150 C.
Excessive heating was avoided to prevent the nitric acid from boiling 
away before oxidation of the organic material was complete. If any of 
the solutions darkened, the flasks were removed and left to cool, a further
5.0 ml concentrated nitric acid added, and then returned to the hot plate. 
When a pale yellow or colourless solution was obtained the temperature v/as 
increased to heat the sample to dryness. The flasks were then removed from 
the hox plate and left to cool. Two reagent blank flasks were prepared with 
each batch of samples and carried through the entire digestion and analyti­
cal procedures. "
The inorganic residues were redissolved by the addition of 1.0 ml aqua 
regia (conc. nitric a.cid: cone, hydrochloric acid; 1:1) and very gentle 
warming. Distilled water was then added to give a final volume of 5.0 ml.
Standard gold solutions. Gold solutions of 1.0, to 7.5 yg/ml v/ere prepared 
similarly to that previously described but to contain 20% v/v aqua regia.
The standard and sample solutions were aspirated into the atomic absorption 
spectrophotometer and the absorbances noted. Additional washing with water 
through the nebuliser was performed between samples to avoid possible 
damage due to the high acid concentration of these solutions. Potential
difficulties associated with the viscosity of concentrated acids were 
not apparent and sample flow through the nebuliser remained satisfactory.
The concentrations of gold in the sample solutions were determined by 
reference to a calibration curve prepared from the readings obtained 
from the standard solutions and the gold content of the samples of 
tissue calculated from the formula.
c x 5 
w
tissue gold concentration in Ug/'g wet weight 
concentration of gold in the sample in yg/ml 
weight of the tissue sample taken for analysis in grams.
2.3.2 Urine Tests
Urine screening tests were performed during attendances at the 
Rheumatology clinics and the commercially available test strips (Ames) 
were used to monitor pH, protein, glucose, ketones, bilirubin and blood.
2.3.3 Haematology
The routine haematological investigations - haemoglobin, red cell count, 
white cell count, mean corpuscular volume, mean corpuscular haemoglobin, 
mean corpuscular haematocrit were determined by the standard laboratory 
method using a Coulter Counter. The platelet counts were similarly . 
measured in the counter and the erythrocyte sedimentation rate was 
determined according to the Westergren procedure. (137)
• * /.
2.3.4 Rheumatoid Factor r v-!
The titre of rheumatoid factor was measured at Guj^’s Hospital by the 
sheep cell agglutination test in serum samples at dilutions of J/i6 to 
1/io2.k, Agglutination was assessed visually.
2.3.5 Clinical Parameters
Quantitative clinical measurements incorporated in these studies included 
an articular index for the assessment of joint tenderness and a score of 
the erosions present in bone.
The index of joint tenderness used was that devised by Ritchie et a l . (138)
The response by the patient to firm pressure exerted over the articular 
margin or to movement of the joint, was observed. Where there was no
x =
where x - 
c ~
w =
tenderness a score of 0 was recorded. A complaint of pain scored +1, 
pain plus wincing scored +2 and pain, wincing and withdrawing counted 
+3. The cumulative scores from all joints examined gave the overall 
articular index. Ritchie et at. demonstrated that the interindividual 
variation in results was quite wide but that one observer could reliably 
obtain consistent results. (138) Therefore all clinical assessments in 
any one study were carried out by the same person.
To monitor the changes in disease activity affecting the bones the 
erosions observed on radiological examination of the hands and feet 
v/ere counted. (139)
2.4 RESULTS AND DISCUSSION
2.4.1 Routine Monitoring of Blood and Urine Gold Concentrations 
During Chrysotherapy
Retrospective Study
Eighty-six patients with rheumatoid arthritis v/ere included in the 
retrospective study. In 74 of these subjects, samples of both serum 
and urine v/ere collected during the same visit to the clinic, on at 
least 5 separate occasions (Table 2.2). The correlation between serum 
and urine gold concentrations frora these temporally matched samples v/as 
statistically significant in 28 (38%) of the cases. When additional data 
were available, a stronger correlation was evident. Thus for 39 of the
patients, ten or more pairs of data were available and significant 
correlations were found in 26 (67%) of thev sets of results. This strik­
ing degree of correlation found in a number of patients is illustrated 
in Fig. 2.1.
Table 2.2 Correlation Between Serum and Urine Gold Concentrations in
Retrospective Study
Total number of patients 86
Number with at least 5 pairs of serum and urine results 74
Number v/ith significant correlation (p<0.05) between 
pairs of results 28 (38%)
Number with at least 10 pairs of serum and urine results 39
Number v/ith significant correlation (p<0.05) between 
pairs of results 26 (67%)
F i g . 2.1 Serum and urinary gold concentrations measured at regular
intervals in a patient receiving sodium aurothiomalate at the 
doses shown and demonstrating the correlation between serum 
and urine gold levels.
Gold inject­
ions (mg)
50 *,
 JL-JLL1
Serum gold 
(ymol/£)
20.
13
Urine gold 
(ymo1/mmol 
creatinine)
0-4'
0-2
3  6  9  1 2
MONTHS
Prospective Study
In this part of the study 22 patients were followed throughout the 
initial one gram course of chrysotherapy. At the completion of the 
course, the clinicians' and the patients' assessment of response was 
used to subdivide the group. No patients suffered a set-back or 
deterioration in condition. Seven had shown no response and v/ere 
unchanged, seven were considered to have improved and eight were 
thought to have benefited markedly.
The mean gold concentrations, for serum and urine, were calculated 
from all the results obtained from all the patients within a particular 
response group. There were no significant differences in either the 
serum or the urine gold concentrations between any of the groups (Table 
2.3) .
Table 2.3 Gold Concentrations in Serum and Urine Samples from 
Patients Demonstrating Different Responses to Gold
Response Group
Number of 
Patients
Serum (ymol/&)
Gold
Urine ]imol/mmol 
Creatinine
Unchanged 7 6.70 ± 3.20 2.49 ± 1.07
Improved 7 10.46 ± 2.59 3.03 ± 0.96
Much Improved 8 7.21 ± 3.30 2.79 ± 1.03
Values are reported as mean ± standard deviation.
Data is from prospective group in the investigation of routine monitor­
ing of blood and urine gold concentrations during chrysotherapy. The 
patients had never previously been treated with gold and were followed 
throughout the initial one gram course with sodium aurothiomalate. 
Samples were collected at the weekly visit to the Rheumatology Clinic 
before the injection of gold.
The correlation between pairs of serum and urine results v/as examined 
as in the retrospective study. In those patients who responded to gold 
and whose condition v/as improved the correlation was greater than in 
those in whom chrysotherapy was ineffective (Fig. 2.2). This difference 
however was not statistically significant.
Fig. 2.2 Significance of correlations between serum and urine gold 
levels (as shown in Fig. 2.1) versus clinical response to 
chrysotherapy in patients included in prospective study.
5
No. of 
patients
Condition:
a b e d
unchanged
% with signi- 
cant correlation 
between serum 
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Aft w.v•A*?;*
ftft
Aft
a b e d
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'•V.
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a b e d
much
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75
a = not significant 
b = p < 0 .05
c = p<0.01
d = p<0.001
Examination of the clinical parameters recorded on the patients accord­
ing to their therapeutic response, is shown in Table 2.4. There v/as 
no difference in sex distribution, duration of the disease, pretreatment 
levels of ESR or rheumatoid factor and the pretreatment presence of 
erosions, between the three clinical response groups. There was a 
trend, which was not statistically significant, towards a less favourable 
response with, increasing age. However, the presence of nodules was 
significantly correlated v/ith failure to respond to chrysotherapy.
In those patients who showed excellent response to gold, the signs of 
improvement v/ere apparent earlier (i.e. after a lower total dose) than 
was found in patients whose response was less marked. Improvement was 
noted in the first grpup after a mean dose of 252 ± SD 145 mg compared 
v/ith 493 ± SD 184 mg in the second group. This difference was 
statistically significant (p<0.025).
Of the 40 patients examined for the incidence of dei’matological side- 
effects, 14 (35%) developed rashes (eczematous-8; maculo-papular-3; 
lichenoid-2; pityriasiform-1) accompanied by either local or generalised 
pruritis. The mean serum gold concentration was not significantly , /
different from that of the full group. The rashes lasted from three 
weeks to one year. No cases of bone-marrow depression developed in any 
of these patients.
The rationale for the routine monitoring of serum and/or urine gold 
concentrations during chrysotherapy would/be that the results may help 
to improve the efficacy of treatment and diminish the incidence of side- 
effects. This argument presupposes that:
(a) a favourable response requires a certain gold concentration in 
the serum,
(b) toxicity is a consequence of increased gold concentration in 
the serum, and
(c) an increased urinary excretion of gold causes a reduction in
the serum gold concentration (see Fig. 2.3a). i/
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Fig. 2.3 Proposed relationships between urinary excretion of gold 
and serum gold concentration.
(a) Serum concentration inversely proportional to urine excretion. 
Smith et at. (101).
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(b) Urine excretion proportional to serum concentration.
Serum Urine Serum Urine Serum Urine
This is the hypothesis which was first elaborated by Smith et al. (101) 
and later reintroduced by Kralik (127) and Lorber et al. (128). The 
number of patients actively followed throughout a period of chrysotherapy 
to verify these suppositions were very few. Isolated reports of cases 
which were inconsistent with the hypothesis also appeared however. Thus 
Jessop described two patients who developed blood dyscrasias but whose 
mean serum gold concentrations (at one week post-injection) were no higher 
than those measured in the other eleven members of the group. (140) Jones 
et al. measured urinary excretion in 48 patients receiving chrysotherapy I
i
and found only one who had a urinary gold excretion which was considerably \
i.
in excess of the others and none who had particularly low rates of j
excretion. (100) These results do not correlate with the incidence of /
• 7
failure to respond or-of toxicity reported in large trials.
On the other hand two reports (78,79) suggested that the hypothesis may 
not be entirely inappropriate. Krusius et al. found that patients who 
eventually developed signs of toxicity had higher levels in the serum 
and urine while those with a poor response to sodium aurothiomalate had 
lower gold concentrations in both fluids. (79) Serum and urine gold 
levels were positively correlated i.e. wex'e consistent with Fig. 2.3b 
but not with 2.3a. The samples were collected during the seven days 
following the injection which brought the total dose to 150 mg. They \ 
did not attempt to monitor levels on a regular basis. Jessop and Johns j
found no correlation between mean serum and urine gold concentrations in j
• j
patients who were being regularly monitored. However, they did find that5 
subjects who developed serious skin reactions (such that chrysotherapy J 
had to be stopped) had significantly higher serum gold concentrations. (78) 
At the same time there were no correlations between serum gold and other 
toxic side-effects.
\ '
The data reported here were obtained from the first study where a large \ 
series of patients were routinely monitored throughout prolonged (up to 
twelve months) periods of chrysotherapy with measurements of serum and 
urine gold concentrations in addition to the usual parameters of disease 
activity. The results obtained are not in accord with any of the tenets 
of the Smith-Kralik-Lorber hypothesis. Clinical improvement was seen to 
occur irrespective of the pre-injection levels of gold in serum. There 
were patients who did not benefit from chrysotherapy but whose serum gold j 
concentrations were in excess of levels in patients who improved markedly j
(Table 2.3). Furthermore there was no correlation between side-effects \ 
and the concentration of serum gold. The only iatrogenic effects found 
in these patients were in a small group who developed skin rashes. These 
subjects were not exceptional in having high gold levels. The long-term \ 
pattern of serum or urine concentrations, e.g. sudden or periodic 
fluctuations in level, also failed to reveal any distinction between 
patients responding in different ways to exposure to gold.
The positive correlation found between serum and urine concentrations of 
gold suggests that it is unlikely that urinary excretion influences the 
concentration of gold in serum (as represented in Fig. 2.3a) but that in 
a stable situation something approaching a constant proportion is 
transferred from the serum to the urine (Fig. 2.3b).
That the correlation between gold levels in serum and urine is stronger 
in the patients included in the retrospective study (most of whom were 
at the stage of maintenance therapy) is consistent with the results 
obtained during the prospective study. As is shown in Fig. 2.2 it is 
the patients who responded favourably to gold, and who would be expected 
to transfer on to maintenance therapy, who had the best correlation while 
patients in whom chrysotherapy was unsuccessful and would possibly cease 
gold treatment showed poor correlation.
The results reported here are consistent with the early reports of .
Jones et at. (100) and Jessop (140) and are also in agreement with most 
of the subsequent data which has examined "the relationship between serum 
gold concentrations and therapeutic response.(80,81,131,132,141) Only 
in somewhat unusual circumstances has there been any suggestion by these 
workers that a correlation between the body burden of gold, (but not the “ 
serum levels) and the response, might exist. With very high doses of
sodium aurothiomalate (two to four times the conventional amounts) ,
Rothermich et at. (131) were able to obtain improved clinical status in ■ 
patients previously resistant to gold while Furst et at. (132) found a 
fivefold increase in the incidence of severe side-effects among a high- 
dose group of patients. - P i
- hri'
The work of Lorber et at. (85,86,142,143), which followed from the 
earlier speculations of '(this author (128) , remains isolated therefore 
from the main stream of evidence referred to previously. He reports that
patients with higher serum gold concentrations are more likely to 
respond with favourable developments of their rheumatoid disease.
These patients were said to notice benefit earlier and for a more 
prolonged period and to experience greater changes in the parameters 
of disease activity. At the same time they suggested that there was 
no increased incidence of adverse reactions compared with the patients 
having lower serum gold levels although it should be noted that the 
total incidence, at 40-50% of patients, is higher than that found in 
most other trials.
The study reported here, also failed to reveal any other laboratory <^ 1?— " 
indices which could be used as alternatives to the serum or urine gold 
concentrations to predict patient response to chrysotherapy. The most / 
useful guides to a successful outcome were found to be the absence of ^
nodules and ea.3r.lier signs of gold having some effect. The physician j
therefore can rely upon very little external help when deciding which 
patients should be treated with gold, whether treatment could be 
improved by modifications to the course of therapy and if toxic side- 
effects will suddenly become evident.
Of the features of the Smith-Kralik-Lorber hypothesis, the proposal that 
it is urinary excretion which modulates serum levels of gold, cannot be 
accepted when the data included in Table 2.2 and in numerous other 
reports are presented. The concept of a therapeutic range for total 
serum gold concentrations during chrysotherapy is similarly opposed by 
the evidence shown in Table 2.3 and by all other workers with the 
exception of Lorber.
2.4.2 Maintenance Chrysotherapy in Rheumatoid Arthritis
At the start of the study to compare maintenance doses there were 58 
patients included but 14 were forced to withdraw before or soon after 
entering the second phase of the investigation (Table 2.5). The remain­
ing 44 were divided into the 2-week group (21 patients) and the 4-week 
group (23 patients). All completed at least six months of maintenance 
chrysotherapy but six were withdrawn before the end of the study because 
of toxic complications. Symptoms of less severe toxicity were experienced 
by a further 11 patients who were nonetheless able to continue with the 
treatment. The frequency of different toxic reactions is shown in Table 
2.6. Relapse in previously improved clinical conditions occurred in five 
patients between eight and eleven months of chrysotherapy.
Table 2.5 Clinical Outcome of Patients Involved in Maintenance
Chrysotherapy Study
Total
Dose frequency during 
maintenance therapy (weeks)
2 4
No. admitted to study 58 - -
No. proceeding to maintenance 
therapy 44 21 23
No. completing 6 months of 
maintenance therapy 44 21 23
No. completing 1 3^ ear of 
maintenance therapy 38 17 21
No. developing toxicity 15 10 5
No. of relapses 5 3 2
Table 2.6 Distribution and Frequency-of Side-Effects During 
M aintenance Chrysothera.py Study
Dose frequency during 
Toxic Reaction maintenance therapy (weeks)
2 4
Rash 6 4
Mouth Ulcer 3 1
Proteinuria 1 -
Total 10 5
Withdrawals 4 2
All patients had shown some improvement in general condition during 
the preliminary phase of weekly injections. The essential clinical 
details at this stage are summarised in Table 2.7 which shows that both 
treatment groups were matched. Clinical (morning stiffness, articular 
index, grip strength and proximal interphalanged joint circumference), 
laboratory (haemoglobin, ESR and gold) and X-ray measurements were also 
similar with no significant differences between the two groups (Tables 
2.8 and 2.9).
Table 2.7 Clinical Details of Patients Followed During One Year of 
Maintenance Chrysotherapy - Details at start of study
Group
No. of 
patients
Sex
M/F
Age
years
Disease
Duration
years
Rh.
Factor Nodules 
Present
2-week
injections 21 9/12 54 ± 10
/ . s'' I r. »C/
5.8 ± 5.0 11(52%) 7(33%)
4-week
injections 23 7/16 55 ± 12 7.0 ± 5.7 12(52%) 7(30%)
Values are reported as mean ± standard deviation.
Table 2.8 Clinical Measurements in Patients Followed During One Year of 
Maintenan.ce .Chrysotherapy - Details during maintenance period
Dosing
frequency
(weeks)
Maintenance Injection (Months)
12
Morning stiff­
ness (mins)
Articular index 
(score)
Grip strength 
sum of 2 hands 
(mm Hg)
PIP joint circum. 
(mm)
25 ± 55 41 ± 67 46 ± 78 35 ± 5 2
12 ± 18 17 ± 3 0  11 ± 20 20 ± 37
6.5 ± 7 . 3  6.6 ± 7 . 8  5.7 ± 7.7 6.1 ± 8.5
3.7 ± 3.5 3.5 ± 3 . 9  3.2 ± 3 , 5  3.2 ± 2 . 8
325 ± 136 ' 322 ± 139 324 ± 141 329 ± 151
292 ± 138 299 ± 135 307 ± 1 4 1  314 ± 140
595 ± 52 597 ± 53 593 ± 5 3  592 ± 55
571 ± 42 566 ± 42 577 ± 43 572 ± 45
PIP (proximal interphalangeal)
Values are reported as mean ± standard deviation
Patients received 50 mg sodium aurothiomalate 
at two or four-weekly intervals throughout the 
period of maintenance chrysotherapy
Ta
bl
e 
2.
9 
L
a
b
o
r
a
t
o
r
y
 
M
e
a
s
u
r
e
m
e
n
t
s
 
in
 
P
a
t
i
e
n
t
s
 
F
o
l
l
o
w
e
d
 
Du
ri
ng
 
On
e 
Ye
ar
 
of
 
M
a
i
n
t
e
n
a
n
c
e
 
C
h
r
y
s
o
t
h
e
r
a
p
y
 
De
ta
il
s 
at
 
st
ar
t 
of
 
s
t
u
d
y
p
d CO 05
•H 1 0 LO
o s o
•f-j 3  d +1 +1
O 0
ft d d CO
M *H 0 05 03
ft O <H to to
05 b-
.•3 COH r-i
f t  tuO.
•H d +1 +1
d 0
O  d b- r~f
P r—i a
W CO 05
d b* b*
d • •
0- CO
3 0
o *d +1 -fl
•h d
P  *H o
d * •
C l>
W
fcO 0 00 CO
d 0 -CO r-i
•H d
d lH +1 +1
d «H
O *H to 05
p 05 r-i
CO
b> O
>-> 0 CO 05
d d
d O +1 +1
1 o
M  ra .o 0505 rH
•o CO O
eH . •
O c>? (£>
b.0 \
+! +'.13 o
d £ 05 00
d p. . •
0 o
CO rd r-f
H - 05
d 05 05
PI ,d
CO \ -fl +1
W  S
n b- t, ■*
05 05
d
•H . b*
40 rH • •
o s H r-i
r-i
bO o +1 +1
o o
6 r-i CO
0 \ i •
d bfl CO 05
w i—! r-i
w
<H p
o d
0 r-i CO
* #rl OJ 05
O P
d
ft
W w
d d
o o
ft X  -ri 44 -H
3 0 P 0 P
O ' 0 O 0 o
d £ 0 £ 0
O 1 'r'5 1 ■r"3I d 1 d
05 -H
d
o
•rl
P
d
•H
>
0
TJ
n
d
T>
9
.p
W
+r
d
d
a
6
ca
d
'd
0
p
u
o
a
<y
o
d
d
W
a
3
rH
d
>
The clinical improvements noted during the period of weekly injections 
were generally sustained during maintenance chrysotherapy in both 
groups. Some parameters however did tend to regress a little as the 
inter-injection interval was lengthened. The duration of morning 
stiffness showed an increase towards the middle of the maintenance 
period which v/as exagerated in the two-week group but then improved 
again over the latter stage of the study (Fig. 2.4). The articular 
index of joint tenderness improved slowly but steadily in both groups 
(Fig. 2.4) as did the grip strength (Fig. 2.5). It might be expected 
that the effects of the disease upon the hands and fingers would 
influence both grip strength and joint swelling at the same time. This 
however, would appear not to be so, for while grip strength increased in 
both groups and the 2_-week group had a slightly better response than the 
4-week, the proximal interphalanged joint circumferences remained 
virtually unchanged throughout and were of similar size in both groups 
(Fig. 2.5). Therefore, grip strength and joint swelling must be seen 
as two distinct .indices of the disease. These long-term trends are 
displayed by the presentation of mean values in Figs. 2.4 and 2.5. The 
full data are tabulated in Table 2.9 which reveals the large standard 
deviations indicative of considerable spread of results. Differences 
between the two groups therefore failed to reach significance as did any 
changes during the course of treatment compared with the pre-maintenance 
therapy results.
After twelve months maintenance therapy one patient from each group had 
reduced number of nodules while four from.4the. two-weekly and two from 
the four-weekly groups had increased numbers.
Laboratory and X-ray Measurements
There was no change in haemoglobin concentrations throughout the active 
period of chrysotherapy studied (Fig. 2.6). By contrast, erythrocyte 
sedimentation rates altered considerabljr during the investigation. There 
was a steady decline during the preliminary phase which reflected the 
general improvement in the patients condition. The decline in ESR v/as 
continued through the first six months of maintenance therapy in those 
patients receiving gold at two-weekly intervals but then gradually 
increased again and at the end of the study the mean values were similar 
for both treatment groups (Fig. 2.6). The serum gold concentration fell
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as anticipated following cessation of weekly injections but levels were 
stable soon after three months maintenance therapy. The patients 
receiving two-weekly injections had values 25% greater than the patients 
in the other group (Fig. 2.7).
Rheumatoid factor titre (as reported from G u y ’s Hospital), fell in 
patients from both treatment groups. Three of those in the more 
frequent dose and tv/o receiving the four-weekly injections eventually 
had undetectable levels of rheumatoid factor. A further five of the 
patients with two-weekly injections had lower titres without becoming 
seronegative. The change in rheumatoid factor titre was significantly 
greater (p<G.005) in the two-week compared with the four-week group.
Very gradual radiological deterioration continued in patients from both 
groups with an equal distribution (Fig. 2.7). The X-ray score increased 
in 23 patients although in nineteen cases this was with five or fewer 
additional erosions and only one patient (on the two-week course) had an 
increase of greater than ten erosions. Radiological improvement with the 
loss of one or more erosions occurred in five patients.
As with the clinical measurements the full data have been tabulated and 
are shown in Table 2.10.
The patients whose condition suddenly deteriorated towards the end of 
rhe period studied were not chaiacterised by any obvious clinical or 
laboratory features. The serum gold concentrations were the same in 
these patients as in their cohorts and there were no signs predictive 
of impending therapeutic failure (Table 2.11).
The purpose of this investigation was to determine whether maintenance 
therapy administered at more frequent intervals would confer benefit to 
the patients by improving the rheumatoid condition without producing 
additional toxicity. More frequent injections will necessarily produce 
an increased body load of gold and higher mean serum gold concentrations 
which have been argued by Lorber to be crucial to successful chryso- 
therapy.
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Table 2.10 Laboratory and Radiological Measurements in Patients 
Followed During One Year of Maintenance Cbrysotherax^y 
Details during maintenance period
Dosing
frequency
(weeks) 3
Maintenance Injections 
6 9
(Months)
12
Haemoglobin 
(g/100 ml) 2 13.5 ± 1.6 13.6 ± 1.8 13.4 ± 1.8 13.4 + 1.2
4 12.6 ± 1.1 12.7 ± 1.3 12.8 ± 1.7 12.8 + 1.5
ESR
(mm/hr) 2 23.0 ± 18.0 23.0 ± 28.0 26.0 ± 24.0 27.0 + 22.0
4 27.0 ± 19.0 28.0 ± 21.0 25.0 ± 22.0 27.0 + 25.0
Serum gold 
(ymol/£) 2 5.7 ± 4.9 6.3 ± 3.1 6.4 ± 2.9 6.4 + 3.4
4 6.0 ± 1.9 4.5 ± 1 . 9 4.7 ± 1.6 4.9 + 1.9
X-ray
score 2 „ 21 ± 37 _ 24 + 39
4 - 20 ± 21 - 21 + 21
Values are reported as mean ± standard deviation
Patients received 50 rag sodium aurothiomalate at 
two or four-weekly intervals throughout the period
of maintenance chrysotherapy.
Table 2.11 Clinical Details of Patients Who Relapsed During Maintenance
Chrysotherapy. Serum Gold Levels at 6 Months Compared With
Non-Relapsing Cohorts
Group
N o . of 
relapsing 
patients
Sex
(M/F)
Mean
age
(range)
years
Mean serum 
gold 
(range) 
ymol/&
Mean serum 
gold of non- 
relapsing 
patients 
(range) 
yraol/£
2—  weekly 
dose 3 3/0
59
(47-68)
8.12
(5.28-12.39)
5.48
(2.54-14.87)
4—  weekly 
dose 2
46 4.62
1/1 (34-58) (3.50-5.74)
5.99
(3.30-9.90)
The results obtained indicated that a maintenance dose of 100 mg sodium 
aurothiomalate per month, administered in divided doses at two-weekly 
intervals confers no advantage over 50 mg per month given as a single 
injection. The signs of benefit demonstrated by clinical and laboratory 
measurements during the preliminary phase of weekly injections up to a 
total dose of one gram were generally sustained by patients from both 
treatment groups and there was a subtle trend towards further improve­
ment as evidenced by results of grip strength and articular index.
The initial response in ESR suggested at first that the frequent admin­
istration of gold might induce a more favourable eventual outcome but 
this was not confirmed by the later results'. Similarly the different 
serum gold concentrations between the two groups v/as not related to any 
clinical, .laboratory or radiological measurement of response. This is 
consistent with the results from the study reported in the previous 
section and fails to substantiate the approach advocated by Lorber 
that improved response is associated with the maintenance of higher 
serum gold concentrations.
Patients receiving the two-weekly injections of gold experienced more 
episodes of toxicity than did those in the lower dose group although 
there was no significant relationship with serum gold concentration.
Furst et at, also noted a higher incidence of toxicity in patients 
treated with 150 mg of sodium aurothiomalate compared with those given 
50 mg. (132) These patients however also received injections with 
greater frequency which may also be a factor relevant to the development 
of undesirable side-effects. These authors also were unable to demon­
strate a relationship between the incidence of side-effects and serum 
gold concentrations. (132)
Incidence of relapse during chrysotherapy is not a feature remarked upon 
in many other studies. Relapse in the five patients in this investi­
gation was not related to frequency of maintenance injections, nor to the 
serum gold concentration. No clinical features singled them out from 
other patients and all had done well prior to the set-back. That some 
patients will relapse even after prolonged periods of complete remission 
and despite continued chrysotherapy has been previously observed (144) 
with one report that deterioration eventually overtakes most patients and 
that only 15% will continue chrysotherapy beyond four years. (145)
The results reported here have shown that the management of maintenance 
therapy is not improved by increasing the rate of administration of 
sodium aurothiomalate from once to twice per month„ Furthermore, the 
incidence of toxic symptoms increases with the two-weekly injections 
compared with the conventional procedures„
It is evident that further studies are necessary to determine the long­
term response to chrysotherapy in patients receiving gold for several 
years„ If relapses are to be avoided consideration may have to be given 
to changes in the maintenance therapy regimes as the periods of treatment 
extend beyond one year0 This problem does not yet appear to have been 
addressed0
2 04 03 Tissue Gold Levels After Chrysotherapy
The gold concentrations in the samples of tissue removed from patients 
undergoing elective surgery are summarised in Table 2.12. The considera­
ble deposition of metal in synovial tissue is immediately apparent and the 
amounts found, were more than five times those present in other sites. The 
spread of results obtained was very wide as is evidenced by the standard 
deviations calculated from the data. Therefore, for further examination of 
the results, the patients were divided into two groups according to 
whether or not they were receiving chrysotherapy at the time of operation.
Table 2.12 Gold Concentrations in Tissues Removed During Surgery From 
Patients Treated With Gold •
Tissue Sample
Synovium Bone Muscle Fat Skin
Joint
Capsule
Bone
Marrow
Tendon
No. of samples H 10 11 8 4 2 3 2
Mean (yg/g) 11.07 1.48 1.89 1.24 1.89 0.91 1.48 0.95
S.D. (yg/g) 20.76 1.62 1.87 1.44 3.60 1.02 0.17 1.34
Results are reported as mean ± standard deviation
Group I included the patients currently receiving gold and Group II 
consisted of patients who had not received gold for some years. 
Fortuitously the mean total doses of gold administered to the groups 
were similar. The two groups were compared by determining the ratio 
between gold in the synovium and in either muscle, bone or fat. Not 
all ratios between all tissue pairs were available for all patients.
Table 2.13 Comparison of gold levels in synovium and striated muscle
removed at operation. Chrysotherapy was provided recently
(Group I) or several years previousljr (Group II).
Group
Mean interval 
since last - 
injection
N o . of 
samples
Mean total 
gold given 
(g)
Mean tissue 
synovium
gold (yg/g) 
muscle
I 4.2 weeks 5 1.46 23.82 2.96
II 4.1 years 6 1. 38" 0.45 1.00
Table 2.13 shows the gold results in the paired samples of synovium
and striated muscle. The gold ratio between these tissues in Group I
was 8.05:1 whereas in the group no longer receiving gold, the ratio was
0.45:1. This difference in ratio was highly significant, p<0.01 using 
Wilcoxon’s nonparametric ranking test. The gold levels in the pairings 
of synovium with bone and synovium with fat samples are shown in Tables 
2.14 and 2.15 respectively. The ratios of mean gold concentrations in 
all three sets of tissues are listed in Table 2.16.
Table 2.14 Comparison of gold levels in synovium and bone removed
at operation. Chrysotherapy was provided recently (Group
I) or several years previously (Group II).
Mean interval Mean total
Group since last N°' ° f gold given Mean tlssue Sold < W V S >  
injection samples (g) synovium b o n e
I 3.6 weeks
II 10.3 years
5 2.13 19.26 2.20
4 2.19 0.80 0.87
Table 2.15 Comparison of gold levels in synovium and fat removed at
operation. Chrysotherapy was provided recently (Group I)
or several years previously (Group II).
Group
Mean interval 
since last 
injection
Mean total 
No. of , ,
samnles B°ld glVe“o d i i i .
(g)
Mean tissue gold 
synovium
(yg/g)
fat
I 5.4 weeks 4 1.97 20.14 1.27
II 3.17 years 4 1.19 1.76 1.22
Table 2.16 Ratios between Mean Tissue Gold Levels for Synovium with 
Muscle, Bojie and Fat
Ratio of synovial gold to:
Muscle Bone Fat
I 8.05:1 8.75:1 15.86:1
II 0.45:1 0.92:1 1.44:1
p <0.01 N.S. N.S.
Data taken from Tables 2.13 -- 2.15
Differences between Groups I and II tested using Wilcoxon’s 
non-parametric ranking list. .
In addition to the patients included in this established study, tissues 
which were removed at post mortem autopsy from two other gold treated 
subjects, were also examined.
Details concerning the duration of chrysotherapy and data of last dose 
were not available for one (R'.C.) and the second (E.A.) had been 
extensively treated with chelating agents following the appearance of 
gold-induced thrombocytopenia (see Section 2.4.4). However, the results 
are included (Table 2.17) in order to allow comparison with those shown 
in Table 2.12 and with those obtained from the literature.
Table 2.17 Concentration of Gold in Tissues (y.g/g) Removed at Post
Mortem from Two Patients
Subject Synovium
Bone 
rib spine
Muscle Fat Skin
Renal
medulla
Liver
RC
EA
0.37
1.49 4.71 4.23
0.80
2.82
0.27
0.84
0.30
3.52
0.37
3.48
The tissue concentrations of gold found (Table 2.12 to 2.17) show very 
little correlation with those previously reported by Gottlieb et at, (98) 
The subject (M.V.) described by these authors had received 2.53 g of gold 
with the last injection eight weeks previously and would therefore be 
comparable with the patients in Group I in Tables 2.13 to 2.16. Synovium 
from the knee of M.V. had a reported gold concentration of 32 yg/g which 
is consistent with the concentrations reported here but for the bone 
(11 yg/g) and muscle (7 yg/g) the results of Gottlieb et at, (98) are 
somewhat higher than those shown in Tables 2.13 and 2.14 while for other 
tissues e.g. skin, bone marrow, renal medulla and liver, their results 
are 30 to 40 gold greater than are reported here.
The results of Vernon-Roberts et at. are more consistent with those 
presented here. (99) These authors measured gold in samples obtained 
at autopsy. With one exception who was still receiving gold, all had 
ceased chrysotherapy at least two years previously and as long as 23 
years before removal of samples. While the tissues examined do not 
exactly correspond to those included here," the pattern of concentration 
is similar with very high levels in the synovium and much lesser amounts 
in bone marrow, skin etc. The highest levels however were found in the 
adrenal and gonads which were not examined in any of the patients in this 
report.
The difficulty with the results of Gottlieb et at. (98) was referred to 
in the previous chapter and a subsequent paper by the same authors 
further adds to the confusion. In determining the excretion of gold 
into the hair, nails and skin they were able to detect the metal in all 
three, even in control subjects who had never received gold therapy.
Other investigators (146) have been unable to measure gold in skin sample 
from control subjects and the amounts measured in patients are consistent
with those shown in Tables 2.12 and 2.17. (146) Therefore in the absence 
of supporting data from any other investigators, the analytical results 
of Gottlieb et al. (98) appear to be suspect.
Factors which will influence the concentration of gold found in body 
tissues include the total amount of metal injected and the latent period 
between the last injection and analysis. Since both groups in this study 
received the same amount of gold this factor does not apply when comparing 
results arid one can therefore examine the effect of time upon the dispo­
sition of gold. V/hile division of the data into a greater number of sub­
groups, each representing different times for the latent period, would 
have been preferable to obtain a clearer picture of long term changes such 
groups would have had only a small number of samples and not necessarily 
yielded reliable information. Therefore just the two groups were chosen.
During active chrysotherapy the fraction of injected gold which is retained 
in the body is selectively concentrated in synovial tissue (the data of 
Vernon-Roberts et at. (93) indicates that adrenal and gonadal glands also 
have this capacity) although all other tissues also retain some of the 
metal. These observations accord with the findings in laboratory animals 
following injection, of gold where selective deposition is also seen to be 
superimposed upon a widespread, generalised distribution.
Continuing excretion of gold following cessation of injections indicates 
the slow removal of gold from the initial sites of storage with the 
consequent lower tissue concentrations measured in specimens obtained 
from the patients of Group II. At the same time however the reduced 
ratio of synovial to non-articular tissue gold levels in this group 
(Table 2.16) suggests that removal of gold from synovial tissue is greater 
than from other types of tissue.
From these results it can be proposed that in patients with rheumatoid 
arthritis a labile gold pool exists (which includes the synovium) into 
which gold enters and is discharged more rapidly than occurs with a wide­
spread pool characterised by a very slow turnover of gold. . The long half- 
life of this second pool is such that gold may still be detected in tissues 
of some patients more than twenty years after treatment has ceased.
Results from experiments to determine gold disposition in animals were 
consistent with the existence of a labile gold pool. In rats, considera­
ble concentration of gold occurred at the sites of artificial inflammation 
(granuloma pouch) but during succeeding weeks the gold rapidly disappeared. 
(97) While availability of tissue limits the determination of synovial 
gold in rats there are also sites such as kidney and spleen where initially 
very high concentrations are quickly depleted.
Specific histocliemical examination of synovial tissue also lends support 
to this hypothesis. Microscopic demonstration of gold in synovial tissues 
removed at surgery reveals large deposits in the lining cells during 
active chrysotherapy but that in patients no longer receiving gold, a 
progressive diminution of concentration occurs with time and the con­
current appearance in deeper connective tissue of gold-rich macrophages. 
This movement of gold however was limited to tissue taken from diseased 
joints for synovium that was free from rheumatoid disease contained very 
little visible gold. With this technique gold deposits were also observed 
at other sites where macrophage populations were large e.g. kidney, spleen, 
adrenal. (99)
It therefore appears that during chrysotherapy gold is deposited in the 
cells of the synovium - probably taken from the gold present in synovial 
fluid and in plasma and also transported by macrophages. After chryso­
therapy has been stopped synovial gold concentration decreases and the 
visible gold deposits are lost. The reason for ihe sudden movement of 
gold is not clear but migration of cells .into deeper tissues or removal 
by macrophages may be responsible for the^ translocation.
2.4.4 Additional Studies 
Possible Foetotoxicity of Gold
Case 1. Exposure to gold occurred when the mother received chrysotherapy, 
for psoriatic arthritis, early in the pregnancy. For the first 8 hours 
after the birth the baby had a respiration rate of 70-80 per minute but 
there was no evidence of recession or distress. He was then noticed to 
be slightly jittery and gradually deteriorated over the next nine hours 
becoming pale and distressed with gasping respiration and unrecordable 
blood pressure. The results of investigations carried out at the time ■ 
were:-
3
Haematocrit 40.6%, white cell count 18,300 per mm , platelets
9
160x10 per litre, sodium 138 ramol/£, potassium 7.2 mmol/£, 
chloride 101 mmol/£, urea 12.5 mmol/Z, blood glucose 1.4 mmol/Z, 
Chest X-ray - patchy changes, heart normal size; abdominal 
X-ray - no abnormalities. Blood culture - no growth.
A provisional diagnosis of septicaemic shock was made and treatment 
with antibiotics and intravenous fluids was commenced. Intubation 
and mechanical ventillation was also established.
A blood clotting screen (Table 2.18) revealed the presence of a coagula­
tion problem and it was decided to perform an exchange transfusion v/ith 
fresh blood and fresh frozen plasma. The baby sustained cardiac arrest 
just as the exchange transfusion was completed. This was corrected by 
massage and bicarbonate. A lumbar puncture at this time gave a clear 
yellow fluid with no pus.
Table 2.18 Results of Blood Clotting Screen in a Neonate Exposed
to Gold in utevo
Results
Reference or Control 
Range
Fibrinogen 0.75 g/Z 1.5-4.0 g/Z
Prothrombin time 29 secs 12 secs
Partial thromboplastin-kaoiin time 145 secs 44 secs
Thrombin time 17 secs. 12 secs
Fibrin degradation products not detected
The condition of the baby then improved and a systolic blood pressure of 
54 mm Hg was recorded. A second clotting screen also showed improvement 
and a repeat of the chest X-ray showed diffuse patchy shadows in both 
lungs. However, a few hours later he developed pulmonary haemorrhages 
which continued over the next four hours until he died at 57 hours of age.
A post mortem examination revealed extensive pulmonary bleeding and an 
intracranial haemorrhage. Samples of liver, kidney and lung tissue were 
taken for gold determination and the results are shown in Table 2.19;
The concentration in the kidney (0.33 yg/g) is of the same order as v/as 
found in patient R.C. (Table 2.17) and a little lower than those reported 
by Vernon-Roberts et al. (99) two or three years after ending gold treat­
ment. Gold in the liver (0.37 yg/g) is about one tenth the amount 
measured both in EA (Table 2.17) and by Vernon-Roberts et al. The results 
obtained by Gottlieb et al. (98) were very much higher for both these 
tissues. There are little data against which to compare the gold concentra­
tion in the lung (0.46 yg/g). Only Vernon-Roberts et al. have reported 
results which were 0.5, 3.0 and 5.0 yg/g from patients last receiving gold
20, 3 and 0 years ago respectively. (99)
Table 2.19 Gold Measurements Associated with Two Cases of Exposure to
Gold in utevo
Case Samples Gold concentration
3. Death at 57 hours aftei' birth. 
Mother received 4 injections 
of gold during pregnancy.
Liver
Kidney
Lung
0.37 yg/g 
0.33 yg/g 
0.46 yg/g
2 Mother continued with chryso- 
■therapy throughout pregnancy. 
Successful delivery of healthy 
child.
Maternal serum 
at delivery:
Cord serum at 
delivery:
Infant's serum 
at two-and-a- 
half weeks:
19.9 ymol/£ 
11.4 ymol/£
2.6 ymol/&
Case 2. Exposure to gold in this case occurred throughout the pregnancy 
which proceeded uneventfully to term when the mother delivered a baby 
girl weighing 2970 g. There were no obvious major or minor abnormalities 
evident on the infant. A venous blood sample was collected from the 
mother at delivery together with a simultaneous umbilical cord blood 
sample. When the baby was two-and-a-half weeks old a venous blood sample 
was taken from her. The serum gold concentrations are also shown in 
Table 2.19.
The cord blood gold concentration, 11.4 ymol/£ (245 yg/100 ml), indicates 
that levels very similar to those measured during active chrysotherapy 
are attained in the foetal circulation when the mother is treated during
pregnancy. The decrease in gold over the next two weeks, to 2.6 ymol/Jt 
(51 yg/100 ml), demonstrates that the neonate has no difficulty with 
elimination of gold, the fall in serum concentration being similar to 
that observed following an injection in patients on maintenance chryso­
therapy.
There have been no animal studies designed to assess the effect of gold 
compounds given at therapeutic levels upon the foetus but at concentra­
tions considerably in excess of those used for chrysotherapy, sodium 
aurothiomalate has teratogenic effects in rats and rabbits. (133) It is 
known that gold administered in conventional amounts will cross the human 
placenta. Some measurements of gold in perfusion fluid from isolated 
placentae have been made in this laboratory as part of a different 
project. An albumin-colloidal gold complex, was administered and gold 
transferred to the foetal circulation. Rocker and Henderson, using 
election micro-probe analysis, detected gold in the liver and kidney but 
not in other tissues examined, from a 20 week aborted foetus. (115) 
Quantitative measurements were not attempted.
The number of documented cases of women receiving or continuing chryso­
therapy throughout pregnancy are very few. The two cases reported here 
therefore are valuable additions to the available information concerning 
gold and foetotoxicity.
The foetus aborted by Rocker had no obvious abnormality upon external 
examination and preservation of tissue for4 histological assessment was 
unsatisfactory. (115) Hollander refers to a series of uneventful 
pregnancies in women receiving gold (147) and Miyamoto, et a l .report on 
26 patients who received gold throughout pregnancy and 43 who discontinued 
chrysotherapy in early to mid pregnancy. (148) All children were normal 
at delivery with the exception of two from the last group who had minor 
hip anomalies.
The two cases described here confirm that gold passes from maternal to 
the foetal circulation at amounts which are comparable, but not in excess 
of, those achieved during conventional chrysotherapy. Accumulating evidence 
suggests that gold therapy in pregnancy can be safely continued in those 
patients whose disease is sufficient^ severe that discontinuation would be 
unacceptable. However, the absence of any long-term follow-up of offspring
exposed to gold vn utevo and the suspicion from the Japanese work and 
the fatal case reported here that toxicity may occur suggest that it 
is prudent to avoid chrysotherapy in pregnancy wherever possible.
Laboratory Investigations in Gold-Induced Thrombocytopenia
Case 1 (Mrs. E.A.) This lady entered hospital with a rash, renal 
damage and thrombocytopenia three months after commencing treatment 
with gold. She was treated with Dimercaprol, initially by intramuscular 
injection, but because of severe bruising this was changed to an intra­
venous infusion in an intra-lipid solution. Transfusions of blood and 
platelets were also given.
The patient remained .in hospital for the next eight months except for 
one period of four days when she was at home. Her condition fluctuated 
considerably with periods when she had bruising, haematuria, melaena 
and epistasis alternating with improvement. Tnere were few problems 
with infection although a klebsiella septicaemia developed on one 
occasion. Five months after admission she became very drowsy and ail 
intra-cranial haemorrhage was suspected but her condition improved with­
out specific treatment. In March 1980, eight months after the onset of 
her symptoms she again became drowsy, disorientated, then unconscious 
and she fell from the bed. Her condition rapidly deteriorated and ten 
hours later she died.
The post mortem examination showed that she had suffered a large right 
cerebral haemorrhage. In addition there were signs of haemorrhage beneath 
the skin, in the mouth and throat, trachea and lungs, heart and urinary 
tract. The course of her disease is summarised in. Fig. 2.8. A fall in 
serum gold concentration was quickly achieved with Dimercaprol and there 
was some increase in the number of circulating platelets during the first 
period of chelation treatment. However in view of the subsequent failure 
for the bone marrow to recover blastic function this temporary response 
could have been a steroid induced release of serai-mature platelets.
q
Thereafter the platelet count fluctuated between 2 and 30 x 10 /Z and 
multiple transfusions of blood and platelets were required to maintain 
even this level. Serum gold concentrations fell during chelation therapy 
and then slowly increased to about 2.54 |imol/&. At later periods 
concentrations fluctuated considerably which may have been consequent 
upon the clinical condition although insufficient measurements were made
to allow a reliable comparison. Urinary excretion of gold was never 
measured. The total amount of Dimercaprol given was 4.9 g.
Case 2 (Mrs. J.G.) This lady also entered hospital after the onset of 
a widespread rash a few months after starting chrysotherapy. At this 
point she had received 450 mg sodium aurothioraalate and regular blood 
and urine tests had revealed no sign which was predictive of toxicity. 
There was no eosinophilia nor neutropenia. The dermatitis responded 
to topical application of steroid but haematological tests after four 
days revealed the development of a pancytopenia which was confirmed by 
bone marrow examination. Treatment with oxymethalone was commenced and 
she was discharged home because of the risk of catching a hospital 
infection. .
A few days later she complained of generalised malaise and vomited blood 
and was readmitted to hospital. Reverse barrier nursing was commenced 
and vigorous antibiotic therapy was instituted to reduce bowel flora.
She required daily transfusions of platelets and blood but her condition 
continued to decline. Chelation therapy with intramuscular Dimercaprol 
was begun the day after admission and maintained for two weeks. Three 
weeks after admission, bleeding occurred from the gums and palate which 
did not respond to local treatment. Two days later she deteriorated 
rapidly and died. Blood cultures taken a few hours before death showed 
a coliform and Staph, albans septicaemia and post mortem examination 
revealed ulceration and haemorrhage in the pharynx, oesophagus and other 
sites also.
As is shown in Fig. 2.9 treatment with oxymethalone failed to produce
any response by the bone marrow and her platelet count was maintained at 
g
10-20 x 10 /£ only by daily transfusions of blood and platelets. She 
received 2.2 g Dimercaprol to chelate and excrete the gold. The pre­
chelation serum gold concentration was 2.08 ymol/£ and after ten days' 
treatment the level had fallen to 1.17 ymol/£. Urinary gold excretion 
during the first day of treatment was 3.51 ymol and after ten days the 
removal rate had,, increased to 4.43 ymol. The day before her death both 
the serum and urine gold levels had increased to 2.44 ytmol/Z and 8.88 
ymol/24 hours respectively even though she had not received chelating 
agent for two weeks.
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Gold induced thrombocytopenia is not a very common development in
/
chrysotherapy and these two cases illustrate that there is no accepted 
form for its treatment. While removal of gold by chelating agents is 
usually attempted, a standard regime of dose, duration etc. has not 
been defined. The chelating agent generally used is Dimercaprol,
200 mg per day given as divided doses by intramuscular injection, 
although with the first patient the Dimercaprol was also given as an 
intravenous infusion with intra-lipid. This technique has apparently 
only been used on one previous occasion and would appear to be effective 
in maintaining low concentrations of serum gold.
Treatment was commenced soon after the symptoms appeared in the first 
case whereas with Mrs.. J.G. chelation was not started until two months 
after the first symptoms and three weeks after, entry into hospital.
I
In neither case was there any attempt to relate chelation to the amount 
of gold given, the serum gold concentrations or to the patient’s clinical 
condition. Platelet production in the bone marrow however remained 
virtually unchanged whatever the intensity of therapy or the concentra­
tion of gold in serumi England and Smith suggested that the total dose 
of Dimercaprol (in grams) to be administered should be thirty times the 
total dose of gold (in grams) and described one case in which this regime 
had proven to be successful in stimulating a bone marrow response. (149)
In these two cases only 50% and 30% of this recommended amount was given 
respectively.
The serum, urine and tissue gold results ('Figs. 2.8 and 2.9 and Table 
2.17) measured on samples taken near to or after death demonstrated that 
the chelation therapy used had failed to remove considerable proportions 
of the body burdens of gold. Whether a more determined course of treat­
ment with Dimercaprol as proposed by England and Smith (149) would have 
proved successful remains speculative. The presence of the residual gold 
would however have been realised if urine rather than serum gold concentra­
tions had been monitored. Possibly therefore a regime of more aggressive
chelation, continued until little further excretion occurs, should be 
/•
considered if such situations arise again.
Demonstration of a persistent body burden of gold is consistent with the 
compartmental model proposed by Gerber et at. (84) The shallow compart­
ment (including the serum) could represent the tissues containing
available gold while the deeper compartment (? includes the bone marrow) 
and possibly less available to Dimercaprol, would have a very much 
slower rate of clearance. At the same time however it is not apparent 
whether, even if gold were removed from the bone marrow, the activity 
of the tissue would be readily restored.
C H A P T  E B T H R E E
STUDIES WITH RADIOLABELLED COMPOUNDS
3.1 INTRODUCTION
From the discussion in the last two chapters it is apparent that previous 
attempts to determine a detailed appraisal of how gold compounds behave 
when introduced into the body and how they operate in conditions such as 
rheumatoid arthritis, have been concerned only with the gold. The 
associated molecules - thiomalate, thioglucose etc. have been ignored, 
overlooked or assumed to be irrelevant.
It is now accepted by almost all authorities that serum gold levels are 
not related to response during chrysotherapy. Therefore in seeking 
parameters which might provide a reliable guide, further features of 
the metabolism of these drugs require to be determined. The chemistry 
of gold compounds (Chapter 1) suggests that thiol complexes will be of 
considerable importance in in vivo reactions, particularly in the forma­
tion of mixed thiol species and in thiol exchanges. The actions of the 
associated molecule might therefore be expected to be not merely as a 
therapeutically inert transporter but also to influence absorption and 
disposition of gold and hence, ultimately, the patient’s response.
In view of the enigma concerning serum gold concentrations and the 
suspected importance of the associated molecule vis a vis therapeutic 
response and gold pharmacology, it was felt appropriate to investigate 
the metabolism of the thiomalate portion of the molecule together with 
that of gold.
In seeking to accomplish this goal, it was considered essential to obtain
sodium aurothiomalate with the thiomalate moiety radioactively labelled.
Such material was not available commercially and the first part of this
14
work therefore involved the radiochemical synthesis of sodium(l,4- C)auro-
14
thiomalate and (1,4- C)thiomalic acid. The preparation of these compounds 
allowed the investigation of disposition, excretion and intracellular 
distribution of gold and radioactive carbon and also -in vitro experimental 
work on the binding of gold thiomalate to protein.
3.2 RADIOCHEMICAL SYNTHESES
Synthesis of carbon-14 labelled thiomalic acid was based upon reactions 
described by Holinberg and Schjanberg. (150) These authors prepared acetyl- 
thiomalic acid from maleic acid and thioacetic acid. Removal of the acetyl 
group was then effected by sodium hydroxide hydrolysis and, upon acidifica­
tion, the thiomalic acid precipitated from solution. Since carbon-14
labelled maleic acid is not available (1,4- C)maleic anhydride was used 
14
to prepare (1,4- C)acetylthiomalic anhydride which was then hydrolysed 
14
to give (1,4- C)thiomalic acid (Fig. 3.1). Gold(l) was added from gold
14
iodide on to the sulphur atom of (1,4- C)thiomalic acid and the sodium 
salt precipitated from solution by the addition of sodium hydroxide and 
ethanol.
3.2.1 Materials and Methods
14
1. Reagents: (1,4- C)maleic anhydride, specific activity 20 mCi/
mmol. Purchased from Amersliam International.
Maleic anhydride, thioacetie acid and mercaptosuccinic 
acid (thiomalic acid) were obtained from Sigma Chemical Co. 
Scintillant reagent: 0.55% 2,5-diphenyloxazole in Synperonic 
NXP (I.C.I. Ltd., Dillingham, Cleveland)/toluene (1:2 v/v). 
Other chemicals were obtained from B.D.H. Ltd.
2. Extraction apparatus. The system shown in Fig. 3.2 was used for
continuous extraction into hot solvent.
3. Thin layer chromatography. Samples were applied to pre-prepared
silica gel G150Q thin layer chromatography plates. Three different
solvent mixtures were used; I methylisobutyl ketone: formic acid: 
water (40:20:20). II water: ethanol (1):9). Ill butanol: acetone: 
acetic acid: water (70:70:20:40). The positions of separated 
compounds were visualised by spraying the plates with 1% w/v 
potassium permanganate. * ‘ ■
4. Measurement of radioactivity. Accurately weighed samples of the
radioactive products were dissolved in distilled water. Duplicate
10 jil aliquots from each solution were added to scintillation vials
containing 4.0 ml scintillant reagent and 0.5 ml distilled water.
The activities were measured in a Packard 2425 liquid scintillation
counter. Counting efficiencies were determined by internal standard-
14
isation using 10 ill ( C)hexadecane of known activity and the radio­
activity, disintegrations per minute (dpm), calculated from the 
formula
cum. t
dpm.t = ---- —~— !------ — x dpm.h where t = test sample
cpm.th - cpm.t -
h = hexadecane
th = test sample + 
hexadecane
9
Radioactivity m  curies was then calculated from, 2,200x10 dpm = 1 Ci.
14 14
Fig. 3.1 Synthesis of (1,4- C)thiomalic acid from (1,4- C)maleic
anhydride and thioacetic acid.
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5. Measurement of gold. Gold containing compounds were accurately 
weighed and dissolved in distilled water. A series of dilutions 
were prepared from this initial solution together with standard 
gold solutions having concentrations in the range of 0.5 to 10.0 
lig/ml. Standard and sample solutions were aspirated into an 
atomic absorption spectrophotometer (operating conditions as in 
Table 2.2) and the absorbance readings noted. The concentration of 
gold in the sample solutions were calculated by reference to the 
standards and from these concentrations, the amount of gold in the 
analyte determined.
6. Nuclear Magnetic Resonance (NMR) . Samj)les for NMR analysis were 
dissolved in deuterated acetone and the spectra scanned using a 
Perkin Elmer R24A high resolution NMR spectrometer.
7. Infra Red Analysis. Infra red spectra of samples were prepared on 
a Perkin Elmer 577 spectrometer.
3.2.2 Procedures
1. Preparation of (1,4-14C)thiomalic acid.
14
1 mCi of (1,4- C)maleic anhydride (specific activity 20 mCi/mmol) was 
supplied in four vials each containing 250 ]iCi. The contents of each 
vial were dissolved in approximately 0.2 ml dichloromethane and the 
combined solutions added to 98 mg (1 mmol) non-radioactive maleic 
anhydride in a weighed glass tube (100x8 mm, 3.0 ml capacity). The 
dichloromethane was gently evaporated under a stream of nitrogen. Cooling 
in an ice-bath was essential to avoid loss of maleic anhydride by volatili­
zation (see below).
Thioacetic acid, 0.1 ml, was added slowly over approximately 30 seconds to 
the maleic anhydride, at 0°C. Air in the tube was displaced by nitrogen, 
the tube stoppered and gently mixed until the contents formed a milky 
suspension which went slowly into solution. After standing overnight at 
4°C a white crystalline mass with no supernatant fluid was present. The 
tube was heated i n  a water bath until the mass melted (71-74°C) and v/as 
then slowly cooled to 4°C. Recrystallization occurred as the temperature 
fell. The solid material v/as dissolved in approximately 1 ml benzene 
warmed to no more than 60°C, allowed to recrystallise slowly and left 
overnight at 4°C under nitrogen. The pale yellow supernatant was decanted 
and the residue washed with a further 1 ml benzene. The crystals were
dried by a stream of nitrogen and the tube reweighed. The yield of 
acetylthiomalic anhydride was 145 mg (83%).
Sodium hydroxide (4.0 mmol) dissolved in 1.5 ml water was added to the 
tube, the air displaced by nitrogen and solution of the contents effected 
by repeated inversion. The mixture was left at 4°C overnight and excess 
sulphuric acid (2.5 mmol in 1.5 ml water) was added. The acidified 
contents were transferred quantitatively to the continuous extraction 
apparatus (Fig. 3.2) and extracted with 75 ml ethylacetate. The optimum 
time for extraction was determined in preliminary experiments by removing 
a few drops of ethylacetate or the aqueous sample solution and adding to 
tubes containing 2% w/v ferric chloride, which forms a blue colour in the 
presence of thiol groups. Extraction for 45 minutes was found to be 
appropriate.
The extract was evaporated to dryness under nitrogen to yield 124 mg (83%) 
of white thiomalic acid, m.pt 149°C (Sigma thiomalic acid, 145~146°C).
Thin layer chromatography using solvent system I revealed a single spot 
with an Rf of 84.4. Examination of the chromatogram using an isotope 
scanner showed a concentration of radioactivity at the position having 
the same Rf value. Thiomalic acid from Sigma had an Rf value of 83.3 
on the same chromatogram. The radioactive content of the prepared 
thiomalic acid was 105 yCi with a specific activity therefore of 
4.88 ]jCi/mg or 732 yCi/mmol.
Comparisons of NMR and infra red spectra ..of prepared and commercial 
thiomalic acid indicated that traces of an acetyl group (probably acetyl­
thiomalic anhydride) were present following prolonged extraction into 
ethylacetate. Residues in these situations were waxy rather than powdery. 
With careful timing of the extraction this contamination was avoided and 
the eventual NMR and infra red scans of synthesised and commercial thio­
malic acid were identical.
The specific activity of thiomalic acid was disappointingly low and since 
the yield (83%) was good considerable loss of radioactivity obviously 
occurred. Large amounts of carbon-14 were not detected in any of the 
residual solutions. It was therefore suspected and confirmed by experi­
ment and communication with Amersham International that small amounts of 
maleic anhydride will readily volatilize from dichloromethane.
Fig. 3.2 Apparatus used for extraction of thiomalic acid
into ethyl acetate.
Ethyl--
acetate
Sample
‘Ethyl acetate
Heat
2. Preparation of sodium(l,4- C)aurothiomalate.
Two techniques were investigated for the addition of gold on to the thiol 
group of thiomalic acid. One used aurous cyanide and the second aurous 
iodide to provide the gold(l) atom.
Aurous cyanide: The incorporation of gold into thiomalic acid from
aurous cyanide was described by Trermer and Bacher (151) (Fig. 3.3).
Gold potassium cyanide, 0.288 g, was dissolved in 5.0 ml distilled 
water and 1.0 ml of 10% v/v hydrochloric acid was added. The solution 
was heated in an evaporating dish to about 50°C whereupon yellow aurous 
cyanide precipitated. The dish was placed on a steam bath and the 
aqueous solution evaporated to dryness with the simultaneous loss of 
hydrogen cyanide. The residue was suspended in water, filtered, re­
washed with water and finally dried over P o0 r .
A o
Aurous cyanide 56 mg (0.25 mmol) was suspended in 20 ml distilled water 
and 104 mg thiomalic acid (0.69 mmol) dissolved in 32 ml distilled water 
was added. The mixture was heated on a steam bath for 30 minutes and 
most of the suspended matter dissolved. When the solution cooled the 
undissolved solids were removed by filtration and the filtrate evaporated 
to dryness on the steam bath. The residue thus formed was triturated 
four times with hot ethylacetate to remove unreacted thiomalic acid and 
dried overnight in a vacuum oven at 100°C.
Since this procedure required 2.75 moles of thiomalic acid per mole of 
gold and the yield was poor (about 10%) it was not used and the 
alternative procedure with aurous iodide was adopted.
Aurous iodide: Details of this method was supplied by Amersham Inter-
19 5national where it is used during the preparation of sodium( Au)auro­
thiomalate (Fig. 3.4).
Gold metal was dissolved in aqua regia and diluted to a concentration 
of 20 mg/ml. 1 ml of this solution was evaporated just to dryness and 
the residue dissolved in 1 ml concentrated hydrochloric acid. 9.5 mg 
potassium chloride was added, mixed and the solution quantitatively 
transferred to a weighed test tube (100x8 mm). Potassium iodide (49.8 
mg in 1 ml water) was added producing a brown, flocculent precipitate. 
Water was added almost to fill the tube and nitrogen blown in to displace 
the residual air. The tube v/as stoppered, the contents mixed and
Fig. 3.3 Preparation of aurothiomalic acid using aurous cyanide as 
the gold(l) donor.
K(Au(CN) ) + HC1 AuCN + HCN + KC1
COOH COOH
c h 2 c h 2
CHSH + AuCN CHS Au + HCN
COOH COOH
Fig. 3.4 Preparation of sodium aurothiomalate using aurous iodide 
as the gold(l) donor.
Au + HC1 A u HCl.
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centrifuged. After removal of the supernatant, the precipitate was 
washed with water and twice with ethanol. The precipitate was dried 
under a stream of nitrogen, in the dark, and the tube reweighed. 32 mg 
pale yellow gold(l) iodide was thus prepared.
14
(1,4- C)thiomalic acid, 15 mg, was dissolved in 1 ml of water and added 
to the gold iodide forming a yellow suspension. 4M sodiumhydroxide was 
added dropwise until the gold iodide just dissolved. The solution was 
poured into a weighed 50 ml tube and about 40 ml ethanol, saturated with 
sodiumacetate, added. After standing overnight, the tube was centrifuged 
and the supernatant removed. The precipitate was washed with ethanol, 
dried under nitrogen and weighed.
The synthesised sodium aurothiomalate had a gold content of 48.9 ymol 
(from an initial 100 ymol) while the radioactivity was 36.5 yCi (amount 
added = 73.2 y C i ) . The yields of gold and carbon-14 were 48.9% and 49.9% 
respectively. Thus the specific activity, 746 yCi/mmol was similar to that 
of the thiomalic acid. Thin layer chromatography using solvent systems 
II and III revealed a compound containing gold and carbon-14 which had 
Rf values of 100 and 46.5 respectively. These W e r e  similar to the Rf 
values found with sodium aurothiomalate obtained from May & Baker Ltd.
(100 and 47.5) and quite distinct from those of thiomalic acid (0 and 84 
respectively).
3.3 EXPERIMENTS WITH RADI0LABELL5D COMPOUNDS
3.3.1 Introduction ... .
14
Despite the poor radioactive yield achieved in the synthesis of (1,4- C) 
thiomalic acid the intermediate and final products were prepared in sufficien 
amounts and with the necessary radiochemical purity for use in the following 
series of experiments.
1. Disposition and excretion of gold and carbon-14.
From the work with patients with rheumatoid arthritis and from earlier
animal experiments the fate of gold after an injection of sodium auro- 
<•
thiomalate is reasonably well understood. The rate of absorption, trans­
port in the blood, uptake into tissues and excretion into the urine have 
been repeatedly examined and were described in Chapter 1. It has also 
been demonstrated that it is the gold which is the effective agent in 
rheumatoid arthritis and that the therapeutic response afforded by myo-
chrisin is not mimicked by thiomalate whereas other gold complexes e.g. 
aurothioglucose are also effective anti-rheumatic drugs.
The thiomalate fraction of the drug has therefore been assumed to be 
unimportant once the injection has been given and that its only role is 
to provide a stable, soluble form of gold(l). The assumption most often 
voiced is that gold will readily dissociate from thiomalate 'in V'i'OO, 
attach to albumin and be transported throughout the body while the 
residual part of the drug will probably be metabolised (possibly via 
the tricarboxylic acid cycle with expiration as CO ), and have no further 
influence upon the activity of the gold.
14 34
By using sodium( C)aurothiomalate and ( C)thiomalic acid both fractions
of the injected compound can be followed and the validity of these
assumptions may be checked.
2. Subcellular distribution of gold and carbon-14.
The fate of gold following its entry into the cell has been examined by 
Danpure and his co-workers (152,153) using sodium(198Au)aurothiomalate. 
These authors suggested that the metal initially goes into the cytosol 
but is then transferred into lysosomes which may contain up to 90% of 
hepatocellular gold. This concentration of gold in lysosomes is in 
agreement with the morphological studies of several others (99,122,154- 
157) and the accumulation within these organelles can be so exaggerated 
as to earn them the descriptive pseudonym "aurosomes".
Recent interest in the metabolism of metals has realised the importance 
of the low molecular weight proteins, the metallothioneins (158). 
Synthesis of these proteins is induced by a primary exposure to a metal 
and with additional exposure accumulation takes place in those tissues 
rich in the protein. The thionein-rich tissues are the liver and kidney 
although the intestine, spleen and probably other organs also contain 
these proteins. While the thionein binds the metal responsible for its 
induction certain other cations can also be incorporated. These proteins 
have been repeatedly isolated as a consequence of exposure to cadmium, 
zinc, copper and mercury and interactions between these metals and the 
proteins have been described but there are also reports of thionein 
synthesis following exposure to other metals including gold.
Metallothioneins are localised within the cytoplasm and therefore at 
least two features to the intracellular metabolism of gold must be 
considered i.e. (a) incorporation into cytosolic, low molecular weight 
binding protein and (b) uptake into the lysosomal vesicles. Whether 
these features are independent or whether gold taken into tissues will 
pass from one system on to the second does not appear to have been 
previously considered.
Additional to these two mechanisms is the relevance or otherwise of the
associated carrier molecule. It has been demonstrated (Fig. 3.10) that
14
radioactive carbon enters cells when rats are given sodium(1,4- C)auro­
thiomalate although it is not apparent whether this takes place before or 
after separation from- gold. If intact drug does enter the cell it is 
relevant to enquire how long the gold and thiomalate remain together or 
do they immediately proceed along separate metabolic paths?
To examine these questions the intracellular fate of gold and radio­
active carbon was followed in rats after the administration of sodium
14 14
(1,4- C)aurothiomalate and (1,4- C)thiomalic acid.
3. Biliary excretion studies.
The normal physiological route of excretion for most metals to which man 
or animals are exposed is via the faeces and with few exceptions urinary 
elimination is quantitatively much less important. However, with most 
metals the major proportion of the faecal Jburden is derived from ingested 
metal which has remained unabsorbed throughout the passage down the gut. 
That fraction of the ingested metal which is assimilated can then be 
excreted into the intestine and enter the faeces either predominantly 
through the bile e.g. copper or. through intestinal secretions, e.g. zinc, 
or through both of these routes, e.g. manganese. (159)
Since sodium aurothiomalate is administered by intramuscular injection, 
faecal gold can only be derived from that which is subsequently secreted 
into the alimentary tract. The work with human volunteers and with 
animals (Chapter' 1) and the results of the disposition and excretion 
experiments reported in Section 3.3.3 have shown that urinary excretion 
of gold is of greater significance during the first 24 hours after an 
injection but that during the following days faecal elimination probably 
assumes a greater importance.
Transfer of compounds into the bile from the liver cell may involve a 
process of passive diffusion as with albumin or occur against a 
concentration gradient and therefore require expenditure of cellular 
energy. More than one mechanism for the transport of components into 
the bile have been described. In addition to hepato-biliary membrane 
transport of small molecular weight compounds such as bilirubin, lysosomes 
and smaller endocytic vesicles convey and release their contents into the 
canaliculi by exocytosis. (160)
Transfer of IgG, and IgM and immune complexes from the liver to the bile 
is accomplished by lysosomes. The experimental work examining the intra­
cellular distribution of gold demonstrated the importance of lysosomes in 
the hepatic metabolism of gold (section 3.3.3). It might be expected 
therefore, that given this concentration of gold in the lysosomes, the 
known association between gold and immune complexes in inflammatorjr cells 
and fluids and the excretion of gold in the faeces, that gold would be 
discharged from lysosomes into the bile. The extent of any entero- 
hepatic circulation upon the passage of gold thence into the faeces is 
unknown but Kapelowitz et at. (102) were able to collect biliary drainage 
in a gold-treated patient and these author’s concluded that less than 50% 
of faecal gold was derived from the bile.
Other experiments reported in this Chapter give no information relevant 
to the movement of thiomalate from the liver, therefore by giving rats 
the radioactively labelled thiomalic acid and sodium aurothiomalate and 
monitoring the appearance of gold and carbon-14 in the bile it should be 
possible to assess the importance of biliary excretion and, by comparison 
with the excreted compounds, to make an estimate of entero-hepatic 
circulation.
4. In vttvo protein binding.
The distribution of gold within the plasma was discussed in Chapter 1.
All reported studies have demonstrated that very large proportions of 
the circulating gold are bound to albumin with the proportion of non­
albumin bound metal found to be between 0 and 25%. Very little attention 
however has been focussed upon efforts to resolve questions concerning 
the nature of the albumin-gold complex.
On the basis of reactions involving albumin, sodium aurothiomalate and 
other thiol compounds, and thiol-blocking agents, Gerber (8) and Danpure 
(93,161) propose that, the interaction is between a cysteinyl residue on
the protein and gold(l). Other workers (162,163), while confirming a
3 —1 4
major binding site with a high affinity constant (6.1x10 M and 3.3x10 
M "S also detected at least three other binding sites with much lower 
affinities.
Gerber (8) added sodium aurothiomalate to albumin and attempted to assay 
free thiol groups as a ferricyanide reducing agent. He was unable to 
demonstrate release of thiomalic acid when the protein-drug complex was 
formed. Mason (162) and Jellum et at. (164) also sought to determine 
whether thiomalate was produced as the complex was formed and both groups 
concluded that there was some release.
The results of Danpure (161) showed both release and retention of 
thiomalate in very simple in vitvo incubation systems. As a primary 
model he examined the interaction between sodium aurothiomalate and 
cysteine and subsequently took the gold compound and albumin. In the 
first experiments thiomalic acid was evolved as the two components 
reacted but with the protein present he was unable to detect the presence 
of free thiol groups. ■ . -
Thus the nature of the major circulating fraction of gold in the blood 
is only partially understood and realistic descriptions of the further 
metabolism of the gold compound can only be made when the composition of 
the complex is determined. It would be expected that in vivo, the presence 
of thiomalate in the albumin-gold complex might influence further thiol 
exchange reactions which have been predicted from the chemistry of gold(l). 
Thiomalate therefore could influence or,modulate the availability or 
movement of gold into other plasma fractions or into tissues. Since this 
point is of such importance to the metabolism of gold and the mechanism 
of its action, the binding of gold and carbon-14 to albumin was examined 
using the radioactive thiomalic acid and sodium aurothiomalate compounds.
3.3.2 Materials and Methods 
Experimental
1. Disposition and excretion of gold and carbon-14.
Groups of three male Wistar Albino rats weighing about 200 g were
14
injected with either (1,4- C)thiomalic acid, 5.3 mg/Kg, or sodium 
14
(1,4- C)aurothiomalate, 8.2 mg/Kg, into the thigh muscle and then 
maintained in glass metabolic cages (Fig. 3.5) for 72 hours. Air was
ig
. 
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drawn through the apparatus by a suction pump, first through soda lime 
in order to absorb the carbon dioxide, then to the animal and finally 
through three liquid traps which collected the expired carbon dioxide.
The three traps were collected in series, each containing 200 ml 
ethanolamine in ethyl digol (12% v/v) and maintained at 0°C. The 
trapping medium was changed at 90 minutes and at 3,6,24,48 and 72 hours. 
Urine and faeces were collected over three successive periods; 0-24 hours, 
24-48 hours, 48-72 hours. Blood was collected at 72 hours by cardiac 
puncture with the animals under barbiturate anaesthesia. The animals 
were then killed and tissues removed for analysis.
To assess the transfer of radioactive compound from the site of injection
in the muscle into the circulation a further experiment was conducted.
14
Rats were injected with either sodium(l,4- C)aurothiomalate or the 
14
(1,4- C)thiomalic acid as previously described but the site of injection 
on the thigh was marked. Twenty-four hours later the animals were killed 
by cervical dislocation. The area of skin approximately one centimeter 
square immediately above the point of injection was removed and the 
underlying muscle dissected awray and weighed. The sample of muscle 
v/as prepared for analysis of radioactivity by solubilization, as 
described below.
2. Subcellular distribution of gold and carbon-14.
(1) Male, Wistar Albino rats were injected sub-cutaneously with either
14 , 1 4
sodium(l,4- C)aurothiomalate, 10.8 pmol/Kg. (1.91 pCi) or (1,4- C)thio-
malic acid, 27.7 pmol/Kg (2.03 pCi) . The doses were selected to provide 
approximately 2 pCi radioactivity per experiment. At 2 hours and 24 hours 
after injection five rats from each group were killed by cervical dis­
location. The abdomen of each rat was opened to expose the liver which 
was removed and washed with ice cold buffered isotonic sucrose solution.
The liver was homogenised and the cellular organelles separated by 
differential centrifugation. Each fraction was analysed for radioactivity 
and for gold and the purity of the separations were assessed by measure­
ment of marker enzyme activities. . . '
(2) Male, Wistar Albino rats were injected sub-cutaneously with sodium
14
(1,4- C)aurothiomalate and killed two hours later by cervical dislocation. 
The livers were removed, homogenised and centrifuged to obtain a mixed 
mitochondrial-lysosomal preparation. This fraction was further separated
by sucrose density gradient centrifugation. The subcellular material 
removed at intervals along the gradient v/as also analysed for radio­
activity, gold and enzyme activities.
Homogenisation and Differential Centrifugation.
Excised liver was washed with ice-cold sucrose (0.25 M sucrose buffered 
in 5 mM Tris,pH7.4), blotted dry and weighed in a tared beaker contain­
ing 20 ml cold sucrose. The liver was cut into small pieces no larger 
than 0.5 cm cubes and placed in a pre-cooled Potter-Elvejhem tube. 
Homogenisation was effected by three complete strokes of the teflon 
pestle at 2,400 r.p.m. Further buffered sucrose solution was added to 
adjust to 1 g liver per 10 ml. The suspension was sieved into a cold 
beaker and then poured into 30 ml centrifuge tubes. The entire procedure 
from killing the rats to commencement of centrifugation was carried out 
with a minimum of delay and was completed within five minutes. All 
solutions and equipment were pre-cooled in an ice-bath before use.
The homogenate v/as centrifuged at 600 g for 10 minutes and the super­
natant poured into a cold beaker. The pellet was resuspended in 
buffered sucrose solution, recentrifuged and the two supernatants 
combined. The sediment, representing a crude nuclear fraction together 
with large cell debris and non-ruptured cells was labelled ’N f . The 
combined supernatants v/ere poured into tubes and centrifuged at 12,000 g 
for 15 minutes using an 8x50 ml angle rotor on an MSE High Speed 18 
centrifuge. The supernatant was removed,/the.pellet resuspended in 
buffered sucrose solution and the contents recentrifuged. The super­
natant was again removed to leave the mitochondrial-lysosomal fraction 
which was labelled *M+L’. The two supernatants were combined for a
further centrifugation step at 120,000 g for 60 minutes in an 8x35 ml
angle rotor using an MSE Super Speed 65 centrifuge. The precipitate, 
represented the microsomal fraction (’M T) and the supernatant, the 
cytosol.
The pellets were resuspended in sucrose solution to a final volume of 
5 ml and the volume of the residual cytosol was measured. These samples
were divided into aliquots and stored at -20°C.
Sucrose Density Gradient Centrifugation.
Buffered sucrose solutions were prepared at concentrations of 0.25 M,
0.3 M, 1.6 M and 2.0 M sucrose .in 5 mM Tris,pH7.4.
In three 20 ml centrifuge tubes, sucrose density columns were prepared 
using a gradient mixer to give linearly decreasing density columns with 
2.0 M sucrose at the base and 0.25 M sucrose at the top. The columns 
were kept at 0°C for about two hours before use.
Liver homogenates were prej)ared as described above and centrifuged to 
remove the nuclear material. The supernatants were centrifuged once 
at 12,000 g to isolate a crude mitochondrial-lysosomal fraction which 
was resuspended in 0.25 M buffered sucrose solution. Using a 2.0 ml 
syringe, 1.5 ml of each M + L suspension was carefully layered on to 
the top of a sucrose gradient and placed into a 3x25 ml swing-out rotor. 
Centrifugation at 9,000 g was carried out for 30 minutes to separate the 
elements of the suspension.
A 50 ml syringe containing 2.0 M buffered sucrose solution was mounted 
with the piston connected to a slow drive motor. The output from the 
syringe led to a narrow tube inserted down the centre of the sucrose 
column. The motor was calibrated to expel buffered sucrose solution 
from the syringe at 4 ml per minute. The buffered sucrose solution 
pumped into the base of the column g r a d u a l ^  displaced the contents 
from the top. Displaced solution containing separated sample was 
collected in aliquots of 1.0 ml and twenty were obtained from each column.
3. Biliary excretion studies.
Male, Wistar Albino rats weighing about 200 g were treated with either
14 ■ 14
(1,4- C)thiomalic acid, 27.7 ymol/Kg (2.03 yCi) or sodium(l,4- C)auro-
thiomalates 10.8 ymol/Kg (1.91 yCi) in saline. The compounds were pre­
administered by sub-cutaneous injection either two or twenty four hours 
before commencement of bile collection or by intravenous injection as 
soon as bile cannulation was achieved and bile flow established. In 
some experiments unlabelled sodium aurothiomalate was given.
Bile Duct Cannulation.
The rats were anaesthetised with sodium pentobarbitone (Sagatal) and the 
bile duct exposed by mid-line incision and displacement of first the skin 
and then the abdominal wall. Polythene tube 0.8 mm internal diameter was 
inserted into the bile duct through a hole cut in the wall of the vessel 
about 1 cm distal to the junction of the hepatic ducts. The cannula was 
retained in position by two ligatures. To prevent dehydration of the 
animal the cut edges of the abdominal wall were stitched together and
the skin incision closed with clips. The bile duct cannula emerged 
between the incision in the abdominal wall and through a small hole 
pierced in the skin.
To allow intravenous administrations the jugular veins were exposed by 
lateral incisions in the neck. The larger vein was supported from 
beneath while the injection was made. The skin was reclosed with clips.
A rectal thermometer was used to monitor body temperature which was 
maintained at 35-36°C by placing the rat on a heated blanket . Careful 
control of body temperature was essential to avoid thermal related 
changes in b i l i a ^  composition. (159) Additional administration of 
Sagatal was provided. intra-peritoneally as necessary to maintain 
anaesthesia. Bile was collected into pre-weighed, metal-free poly­
propylene tubes and blood was collected into hepari'nised tubes by 
sectioning the tail vein or by cardiac puncture at the termination of 
the experiments.
4. In V'i’tro protein binding.
Id-
Ca) Binding of (1,4- C)thiomalic acid to albumin.
To 10 ml of albumin solution (4% w/v, Bovine fraction V albumin,
Sigma, London, in 0.066 M phosphate buffer pH7.4 containing 0.9% w/v
sodium chloride and 0.005% w/v sodium azide (hereafter called phosphate
14
buffer)), 54.0 yg thiomalic acid and 50 nCi (1,4- C)thiomalic acid were 
added in a volume of 10 |ll. The solution, was mixed and stood at room 
temperature for 30 minutes. 1.5 ml was removed and separated by gel 
filtration on a 20x250 mm column containing Sephadex G75 (Pharmacia, 
London) at a flow rate of 4 ml per hour. Fractions of the eluate were 
collected every 30 minutes for 20 hours. A further 1.5 ml was similarly 
separated after an incubation period of 24 hours.
14
(b) Binding of sodium(l,4- C)aurothiomalate to albumin.
(i) To 10 ml of 4% albumin solution in phosphate buffer, 142.9 ]Jg
14
sodium aurothiomalate and 50 nCi sodiura(l,4- C)aurothiomalate were 
added in a volume of 10 pi. The solution was mixed and incubated at 
room temperature. 1.5 ml was removed and separated by gel filtration 
as described above after incubation periods of 0,5,15 and 30 minutes,,
24 hours and 7 days.
(ii) The gold and radioactive distribution at different molar ratios
of sodium aurothiomalate and albumin were investigated. 10 ml of 4%
albumin solution in phosphate buffer was taken and an appropriate
amount of unlabelled sodium aurothiomalate was added. 50 nCi sodium 
14
(1,4- C)aurothiomalate was also added, the samples mixed and 1.5 ml 
removed for separation by gel filtration. The amounts of sodium auro­
thiomalate added to 10 ml of albumin solution were 14.3 yg, 71.4 yg, 
142.7 yg, 285.5 yg, 713.7 yg and 1427.0 yg (i.e. 3.66, 18.3, 36.6, 73.2 
182.9 and 365.9 ymol/£) which gave albumin to drug molar ratios of 161: 
32:1, 16:1, 8:1, 3.2:1 and 1.6:1 respectively.
14
(c) Binding of sodium(l,4- C)aurothiomalate to Sephadex G75.
1.5 ml phosphate buffer containing 21.4 yg sodium aurothiomalate and
14
50 nCi. sodium(1,4- C)aurothiomalate was eluted through the same 
Sephadex G75 column.
The concentrations of albumin and sodium aurothiomalate used were 
selected so as to provide approximately the same levels as would be 
found in a patient during the first hour after an intramuscular 
injection of sodium aurothiomalate.
Analytical
1. Measurement of radioactivity.
Five scintillation systems were used:
(!) 0.55% 2,5-diphenyloxazole in toluene containing 4% thixotropic gel 
(Packard, La Grange, II, USA).
(2) 0.55% 2,5-diphenyloxazole in Synperonic NXP (I.C.I. Ltd.)/toluene 
(1:2 v/v).
(3) Instagel (Packard),
(4) 0.68% 2 (4^-t-butylphenyl)5 - (4^-bi.phenylyl)-1,3,4oxadiazole in 
Triton X 100/toluene (1:2 v/v).
(5) Pico-fluor 30 (Packard).
f*
Samples were treated as follows:
Methanol (4 ml) was added to 5 ml CO trapping medium and the solution
&
counted for radioactivity in 10 ml of scintillant 1.
Urine was diluted as appropriate and 100 yl suspended in 4.0 ml 
scintillant 2.
Faecal homogenates were prepared in 0.1 M phosphate buffer, pH7.4, to 
a concentration of 5% (w/v). Samples (500 yl) of the homogenates, were 
dispensed into glass scintillation vials and heated with 3.0 ml hyamine 
hydroxide (Packard) at 55-60°C for five hours. After cooling, 30% 
hydrogen peroxide (250 yl) was added and the solution decolourised over­
night. Digests were neutralised with 250 yl 12 M hydrochloric acid 
and suspended in 10 ml scintillant 3.
Tissue snips (250 mg), were added to 1.0 ml of a mixture of sodium 
hydroxide (8.0 g ) , methanol (30 ml), water (60 ml) and Triton X 405 
(10 ml of 75% aqueous solution) in glass scintillation vials and heated 
at 55-60°C for 1 hour. After cooling, 250 yl 30% hydrogen peroxide 
was added and left overnight. Digests were neutralised with 4 M nitric 
acid (500 yl) and suspended in 10 ml scintillant 4.
To 500 yl resuspended subcellular fractions prepared from homogenised 
liver samples, 3 ml hyamine hydroxide was added and the mixture incubated 
for one hour at 50°C. After cooling, 250 yl 30% hydrogen peroxide was 
added and the solution decolourised overnight. The samples were 
neutralised with 250 yl concentrated hydrochloric acid and 10 ml 
scintillant 3 added.
Samples of separated M + L fractions, plasma and bile (500 yl, 20 yl 
and 200 yl respectively) were added to 4...Q ml scintillant 5, mixed and 
left overnight at 4°C and the activity counted.
Samples (0.5 ml) of the fractions eluted from the Sephadex column were 
added to 4.0 ml scintillant 2, mixed and counted.
Activity was counted using either a Packard 2425 or a Packard Prias
scintillation counter. Counting efficiencies were determined by internal
14
standardisation using ( C) hexadecane and radioactivity calculated as 
described in section 3.2.1.
2. Measurement of gold.
Tissue and faecal samples requiring destruction of organic material were 
prepared for analysis using the acid digestion technique (see section 2.3.1)
Gold concentrations were determined by atomic absorption spectroscopy 
either by aspiration into the flame or, when further sensitivity was 
required, by electrothermal atomization using the Pye SP9 Video Furnace 
AAS (Table 3.1).
Biliary gold was measured by pulse sampling atomic absorption spectro­
photometry. 100 yl of sample was pipetted into the conical base of 
an auto-analyser sample cup. The nebuliser capillary of the atomic 
absorption instrument was inserted into the cup and the sample 
immediately aspirated completely into the flame. The transient signal 
was recorded on a rapid-response chart recorder. All analyses were 
performed in duplicate and excellent precision (less than 5% difference 
between paired peak_heights) was routinely obtained. The peak heights 
were compared against those obtained from 100 yl of aqueous gold 
standards similarly aspirated into the flame.
Gold in plasma was measured either by pulse sampling atomic absorption 
spectrophotometry or by flame aspiration using the method of internal 
standardization described in section 2.3.2.
Samples collected from the Sephadex column were analysed by flame 
aspiration and the signals compared with those given by gold standards 
diluted in phosphate buffer.
3. Thin layer chromatography.
From the samples of urine collected during the first 24 hours of the 
metabolic experiments, 10 yl were separated on silica-gel G1500 thin 
layer chromatography plates using butanol, acetone, acetic acid, water 
(70:70:20:40) as the developing solvent. No pre-treatment to the urine 
was made. Standard solutions of commercially available thiomalic acid 
and sodium aurothiomalate were run on the same plate.
Autoradiographs of the developed chromatograms were prepared to identify 
the radioactive excretory compounds. To prevent powder adhering to the 
radiograph the chromatography plate was covered by a thin film of 
cellophane (Clingfilm) stretched over the silica-gel and sealed to the 
reverse side of the plate. X-ray film, Kodak NS-2T was firmly sandwiched 
between the silica-gel surface of the TLC plate and a sheet of glass 
which were then secured together with adhesive tape. The plate was then
Table 3.1 Instrumental conditions used with Pye SP9 Video- 
Furnace for the determination of gold by electro­
thermal atomic absorption spectroscopy.
Final temp 
(°C)
Ramp rate 
(°C sec“l)
Time held 
at temp 
(sec)
DRY phase 120 2 10
ASH phase 1000 20 10
ATOMISE phase ' 2500 >2000 5
CLEAN phase 3000 >2000 5
Wavelength - 242.8 nm, band pass - 0.5 nm, lamp current - 8 m A .
During the atomise phase the temperature control and gas stop options 
were applied. Auto zero was operated at the start of the DRY and 
ATOMISE phases.
wrapped in at least three layers of light proof paper and placed in a 
press to ensure no movement of the X-ray film relative to the chromato­
graph. An exposure period of eight weeks was allowed before the film 
was developed. Kodak developer and fixer were both diluted, 50 ml +
200 ml water and the films immersed in each solution (developer followed 
by fixer), for four minutes in each. After washing in running tap 
water for 3-4 hours the films were suspended until dry. Preparation 
of the autoradiographs and their development were carried out in a 
photographic dark room.
After development of the films the TLC plates were sprayed with 0.5% 
potassium permanganate to determine the position of the thiomalic acid 
and sodium aurothiomalate markers.
Chromatography and autoradiography of samples of bile was carried out 
using the same procedures.
4. Measurement of enzyme activities and protein concentrations.
The following enzyme markers for subcellular particles were used; 
succinic dehydrogenase-mitochondria, acid phosphatase-lysosomes, 
S^nucleotidase-membranous material and glucose-6-phosphatase-endo- 
plasmic reticulum (microsomes).
Aliquots of resuspended subcellular fractions and samples of cytosol 
were allowed to thaw and diluted fortyfold ana twentyfold respectively 
with 0.25 M buffered sucrose solution. - The separated M + L fractions 
v/ere diluted fivefold with 0.25 M buffered sucrose solution.
Protein: Protein concentrations v/ere measured by the method of Lowry
using a continuous flow system for analysis. (165)
Succinic dehydrogenase, 5 ^nucleotidase and glucose-6-phosphatase were 
determined using the methods of Pennington (166), Prospero, Burge,
Norris et al. (167) and Prospero and Hinton (168) respectively.
Acid phosphatase: A method developed at the Robens Institute,
University of Surrey by Hinton and Dobrota was used. Sample (0.5 ml) 
was added to 0.3 ml 0.3 M sodium acetate buffer, pH5.0 and 0.1 ml 0.016% 
v//v digitonin. Solutions v/ere warmed to 37°C and the reaction started 
by the addition of 0.1 nil 1 M jjglycerophosphate,pH5.0. The reaction
was terminated after 60 minutes by adding 1.5 ml 6.0% w/v trichloro­
acetic acid and the tubes were centrifuged to remove precipitated 
protein. The supernatants were taken for the measurement of released 
phosphate. All analyses were carried out in duplicate and a substrate 
blank using 0.25 M sucrose instead of sample was set up. Digitonin v/as 
used to release the enzyme from lysosomes and unlike Triton (an 
alternative releasing agent) does not interfere in the subsequent measure­
ment of phosphate.
Phosphate: The phosphate concentration in samples after enzyme reactions
had been completed, v/ere determined by the reaction v/ith ammonium 
molybdate followed by reduction of the phosphomolybdate complex to 
molybdenum blue. These reactions were carried out using a continuous 
flow system for analysis. (169)
Eluate from the Sephadex column v/as continuously monitored for total 
protein content by recording the absorbance at 280 nm.
3.3.3 Results
1. Disposition and excretion of gold and carbon-14.
The cumulative excretion of radioactive carbon from the rats injected 
14
with (1,4- C)thiomalic acid is shown in Fig. 3.6. Excretion of 
carbon-14 via the faeces was relatively trivial and accounted for no 
more than ?.% of the injected dose. Father more was eliminated by the 
lungs and about 10% of the administered radioactivity was collected from 
the expired air, most appearing within the first 3 hours. The major 
route of excretion was via the kidney wTith 50% of the injected carbon-14 
removed into the urine and as with the CO^ very little was lost after 
the first 24 hours.
The pattern of excretion of carbon-14 from the animals given sodium
14 x
(1,4- C)aurothiomalate is given in Fig. 3.7. As v/ith the thiomalic
acid treated animals, it was the first 24 hours which were important
and very little radioactivity was found in samples collected later.
14
Again, as v/ith the rats given (1,4- C)thiomalic acid, excretion via
the faeces was not important while the expired air accounted for slightly
more at 12-15% of the given dose. Although renal excretion was again
the main route for elimination, a greater proportion of the dose (75%)
14
v/as removed compared with the (1,4- C)thiomalate treated rats.
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Fig. 3.6 Excretion of carbon-14 in expired air, urine and 
faeces by rats given (1,4~14c)thiomalic acid by 
intramuscular injection. Results are expressed as 
mean ± standard deviation, n = 3.
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F i g . 3.7 Excretion of carbon-14 in expired air, urine and
faeces by rats given sodium(l,4-1-4C)aurothiomalate 
b y  intramuscular injection. Results are expressed 
as mean ± -standard deviation, n = 3.
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The total and urinary excretion of carbon-14 from both experiments are
shown together in Fig. 3.8 and the significantly greater (p<0.01)
removal in the aurothiomalate treated animals is evident. As a
consequence of the different level of excretion there v/as also a
significant difference in the amount of retained radioactivity within
the bodies at the end of the experiments with 30-35% of the thiomalic 
14
acid - C unaccounted for compared with only 2% remaining from the 
aurothiomalate - .
Chromatography and autoradiography of urine samples collected during
the first 24 hours after injection showed that 2 major and at least 3
14
other compounds containing carbon-14 v/ere excreted by the (1,4- C)
thiomalic acid treated animals (Fig. 3.9). The densest spot on the
autoradiogizaph had an Rf value which was identical to that of thio-
14
malic acid. Urine samples collected from the sodium(l,4- C)auro- 
thiomalate injected rats contained a greater number of radioactive 
compounds, with 4 dense and at least three other spots (Fig. 3.9).
Two of the dense areas of radioactivity coincided with the positions 
of sodium aurothiomalate and with thiomalic acid.
In subsequent experiments other small molecular weight thiol compounds 
were chromatographed together with the same urine samples in attempts 
to identify the radioactive components v/hich were not established as 
either thiomalic acid or sodium aurothiomalate. The compounds 
investigated were cysteine and glutathione. Equimolar mixtures of 
these two with sodium aurothiomalate and with thiomalic acid were also 
prepared and chromatographed. Table 3.2 documents the Rf values 
obtained for these compounds and the mixtures and compares these values 
with those derived from the urine sample autoradiographs.
Both cysteine and glutathione travelled to give spots that were 
distinct from those of the two injected compounds. From the equimolar 
mixture of glutathione and thiomalic acid three spots were identified 
two of which corresponded to the individual components of the mixture 
while a third with an Rf of 39 suggested that a mixed species was also 
present. The 'mixture of cysteine and thiomalic acid however resolved 
into just two spots identified as the compounds added. From this 
observation it is inferred either that no association occurs betv/een ' 
cysteine and thiomalic acid or that the chromatographic conditions cause 
the separation of any weak bonding between them. Likewise sodium
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% of
inj eeted 
dose
Fig. 3.8
at 1 T*la-
Total
a
d Urine
■0 Total
Urine
Thiomalic acid
Sum— —    -.fc— i-.. i— .— —    n ..... . .......11, ■ —
o 1 2 3
Days
Comparison of total carbon-14 excretion (-0— ) and excretion 
in the urine (— Q —) between rats given (1,4-14C)thiomalic 
acid and sodium(l,4-14C)aurothiomalate by intramuscular 
injection. Results expressed as mean ± standard deviation, 
n = 3, a = significant difference between the two groups
(p<0.01).
Solvent
front
Fig- 3.
G
G
V V V V  r Origin
Position of 
thiomalic 
acid (Sigma 
Chem. Co.)
Urine from 
rat given 
( ^ C )  thio­
malic acid
Urine from 
rat given 
sodium 
(i^C)auro­
thiomalate
Position of 
sodium auro­
thiomalate 
(May ?i Baker 
Ltd.)
14
Radioactive metabolites in the urine of rats given (1,4-~~C)thio­
malic acid and sodium(1,4-14q )aurothiomalate by intramuscular 
injection. Metabolites separated by thin layer chromatography on 
silica gel G1500 using butanol, acetone, acetic acid, water 
(70:70:20:40). and located by autoradiography. Non dense spots 
shown by dotted o u t l i n e .
Table 3.2 Rf values obtained by thin layer chromatography and auto­
radiography of rat urine samples collected for 24 hours
14
after administration of (1,4- C)thiomalic acid and 
14
sodium(1,4- C)aurothiomalate, together with Rf values 
for thiol compounds and mixtures. Chromatography was on 
silica gel G1500 plates and developed with butanol, acetone, 
acetic acid, water (70:70:20:40:).
Rf value
Samples:
84
48
20
54
84
39
16
9
82
54
44
24
77
51
48
87
84
82
65
50
87
84
82
76
47
Sample
number
6> 10
1. thiomalic acid (tma) 6. tma - cys
2. aurothiomalate (atm) 7. atm - GSH
3. glutathione (GSH) 8. atm - cys
4. cysteine (cys) 9. urine from tma-treated rats
5. tma - GSH 10. urine from atm-treated rats
aurothiomalate and glutathione did not appear to give a mixed species 
when the sample was chromatographed but v/ith cysteine a third component 
to the chromatograph was generated when the gold compound was added.
Thus there is some evidence for complexes between thiomalic acid and 
glutathione and between cysteine and sodium aurothiomalate which are 
sufficiently stable to be chromatographed using the system employed 
here. Of the radioactive components separated in the urine samples 
only one could possibly be considered as coinciding with any of the 
mixed compounds. Urine from the rats given the radioactive gold 
compound had a dense spot at an Rf position of 76 which compared with 
the third cysteine-sodium aurothiomalate spot located with an Rf of 77.
The distribution of retained radioactivity within the tissues examined 
is shown in Fig. 3.10. The amount of radioactivity in each sample 
taken for analysis was determined. bjr internal standardisation and 
calculated to express the result as nCi per gram of tissue. Since 
slightly different amounts of radioactivity v/ere administered in the 
two experiments the results were then recalculated to give the percent­
age of the total administered dose per gram of tissue. These values
were then multiplied by 1000 to avoid very small numbers. The
 ^• ... nCi/g x 100 t
recalculation therefore was — — — ;— —— -— -r x 1000. In this way direct
nCi injected
comparisons can be made between the two groups of animals.
The radioactive distribution pattern was similar for both the earbcn-14
labelled compounds. Surprisingly the highest concentration was found
in the bone (a rib was taken for this analysis) with the second greatest
level of activity present in the kidney. However, this was only one
fifth the amount found in the bone. The liver, lungs, spleen and heart
contained somev/hat smaller concentrations with the lowest levels measured
in fat, muscle, skin and the testis. In no tissue was radioactivity not
detectable. Although the distribution was approximately the same in both
sets of animals there were certain tissues - bone, skin and heart but
particularly the kidney where retention of carbon-14 v/as significantly
14
greater from the injected sodium(1,4- C)aurothiomalate as. compared with
. ■ „ ■ 14
that found in the same tissues from the (1,4- C)thiomalic acid treated
rats.
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The excretion of gold from the animals treated with sodium(l,4- C)auro­
thiomalate is shown in Fig. 3.11. During the first 24 hours, equal amounts 
of the metal were lost in the urine and faeces. Thereafter the urinary 
removal of gold fell off very rapidly whereas that found in the faeces was 
maintained at about the same level. At the end of the experiment i.e. 72 
hours after the injection, about 30% of the administered gold had been 
recovered in the excreta with two-thirds of this in the faeces (Fig. 3.12).
Table 3.3 shows the concentrations of gold measured in the sera, and in 
tissues removed after 72 hours. The concentrations v/ere low and with the 
limited weight of material available gold was not detected in every sample. 
The greatest concentration was found in the kidney with a mean value of 
1.24 jig/g. Smaller amounts were present in the liver, lung, and spleen 
with even lower levels in the heart, skin, muscle and fat. The mean serum 
gold concentration was 10.7 ymol/£ (210 yg/100 ml).
The total amount of gold present in each organ was calculated or, where 
organ weights were unavailable (e.g. for skin), from standard tables. (170) 
By adding the amount of gold measured in these tissues and the gold 
excreted, 45% of the injected gold was accounted for. The remaining 55% 
was presumably distributed throughout the organs not analysed.
Radioactivity measured at the site of intramuscular injection 24 hours 
after administration of the labelled compound was calculated as the 
percentage of the total dose per gram of muscle (NB - less than one gram 
of muscle was removed from the point of injection). From the rats injected 
with labelled sodium aurothiomalate, less' than 2% of the dose was found 
per gram, whereas the samples from the animals given thiomalic acid 
contained considerably more, 11.3 ± 4.1% per gram. -
2. Subcellular distribution of gold and carbon-14.
Enzymes ^
The activities of the marker enzymes in the subcellular fractions obtained 
by differential centrifugation are shown in Figs. 3.13 and 3.14. The 
distributions were similar in all experiments indicating that the admini­
stration of sodium aurothiomalate or thiomalic acid had no acute effect 
upon hepatocellular enzyme activity.
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Table 3.3 Concentration of gold and carbon-14/gold ratios measured
in serum and tissues of rats 72 hours after administration 
14
of sodium(l,4- C)aurothiomalate by intramuscular injection.
Gold
]Jg/g
l4C/Au
ratio
Liver 0.85 ± 0.11 14
Kidney 1.24 ± 0.10 14
Spleen . ~ 0.79 ± 0.09 11
Heart 0.59 ± 0.11 15
Lung 0.83 ± 0.16 q
Fat 0.16 ± 0.05 28
Skin 0.32 ± 0.05 . 21
Muscle 0.18 ± 0.03 23
Serum ( |i raol/£)
( p g/100 ml)
10.7 ± 1. 32 
210 ± 2 6 2.4
Results are expressed as mean ± standard deviation, n = 3.
14
C/Au ratios were determined from the data shown in Fig, 3.10 
for radioactivity and the gold concentrations given in this table.
v ana. j iucas?ui'^u -in tjuucfcJiiuiHr iraccions
14.
prepared from liver homogenates of rats given (1,4- C) 
thiomalic acid, 2 <tzi> and 24 (jgyjj) hours before 
killing (n = 5).
200.
Carbon-14
10
CITS®. iJtUianJUM Succinic dehydrogenase
10
Glucose-6-phosphatase
5
"*‘55$. r-— 5 nucleotidase
N Mic
Acid phosphatase
N — nuclear, 1,1 + L — mitochondrial-lysosomal, Mic = microsomal, 
cyt = cytosol. '
«•«
No format for differential centrifugation produces exquisitely purified 
fractions of subcellular organelles (171) and some contamination between 
fractions was evident in these preparations.
The limited amounts of succinic dehydrogenase (SDH), acid phosphatase (AP) 
and glucose-6-phosphatase (G6P-ase) activities in the crude, nuclear 
fraction demonstrated the presence of both intact cellular material and 
the heavier cell fragments in addition to actual nuclear particles.
The SDH activities further indicated that, included with the nuclear and 
microsomal pellets, there were respectively a small number of heavier and 
lighter elements of the mitochondrial particles. Hov/ever approximately 
70% of the total SDH activity was present in the M + L fraction.
About 10% of the total AP activity was located with the microsomal 
fraction suggesting that lighter lysosomal particles separated v/ith the 
homogenisation products of the endoplasmic reticulum. The limited propor­
tion of G6P-ase activity (15% of the total) determined in the M + L 
fraction indicated that some of the microsomal material was trapped with 
the particulate matter derived from mitochondria and lysosomes.
The negligible activity of any of the enzymes assayed in the cytosol 
demonstrated that the high speed supernatant was free from contamination 
by organelles. This low level of enzyme activity was also apparent when 
expressed per milligram of protein and was not an artefact due to the 
large volume of the cytosol.
As a marker of membranous particles, 5^-nucleotidase (5-NT) activity was 
determined in all fractions although the M + L and especially the cytosol 
were distinct in having low levels (one tenth to one third) compared with 
the nuclear and microsomal fractions.
Despite this evident and anticipated cross-contamination between samples 
prepared by this classical procedure of differential centrifugation, each 
fraction appeared to be sufficiently pure (70-85% according to the major 
enzyme marker) to be able to demonstrate subcellular separation and 
distribution of the injected compounds.
Marker enzyme activities in the samples prepared from the sucrose gradient 
separation of the mitochondrial-lysosomal fraction also showed that there
was only trivial contamination from other elements (Fig. 3.15). The 
GGP-ase and 5-NT activities were of little consequence (Vso ~ Vi o) 
compared with the levels found in other samples prepared by differential 
centrifugation. The lysosomes and mitochondria were well separated by 
the gradient as demonstrated by the position of acid phosphatase and SDH 
activity and also the distribution of protein. (172) The lighter 
lysosomes occupied fractions 1 to 6 and the mitochondria were located in 
fractions 11 to 18.
Radioactivity
Two hours after the injection of radioactive thiomalic acid 1.65% of the 
administered dose had been taken up by the liver. Of this radioactivity 
the major proportion, 76%, was located within the cytosol. The mito­
chondrial-lysosomal fraction contained about 15% while the residual 9% 
was distributed among the other organelles. One day later the radio­
activity contained within the liver had decreased to 0.5% of the injected 
dose. There was an unequal loss from the various cellular sites and the 
cytosolic radioactivity then accounted for only 70% of the hepatic load 
while within the formed elements the relative proportions were somewhat 
increased (Table 3,4 and Fig. 3.13).
The subcellular distribution of carbon-14 in the animals given labelled 
sodium aurothiomalate was only slightly different to that of thiomalic 
acid with 80% present in the cytosol and about ]0% in the :mib©choi5<ifiVl“ 
lysosomal elements (Fig. 3.14). As with the thiomalic acid the total 
content decreased by about two-thirds at 24 hours (Table 3.4).
Using the technique of sucrose density gradient centrifugation it v/as 
found that virtually all. the radioactivity in the WilHoch©fl^ti!ol-lysosomal 
fraction was present in the mitochondria (Fig. 3.15).
Gold
Analysis of the cellular fractions of gold in the sodium aurothiomalate 
treated rats indicated that the metal initially accumulated in the cytosol
t*
but was cleared into organelles with the greatest concentration of gold 
per milligram of protein found in the mitochondrial-lysosomal material.
The clearance was particularly efficient so that 24 hours after the 
injection, approximately 10% of the cellular gold was contained within the 
cytosol (Table 3.4). From the sucrose density gradient separation of the

Table 3.4 Retention of gold and carbon-14 in the liver and liver sub-
14
cellular fractions in rats given (1,4- C)thiomalic acid and 
14
sodium(1,4- C)aurothioraalate.
Thiomalic acid 
treated rats
Sodium aurothiomalate 
treated rats
2' t ' hrs 24 hrs 2 hrs 24 hrs
CARBON-14
% of injected 
dose found in 
liver 1.65 ± 0 . 5  0.5 ± 0.2 3.0 ± 0 . 8 1.1 ± 0.3
% of liver 
14C found in 
each fraction 
cytosol 76.0 ± 8.2 70,0 ± 5.9 80.0 ± 8.5 72.0 ± 6 . 3
Mitochondria-
lysosomes 14.9 ± 1.7 17.0 ± 1.2 10.6 ± 1 . 1 10.7 ± 1.0
Other fractions 9.1 ± 1.1 13.0 ± 1.3 9.4 ± 1.0 17.2 ± 1.4
GOLD
% of injected 
dose found in 
liver 0.8 ± 0.2 3.6 ± 1.0
% of liver Au 
found in each 
fraction 
cytosol 56.8 ± 6.3 10.3 ± 1 . 6
Mitochondria-
lysosomes 15.8 ± 3 . 5 44.8 ± 4.2
Other fractions 27.4 ± 3 . 3 44.9 ± 4.0
Results are expressed as mean ± standard 
deviation, n = 5 .
mitochondrial-lysosomal fraction the gold was found in the tubes contain­
ing acid phosphatase activity, i.e. within the lysosomes (Fig. 3.15).
3. Biliary excretion studies.
Secretion of components into the bile may be expressed as weight per 
minute per unit of body weight or weight per unit volume of bile. Provided 
that bile flow is constant throughout the course of an experiment either 
technique is valid. In the experiments conducted here, biliary flow, 
measured by the weight of bile collected, was found to remain constant 
for at least four hours.
The clearance of radioactive carbon-14, from the plasma of rats given 
14
(1,4- Othiomalic acid was extremely rapid (Figs. 3.16 and 3.17). Within
three minutes of intravenous injection, only about 10% of the administered
radioactivity was present within the blood (assuming a blood volume of
12 ml in a 200 g rat and rapid equilibration of the thiomalic acid between
plasma and cells). That the low plasma levels of carbon-14 were due to
efficient clearance and not faulty injection is suggested by - (i) blood
was drawn into the syringe before the injection was given, (ii) in one
experiment the radioactivity retained in the liver at the conclusion was
measured and found to represent approximately 10% of the injected activity.
Therefore a reasonable proportion of the dose had been transported from the
neck to the abdomen - i.e. through the blood. The half life calculated from
the disappearance curve (Fig. 3,17) was 14 minutes. Very low levels of
radioactivity were measured in the bile (Fig. 3.16) and none was detected
14
later than 120 minutes after injection. Whbn the (1,4- C)thiomalic acid 
was preadministered 24 hours before bile was collected, no radioactivity 
could be measured in either the plasma or the bile.
With the radioactive gold compound however the plasma carbon-14 half life 
was somewhat longer (Figs. 3.17 and 3.18). At 3 minutes post-injection 
more than 40% of the administered material was still within the circulation. 
The disappearance curve showed an initial distribution phase lasting 
approximately 60 minutes followed by a steady loss of activity with a t|; of 
70 minutes (Fig.^ 3.17) and radioactivity could be detected in the plasma 
for at least four and a half hours.
Although there was more radioactivity in the plasma compartment a similar 
proportion of the administered carbon-14 was secreted into the bile as was 
found with the labelled thiomalic acid (Fig. 3.18).
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Fig. 3.17 Plasma clearance of carbon-14 from rats given (1,4- i
14
thiomalie acid or sodium(l,4- C)aurothiomalate by 
intravenous injection.
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The disappearance of gold from the blood and its appearance in bile are 
shown in Fig. 3.19 and a picture completely different to that seen for 
carbon-14 was found. Approximately 40% of the administered gold was 
present in the plasma at the time when the first blood sample was collected 
(3-5 minutes after injection). This calculation assumes a blood volume 
of 12 ml of which the plasma, where gold is confined, is about 6 ml. After 
30-40 minutes the plasma gold concentration was increased by about 10% but 
thereafter decreased gradually. The plasma gold half life calculated from 
this linear section of the curve was 242 minutes. Biliary gold concentra­
tions were approximately 1% of the plasma concentration. A peak of secret­
ion occurred 10-15 minutes later than the point at which maximum plasma 
gold levels were attained. There was then a gradual decrease in the biliary 
gold output which paralleled the fall in plasma gold although at three hours 
post-injection a slight increase in biliarjr gold was evident. The total gold 
secreted during the first three hours following intravenous injection was 
0.55 ± 0 . 1 6  yg or 0.44% of the injected gold.
Thin layer chromatography and autoradiography of bile collected during the
34
first 20 minutes following injection of sodium(l,4~ C)aurothiomalate 
revealed just a single radioactive component with an Rf value of 84 which 
was the same as was found for thiomalie acid (Fig. 3.20).
4. In vi-tro protein binding.
Elution of protein: The purpose of the experiment was essentially to
separate material bound to albumin (approximate molecular weight 70,000) 
from compounds with very low molecular weights - less than 1,000. Therefore 
a very simple separation system was all that was required. Using G75 the 
albumin eluted as a sharp peak between fractions 10 and 16 (collection of 
the first fraction was commenced when all the sample had just entered the 
column). The elution volume Ve was 25 ml and was well away from the bed 
volume of the column at which point the low molecular weight, unbound 
compounds appeared (Fig. 3.21). Thus this separation system was satisfactory.
The concentrations of gold and albumin in the time course experiment were 
.selected to give approximately the values which would be found in the plasma 
of a patient soon after receiving an intramuscular injection of sodium auro­
thiomalate. The distribution of gold and carbon-14 between the albumin and 
non-albumin bound fractions following Sephadex separation is shown in 
Table 3.5. The major proportion of the gold but no more than 10% of the 
radioactivity was associated with the albumin at 30 minutes after addition
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Fig. 3.20 Autoradiograph of thin-layer chromatographic separation of
bile collected from rat for 20 minutes after intravenous
14
injection of sodium(l,4- C)aurothiomalate. Chromatographic 
conditions as given in Table 3.2.
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of the drug. Distribution at earlier times was very similar but there 
was relocation with longer periods of incubation. The proportion of 
albumin bound gold increased to approximately 90% while a greater 
proportion of the carbon-14 moved onto the albumin only to be displaced 
after 7 days.
Fig. 3.22 shows that divorce of gold from carbon-14 was not effected 
merely by passage of the sodium aurothiomalate through the Sephadex.
The elution profile of these two components of the labelled compound 
were identical when albumin was omitted from the medium and showed no 
evidence of separation.
Thiomalie acid does not appear to bind to albumin. Fig. 3.23 shows that 
the radioactivity was well separated from the protein and appeared at 
the solvent volume, Vs. The inference from these data is that in the 
sodium aurothiomalate experiments any carbon-14 which was found in 
association with protein can only be as the intact aurothiomalate and 
not as thiomalie acid.
In Table 3.6 the distribution of gold and carbon-14 at different 
albumin : sodium aurothiomalate molar ratios is shown. Where the 
proportion of protein to drug was high, all the detectable gold was 
protein bound but v/ith increasing concentration of sodium aurothiomalate, 
progressively more of the total appeared in the unbound fraction. A 
similar shift in the distribution cf radioactivity also occurred although 
far less was initially associated with the/protein. Using the data 
obtained the amounts of gold and carbon-14, bound to albumin were plotted 
according to the method of Scatchard to determine the binding characteris­
tics (Figs. 3.24 and 3.25). These plots are characteristic of multi- 
component systems and show the typical features of high affinity - low 
capacity and low affinity - high capacity binding sites. Apparent affinity 
constants and binding capacities were calculated according to the equations 
derived by Scatchard and are shown in Table 3.7.
3
Affinity at the main binding site was greater for gold, 1.02x10 compared
* 3
with carbon-14 0.42x10 and similarly the maximum binding capacity for 
gold was greater than for carbon-14 (4.7 and 5.5 ymol/mmol respectively). 
Binding to the secondary site(s) exhibited similar differential results 
for both the gold and carbon-14.
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Gold bound; ymol/mmol albumin.
Fig. 3.24
Scatchard plot of gold binding sites on albumin. The ratio of the 
bound to free gold is on the vertical axis.
The association constant of the high affinity site was obtained from 
the slope of the straight line at low gold concentrations after correction 
for the contribution of the low affinity site(s) at higher gold concentra­
tions. The maximum binding capacities were calculated from the intercepts 
on the horizontal axis.
0-25
1 0  ~ 2 0
Carbon-14 (aurothiomalate) bound; ymol/inmol albumin 
Fig. 3.25 '
Scatchard plot of carbon-14 (aurothiomalate) binding sites on albumin. 
The ratio of the bound to free carbon-14 is on the vertical axis.
The association constant of the high affinity site was obtained from 
the slope of the straight line at low aurothiomalate concentrations 
after correction for the contribution of the low affinity site(s) at 
higher aurothiomalate concentrations. The maximum binding capacities 
were calculated from the intercepts on the horizontal axis.
Table 3.7 Apparent affinity constants and binding capacities of the 
gold and carbon-14 binding sites on human albumin. Site I 
is a high affinity, low capacity site. Site II is one (or 
representative of several) low affinity, high capacity site 
The contributions of the low affinity binding site(s) were 
subtracted from the results of the high affinity binding 
sites before completing the calculations. Results were 
calculated from Figs, 3.24 and 3.25.
Maximum binding capacity Apparent affinity constant 
pmol/mmol albumin L/M“l
Site I Site II Site I Site II
Gold
Carbon-14
47
5.5
140
61
1.02xl03 15
0.42xl03 1
3.3.4 Discussion
1. Disposition and excretion of gold and carbon-14.
If a rapid separation of gold from, the carrier takes place as has hitherto 
been assumed, the excretion and tissue distribution of radioactive carbon 
would be the same in rats injected with either sodium aurothiomalate or 
thiomalie acid. The results obtained are inconsistent with this assumption.
(i) during the initial 24 hours, which is the period when metabolic 
activity was particular^ dynamic, more aurothiomalate-carbon-14 than 
thiomalie acid-carbon-14 was removed by the kidney (Fig. 3.8) and there 
was an increased deposition of radioactivity in the kidney, bone and skin 
(Fig. 3.10).
(ii) the balance of radioactivity unaccounted for by excretion and tissue 
retention was approximately 35% in the thiomalate treated rats and only 
1-2% in the gold treated animals.
(iii) the labelled compounds detected in the urine by autoradiography 
(Fig. 3.9) were dissimilar and there were fewer in the samples from the 
non-gold treated rats.
However, the considerable differences in the patterns of excretion of gold
14
and radioactive carbon in the rats injected with sodium(1,4- C)auro­
thiomalate indicates that much of the gold is removed from the labelled 
portion of the drug (thiomalate) within a. few hours.
An explanation for the contrasting rates of excretion of radioactive carbon 
between the two groups of animals and also for the apparent enigma concern­
ing the carbon-14 which was unaccounted for in the rats given labelled 
thiomalie acid may be derived from the results of the measurements of 
radioactivity retained in the muscle at the site of injection.
The free sulphydryl group on thiomalie acid would appear to allow the 
formation of stable complexes within muscle. When this group is masked 
by the gold atom the molecule is less likely to be retained and entry to 
the circulation is virtually complete. Therefore the lower levels of 
radioactivity measured in the excreta and tissues of rats given thiomalie 
acid could be merely a reflection of the de facto reduced dose.
This proposal however does not provide an explanation for the patterns 
of urinary metabolites which were found and a rapid removal of all the 
gold from the thiomalate upon entry into the circulation cannot there­
fore be assumed.
2. Subcellular distribution of gold and carbon-14.
The very similar patterns of intracellular distribution of carbon-14 
(Figs. 3.13 and 3.14) when administered either as sodium aurothiomalate 
or as thiomalie acid suggests two possibilities. Gold may be stripped 
from the thiomalate upon entry into the body so that essentially the 
same labelled compound is metabolised in both experiments. Alternatively, 
while some or all of the aurothiomalate remains intact within the 
circulation and enters the liver, the gold is removed from thiomalate 
during or very soon after passage across the cell membrane so that the 
liver cell is exposed only to labelled thiomalie acid.
Very little (less than 25%) of the radioactive carbon within the liver 
became incorporated into the formed structures of the cell and most of 
this was located in the mitochondria (Fig. 3.13, Table 3.4). The mito­
chondria of Kupffer cells are much smaller than mitochondria of hepatocytes. 
Therefore if the thiomalate-carbon-14 was primarily in Kupffer cells the 
peak of radioactivity in Fig. 3.15 would be biased towards the lower side 
of the peak of SDH activity. However, the exact parallelism observed 
between carbon-14 and enzyme activity indicates that the labelled material 
is within all cells or even predominantly within the more numerous hepato­
cytes .
Incorporation of gold into the liver (Table 3.4) was similar to that found 
by other workers (95,153), and is consistent with the results in Table 3.3. 
Histochemical and electromicrographic examinations of the liver tended to 
show most gold within the hepatocytes. (156) Furthermore, since biliary 
excretion occurs and is presumably responsible for at least some of the 
faecal elimination of gold (Chapter 1 and Figs. 3.11 and 3.12), meta­
bolism of gold must be mainly within the hepatocyte.
However, removal of gold from the circulation has been attributed to the 
activity of the hepatic reticulo-endothelial cells and the concentration 
of gold v/ithin the Kupffer cells was reported to be double (per unit of 
protein) that found in hepatocytes. (173) Even so, the majority of the total 
hepatic gold was located within the more numerous fundamental liver cell
type. (173) Some hepatocellular gold may nonetheless be passed from 
Kupffer cells as is known to occur with iron. (174)
Therefore, while the phagocytic activity of the Kupffer cells may result 
in some gold and carbon-14 uptake, quantitatively the incorporation into 
hepatocellular tissue, either directly or via the Kupffer cells will be 
of greater importance in the metabolism of aurothiomalate.
The results presented in Table 3.4 and Fig. 3.14 and Fig. 3.15 are 
consistent with the findings of Lawson et at. (153) that within the liver 
cell there is a concentration of gold into the lysosomes within a few hours 
of intra-peritoneal injection of sodium aurothiomalate. From Table 3.4 it 
is seen that in the e.arly phase of gold metabolism, cytosolic gold represents 
a high proportion of the hepatic gold content. Lawson et at. (153) further 
examined this fraction and found the gold associated with four separate 
complexes one of which was only detected when the gold was pre-administered 
by at least 7 days.
This fraction was not further characterised and the authors avoided 
speculation as to whether it might represent a thionein protein although 
its appearance only after preliminary exposure to gold, the low absorbance 
at 280 nm and the approximate molecular weight of 10,000 are consistent 
features of thionein. Evidence for the formation of gold-thionein in the 
kidney following exposure of rats to sodium aurothiomalate is presented 
in the next chapter.
From the data of Lawson et at. (153) and .that given in Figs. 3.13 - 3.15 
and Table 3.4 the following course of events can be suggested for the 
sodium aurothiomalate entering the liver. As aurothiomalate crosses the 
cell membrane into the cytosol the cellular proteins-albumih and ligandin, 
strip gold from thiomalate. Where previous gold exposure has occurred a 
significant proportion of the gold also binds to a low molecular weight 
protein that may be metallotliionein. Some metal also complexes with thiol 
compounds such as glutathione and cysteine. Gold which is removed from 
thiomalate within the circulation may be expected to follow a similar 
course upon entry into the hepatocyte.
From the cytosol the major fraction of hepatocellular gold is eventually 
concentrated in lysosomes so that within twent 3^ four hours of injection 
most of the hepatic gold is found within these subcellular structures 
(Table 3.4) .
Thiomalate, either liberated intracellularly from gold or taken in from 
the plasma largely remains within the cytosol. Approximately 10% enters 
the mitochondria where some conversion to carbon dioxide takes place (see 
Figs. 3.6 and 3.7) but most is static within the cell(Table 3.4). Intra­
cellular location of thiomalie acid is consistent with the observations on
the binding of the compound at the site of injection and the very short
14
plasma half life following intravenous injection of (1,4- C)thiomalie 
acid.
3. Biliary excretion studies.
The most remarkable feature of the experiments with thiomalie acid was the 
v e r y  rapid disappearance from blood (Fig. 3.16). Removal from the 
circulation at this rate could be achieved by intracellular sequestration 
by compounds with extremely high avidity for thiomalie acid. Alternatively, 
dilution may take place by equilibration throughout the total body water 
as occurs with e.g. fucose, p-amino hippuric acid. In either case entry 
of the compound into the bile would be limited, as was found with thiomalie 
acid (Fig. 3.16) and would be accomplished by diffusion and leakage across 
the hepato-biliary membrane.
Movement of carbon-14 was quite different when the thiol group was masked 
by gold. The results obtained (Fig. 3.18) are in agreement with those 
presented above (Figs. 3.8 - 3.10) which provided evidence for the 
maintenance of some intact drug and do not support the hypothesis that 
gold is immediately lost from the thiomalate moiety upon entry into the 
circulation. Disappearance of radioactivity was retarded compared with 
the non-gold compound, possibly due to the formation of a mixed albumin- 
gold- thiomalate species (see below). By contrast however, as soon as 
radioactivity derived from aurothiomalate has entered the liver, it 
follows a course which is very similar to that of thiomalie acid-carbon-14 
with a slow trickle into the bile. This similarity in the handling of 
carbon-14 from both thiomalie acid and aurothiomalate was also found in 
the subcellular distribution experiments and suggests that the gold portion 
of any intact drug which is taken into the hepatocyte is rapidly removed 
to expose the thiol group.
Examination of the biliary components by thin-layer chromatography and 
autoradiography provided further evidence to support this suggestion with 
a failure to detect the presence of sodium aurothiomalate carbon-14
even though a radioactive compound with the same Rf as thiomalie acid 
was found (Fig. 3.20).
The plasma gold half life calculated from the data available during the 
three hours after intravenous injection was 242 minutes. This figure 
is compared with the half times determined by other workers in Table 3.8 
from which it is apparent that the movement of gold from blood follows a 
complex course. Fig. 3.19 shows that within the first hour there are at 
least two different phases with removal of gold from the plasma (60% of 
the injected dose) during the first few minutes followed by a return back 
into the blood so that there is a rebound in plasma concentration before 
a third, stable, phase is established Avhich exists for at least a further 
two hours.
This early period of gold pharmacokinetics has not been examined in any 
detail by other workers who have generally confined their attention to 
the disappearance of gold over much longer periods, usually commencing 
several hours after the injection. Such studies have produced data which 
effectively integrate any short-term subtle changes which occur during 
these times. Harth (83) recognised that there were at least two components 
to the long-term decline in plasma gold. He differentiated a period up to 
36 hours which was characterised by a much shorter half life than during 
the subsequent 5-6 days (Table 3.8).
A sequence of events to describe the movements of.gold in plasma observed 
during these short-term experiments can be' envisaged. The injected sodium 
aurothiomalate distributes throughout the -plasma and extracellular fluid 
but binding to albumin draws some gold back into the plasma compartment. 
These fluctuations, which last for about one hour, are superimposed upon 
the removal of gold into tissues such as the kidney and liver. From the 
data obtained during the long-term experiments (77,83,84) there appears to 
be a certain amount of re-release of gold from the tissue sites back into 
the circulation several days after the injection of aurothiomalate and 
therefore the measured half life becomes longer as observations over more 
extended periods are made.
ft
Gold which enters the tissues during the immediate post-injection period 
passes passively across the biliary-hepatocyte membrane so that the 
concentration of gold in bile reflects, with a short time-lag, the 
fluctuations in plasma gold concentration. It is seen in Fig. 3.19 however
Table 3.8 Calculated half lives for plasma gold clearance following 
administration of sodium aurothiomalate to rats (intra­
venous and intraperitoneal injections) and to man (intra­
muscular injections).
Period of observation 
following injection 
(lirs)
Route of 
administration
Half life 
(hrs)
Reference
0.05 - 3 i.v. 4 This work
4 - 3 6 i.m. 9.7 Harth (83)
1 - 168 i.p. 36 Lawson et at. (153)
3 6 - 1 6 8 i.m. 143 Harth (83)
24 - 192 i.m. 108 Gottlieb et at. (77)
24 - 240 i.m. 132 Gerber et at. (84)
i.v. = intravenous, i.p. = intraperitoneal, i.m. = intramuscular
that the biliary gold concentration appears to be increasing at three 
hours even though the plasma gold concentration is falling. This increase 
could be due to the start of a breakdown in hepato-biliary function in the 
rats maintained in the experimental, anaesthetised condition or it could 
be the first sign of the appearance in bile of gold previously accumulated 
, in lysosomes.
Enrichment of the biliary concentration by a mechanism such as discharge 
of accumulated lysosomal gold would account for the disparity between the 
amount of gold found in the faeces (10%) in the metabolic experiments 
described above (Fig. 3.12) and the calculated rate of secretion of gold 
into the bile. If gold continued to be secreted at the same rate as was 
measured in the first-three hours, and if there were no entero-hepatic 
circulation, the total excretion after 24 hours would be approximately 
3.5% of the administered dose.
4. In vi-tro protein binding.
The results presented indicate that even in a relatively simple tn V'itro 
system, set up at physiological pH, some 'metabolism* of sodium aurothio­
malate is effected by albumin. Given therefore that there is considerable 
separation of gold from the thiomalate when the two compounds are incubat­
ed, one can anticipate three possible protein bound species being formed 
i.e. albumin-Au-tma, albumin-Au and albumin-tma. The results from the 
experiment with albumin and thiomalie acid showed however that any 
association between these two compounds was very labile and complete 
separation is readily achieved by passage through Sephadex. Therefore 
it can be concluded that in the binding of carbon-14 to albumin which 
was demonstrated with sodium aurothiomalate, the gold atom must form an 
integral part of the complex i.e. albumin-Au-tma. Since more gold than 
carbon-14 was bound to albumin the metal-protein complex, albumin-Au must 
also exist.
The nature of the non-protein bound species can also be considered. From 
our knowledge of the chemistry of gold the existence of 'free Au(l)* can 
be discounted and any gold in this fraction must therefore exist with a 
suitable ligand, i.e. in this simple system as unchanged sodium aurothio­
malate. Unlike gold the majority of radioactivity remained within the 
non-protein bound compartment, therefore most of the carbon-14 would 
represent the drug after removal of the gold i.e. thiomalie acid.
It is therefore concluded that when sodium aurothiomalate is added, 'in 
vitro, to albumin, four compounds are formed. The relative proportion 
of each are shown in Fig. 3.26. Although this static system has only 
a limited resemblance to the complex dynamic environment which is the 
plasma of a patient with rheumatoid arthritis it does nonetheless allow 
for discussion and arguments to be developed and to include compounds 
which are known to form. The results presented indicate that about two- 
thirds of the sodium aurothiomalate is very rapidly disrupted with the 
gold sequestered by albumin. Some drug however remains intact and is 
divided between the bound and unbound fractions. A small amount of 
relocation and further disruption of the residual sodium aurothiomalate 
occurred but was very slow and presumably therefore has little significance
to the situation that pertains in vivo.
Rapid formation of albumin-gold complexes were similarly demonstrated by 
Gerber (8) and McKinley (3). McKinley (3) also showed that the pH of the 
reaction environment was important and that in an unbuffered system at pH 
5.1, association (monitored by circular dichroisra spectra) was initially 
very weak and several days incubation were required before equivalent 
size peaks were observed.
Yfhen Gerber (8) and Danpure (161) incubated albumin and sodium aurothio­
malate they were unable to detect release of thiomalie acid from the 
complex, (measurements were made in situ, not following a separation of 
bound and unbound components). This would suggest that either (a) the 
sodium aurothiomalate binds to albumin without being metabolised or that 
(b) an albumin-Au species is formed but the thiomalate is retained within 
the environment of the complex by weak bonding forces. The interaction 
between aurothiomalate and cysteine was investigated by Danpure (161) as 
a model for the interaction at the albumin binding site. Under these 
conditions thiomalie acid was released from the cysteine-gold complex 
suggesting that option (b) is the most appropriate explanation for the 
observations of Gerber (8) and Danpure (161). This option, a weak 
attraction of thiomalate to albumin, is not inconsistent with the results 
presented in Fig. 3.23. Passage through the Sephadex during gel chroma-
i*
tography might provide appropriate conditions for breakdown of the weak 
bonding forces with the clear separation of albumin and thiomalie acid.
Fig. 3.26 Representation of "metabolism” of sodium aurothiomalate by
albumin. Data taken from Table 3.5. Number within symbol
14
indicates % of material (gold or C) present in each fraction.
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Thiomalie acid, bound to albumin either through gold or weakly held close 
to the complex would remain available for the formation of further mixed 
thiol species or for participation in the thiol exchange reactions which 
occur in solution and could be expected to occur 'in V'ivo (Chapter 1).
Characterisation of the albumin-drug binding sites (Table 3.7) produced 
results which are similar to those determined by other workers (162,163) 
even though different techniques were employed to differentiate the bound 
and unbound species. The detail of the multi component nature of gold 
binding to albumin has not been extensively explored although it is 
evident from the Scatchard and similar plots prepared by these authors 
and from Figs. 3.24 and 3.25 that there are two or more low affinity 
sites.
With the exception of the attempts to measure release of thiomalie acid 
(which were referred to above), binding of the non-gold component of 
sodium aurothiomalate to albumin has not previously been investigated.
The maximum binding capacities observed at sites I and II for both gold 
and radioactivity are consistent with the hypothesis that binding of this 
non-gold component is through the metal atom and not directly onto the 
albumin molecule. The key role of gold in the binding of aurothiomalate 
at site I is emphasised by the greater avidity demonstrated for the 
metal in comparison with the thiomalate label which is also consistent 
with the formation of an albumin-Au-thiomalate complex.
Assembling together the results from the/metabolic, subcellular 
distribution, biliary excretion and -in vitro binding experiments, it 
becomes possible to propose an overview which describes many features of 
the metabolism of sodium aurothiomalate (Fig. 3.27) and to present some 
ideas concerning the effect of thiomalate upon reactions involving gold. 
Much of the information used has not previously been available and certain 
features are therefore novel with no support from independent data. Since 
particular attention has been focussed upon the liver this description is 
necessarily directed at events in this tissue and reference to other sites 
particularly the joints can be by implication and extrapolation only and 
it is important to differentiate between generalisations and conclusions 
from specific experiments.
Fig. 3.27 Representation of features in the cellular metabolism 
of sodium aurothiomalate.
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Intramuscular injection provides an efficient means for the administration 
of aurothiomalate. The almost full recovery of radioactivity (Fig. 3.8) 
indicated that very little residue was left at the application site, an 
inference which was confirmed by examination of muscle at the point of 
injection. Most or all of the aurothiomalate is absorbed from the inject­
ion site unchanged. The carbon-14 recovery and retention experiments with 
thiomalic acid suggest that if gold were removed from thiomalate intra­
muscularly a large proportion of the labelled material would not have 
become available for circulation, tissue uptake and excretion. Because 
the aurothiomalate enters the blood unchanged the administration of the 
compound by intravenous injection can be claimed to be valid with the 
Qualification that rate of entry is much more rapid than occurs from an 
intramuscular depot.
A major redistribution of gold occurs within a few minutes of entry into 
the blood and if the results from the •in V'ltvo system also apply 'in V'ivo 
approximately two thirds of the gold is remoi^ed from the thiomalate and 
is complexed with albumin (Table 3.5). The unchanged aurothiomalate 
distributes between albumin and other complexes (presumably cysteine and 
other thiol-containing compounds). The non-protein bound fraction is 
greatest with the higher total gold concentrations (Table 3.6). These 
high concentrations are found soon after injection which is also the 
period when greatest renal excretion occurs. It is probable therefore 
that gold transported as the non-protein bound fraction in the plasma is 
filtered at the glomerulus and only some (if any) is reabsorbed by renal 
tubular cells. The importance of other possible mechanisms e.g. incorpora­
tion of gold into renal protein and subsequent excretion, dissociation of 
albumin-gold complex in the kidney, excretion of gold complexes formed 
in other organs and later brought to the kidney, cannot be judged but may 
become more relevant at much later times.
The liberated thiomalate has a very short existence in plasma (Figs.
3.16 and 3.17) and almost immediately is dispersed throughout the total 
body water, entering all tissues. Some gold (it is not apparent which 
plasma fraction(s)) also became incorporated intracellularly. Within 
the liver it appears to be irrelevant whether gold enters with the thio­
malate ligand or as some other complex since the hepatic metabolism of 
carbon-14 from either thiomalate or aurothiomalate is identical and it 
is concluded therefore that intracellularly the thiomalate is immediately 
separated from the gold.
Intracellular thiomalate therefore is derived from two possible sources, 
that released as gold forms a complex with plasma albumin and that which 
is given up actually within the cell. Most of the thiomalate remains in 
the cytosol with about 10% entering mitochondria where further metabolism 
takes place with the eventual pulmonary excretion of carbon dioxide. 
Cytosolic thiomalate is removed to the kidney and is excreted (Figs. 3.6 
and 3.9) although the mechanism whereby relocation and concentration in 
the kidney is achieved, is not clear.
In the liver cell, gold concentrates initially in the cytosol where 
complexes with non-specific binding proteins, small molecular weight 
compounds and a gold-induced protein are formed. Some gold diffuses 
across the hepato-biliary membrane but an extremely efficient concentra­
tion mechanism subsequently localises the metal within lysosomal vesicles 
which eventually discharge their contents into the bile. Biliary excretion 
therefore probably accounts for at least some of the faecal elimination of 
gold although losses into the gut from intestinal cells or with digestive 
secretions may also take place.
The role of lysosomes in concentrating gold in the liver cell allows 
speculation concerning the phagocytic activity of other cells and in 
particular, the macrophages. Given a similar exposure to gold cells with 
exceptional phagocytic ability will necessarily concentrate greater amounts 
of gold. In rheumatoid arthritis macrophages gravitate towards the inflamed 
joints and will thereby effectively scavange and transfer gold in large 
concentrations to the loci of the disease where the palliative properties 
can be applied.
In the introduction to this Chapter the question was raised as to the 
importance of thiomalate in the metabolism of gold and it was suggested 
that the formation of complexes with simple thiol containing compounds 
would be central to some of the problems associated with chrysotherapy.
The evidence that has emerged indicated that gold has a greater impact 
upon the metabolisjn of thiomalic acid than V'ice versa. The addition of 
gold masks the active thiol group which otherwise is responsible for 
retention (in the muscle and hepatocellular cytosol) and the rapid 
clearance from plasma. It has been shown that aurothiomalate is totally 
absorbed from the muscle and that thiomalate and gold are fully separated
intracellularly. It is therefore the plasma and cellular environments 
which expose gold to factors which may influence its metabolism. Associa­
tion with proteins such as albumin - both in plasma and in cytosol which 
is the major quantitative factor although thiomalate (in plasma) and other 
thiols could provoke subtle changes in the availability of gold.
It is therefore to the distribution of gold between protein and non-protein 
fractions that further attention must be given. The concentration of 
albumin provides the opportunity for variation in gold distribution between 
individuals who are apparently similar with reference to dosage, total plasma 
gold concentration etc. At the same time other drugs and molecules which 
compete with gold for the same binding site can further shift the balance 
between bound and unbound gold. To ascertain whether there is a direct 
link between therapeutic and toxic responses and the plasma or tissue 
concentration of proteins and the gold distribution pattern has now become 
an important step.
C H A P T E R  F O U R
SOME EFFECTS OF GOLD UPON THE KIDNEY.
TRACE METAL INTERRELATIONSHIPS AND MECHANISMS OF TOXICITY
4.1 INTRODUCTION
Patients receiving chrysotherapy and animals given gold concentrate the 
metal in the kidney (Sections 1.5.2, 2.4.3, 3.3.3, and Table 3.4). The 
kidney is one of the organs in which gold may produce toxic damage and 
renal toxicity is the second most common side-effect associated with 
chrysotherapy (Table 1.5). All patients who are treated with gold should 
therefore be screened at regular intervals for the presence of urinary
protein so that renal damage may be detected and treated at an early stage.
Gold nephropathjr does not represent a single entity and renal damage induced
by the metal may take different forms. Mild proteinuria is the main feature
(106) although in a very few cases the urinar^r excretion of protein is much 
increased (greater than 5 g per 24 hoiurs) and a typical nephrotic syndrome 
develops. (175) Microscopically a membranous glomerulonephritis is seeii 
with thickening of the glomerular basement membrane, shown by immuno- 
fluorescent staining to contain immune complexes. (176) Gold-containing 
inclusion bodies are found in cells of the proximal tubule but not in those 
of the glomerulus. It is suggested (107) that acute tubular necrosis (which 
may be fatal) and tubular degeneration, are consequences of local gold 
toxicity while the glomerulonephritis represents an immunologically mediated 
response to gold.
Animals exposed experimentally to gold compounds also develop renal damage 
but the toxic manifestations are usually confined to the kidney tubule. (107) 
The inclusion bodies appear as dense, filamentous structures when viewed with 
the electron-microscope and gold can be detected by microprobe analysis. 
(156,157,177) They are observed in the proximal tubule cells and also in 
the interstitial macrophages. Thus toxic nephropathy in animals and in man 
has been well characterised morphologically but very few biochemical 
features have been detailed.
It is now appreciated that the low molecular weight binding proteins, 
metallothioneins, are involved in the homeostasis of essential elements,
(178) offering control - e.g. over discharge of metal from the intestinal 
mucosal cell into blood, the uptake of metal from blood by the liver. However, 
it was. as a consequence of its role in metal toxicology that metallothionein 
was first discovered. In this context thionein provides a protective de­
toxifying mechanism whereby the metal, e.g. mercury or cadmium is effectively 
rendered innocuous with the formation of an unavailable complex. (179)
When referring to hepatic metallothionein in the previous chapter 
(Sections 3.4 and 3.5) it was noted that the protein not only binds the 
cation which was responsible for induction of its synthesis but also other 
metals including the essential ions such as zinc and copper. Since it is 
the kidney that contains the greatest concentration of these proteins it 
is pertinent to consider whether gold-thionein might be responsible for 
alterations in the balance of trace-metals in this (or other) organ(s) 
and whether such changes might feature in gold toxicity.
Accordingly, experiments were conducted to determine whether significant 
levels of thicnein were synthesised following exposure of rats to gold and 
if so, whether there were changes in the metal composition of body fluids 
and tissues. Assessment of tissue damage was made by examining the 
proteins in urine, by light and electron microscopy and by electron 
microprobe analysis of cellular structures.
4.2 METHODS
4.2.1 Experimental
(1) Fifteen M a l e W i s t a r  Albino rats initially weighing 150 g were 
distributed randomly into three groups of five animals. Sodium auro­
thiomalate v/as administered by sub-cutaneous injection twice a week for 
four weeks at the following doses: Group I, 0 (0.1 ml 0.9% w/v saline was 
given), Group II, 1.5 mg/kg in saline, Group III, 7.5 mg/kg in saline.
Two days after the final injection the rats were placed in glass metabolic 
cages and urine samples were collected for 24 hours. The animals were 
killed by cervical dislocation and the kidneys removed for determination 
of copper, zinc, iron, calcium and magnesium, isolation of cytosolic 
proteins and microscopic examination.
(2) Twelve Male Wistar Albino rats initially weighing about 150 g were 
divided into two groups each containing six animals. The test group were 
injected sub-cutaneously with 0.1 ml of sodium aurothiomalate solution 
(10 mg/ml) twice a week for five weeks. The second (control) group were 
similarly injected with 0.9% w/v saline.
t*
Eighteen days after the start of the experiment (two days after the fifth 
injection) animals were placed in individual glass metabolic cages and - 
their urine and faeces collected for 24 hours. Collection of excreta was 
repeated five days after the final (tenth) injection, immediately prior to 
killing the animals.
The rats were anaesthetised using pentobarbitone, blood removed by cardiac 
puncture and allowed to clot. The liver, kidney, spleen, heart, lung and 
testis were removed and weighed. The femur and a portion of the adjoining 
striated muscle were dissected from a rear leg.
(3) Biliary excretion of metals. Twelve Male Wistar Albino rats weighing 
about 200 g were divided into three groups. Group I (3 animals) were given 
sodium aurothiomalate 2.5 mg/kg by intraperitoneal injection two hours 
before cannulation of the bile duct and collection of bile. Group II (3 
animals) were anaesthetised and biliary cannulation established 5-10 minutes 
before sodium aurothiomalate 2.5 mg/kg was administered by intravenous 
injection. Group III (6 animals) were the controls and received no auro­
thiomalate by either route. The procedures for the administration of 
sodium aurothiomalate and collection of bile were as described in Section 
3.5.2.
4.2.2 Analytical
Metals. All metals were analysed by atomic absorption spectroscopy.
2+
Reagents. Lanthanum chloride; 0.1% w/v La
TCA-TGA solution; 100 g trichloroacetic acid and 30 ml thio- 
glycollic acid were dissolved in 166 ml hydrochloric acid and 
the total volume made up to one litre.
Nitric acid; aristar grade.
Perchloric acid Sp. Gr. 1.54; aristar grade.
Aqua Regia; 50 ml conc. nitric acid was carefully added to 
50 ml conc. hydrochloric acid and mixed.
All glassware used in these analyses were soaked overnight in 10% v/v 
hydrochloric acid and thoroughly rinsed in distilled water.
Serum; Calcium and magnesium were measured after fiftyfold dilution in 
lanthanum chloride solution, samples for copper and zinc were diluted 
1 + 4 in distilled water (180) and iron was measured after precipitation 
of the protein by addition of an equal volume of TCA-TGA solution. (181)
Gold was measured as described in Section 2.2.1.r
Urine; All metals were measured using methods of standard additions to 
calibrate the analyses. Samples were diluted as was found to be appropriate 
in order to achieve linear standard plots.
Faeces and tissues; Samples were prepared for analysis by acid digestion 
as described in Chapter Two (Section 2.3.1).
Bile; Copper, zinc, iron and gold were measured by pulse sampling flame 
atomic absorption taking 100 for each determination (Section 3.5.2).
Creatinie&was determined in serum and urine by an auto-analyser procedure 
using the alkaline picrate reagent.
Urine Proteins
Reagents. Suiphosalicylic acid, 3 g/100 ml.
Barbitone buffer, 0.06 M, pH8.6; Sodium barbitone, 35.5 g, 
diethylbarbituric acid, 4.52 g and sodium acetate trihydrate,
26 g were dissolved in distilled water and the volume made 
to 4.0 litre.
Nigrosin stain; Nigrosin (1.0 g ) , glacial acetic acid, (150 ml), 
glycerol (50 ml), 0.1 M sodium acetate, (400 ml), and methanol 
(100 ml) were dissolved in distilled water and the total volume 
made to 1.0 litre.
Acetic acid 5.0% v/v.
Total protein concentration
Suiphosalicylic acid (3 ml) was added to 1.0 ml urine and the turbidity 
measured at 650 nm after 5 minutes using a Gilford 300 spectrophotometer. 
Turbidity was measured against a blank prepared from 1.0 ml urine plus 
3.0 ml water.
Standards were prepared from dilutions of a freeze-dried serum sample 
of known protein concentration. Standards having concentrations in the 
range 0.1 to 1.5 g/il were used and turbidities determined as for the 
urine samples.
Cellulose acetate electrophoresis
Urine samples were separated without prior concentration. Conventional
r
equipment and conditions were used. The cellulose acetate strips were 
stained in nigrosin solution for 2 to 3 minutes then destained in 5% 
acetic acid. The protein positions were revealed as black bands.
Isolation and characterisation of cytosolic proteins
Reagents. Ammonium formate buffer, 0.015 M, pH8.0; A I M  stock solution 
(6.306 g ammonium formate in 100 ml water) was prepared. 
Fifteen ml of this solution was diluted to 1 litre with 
distilled water and the pH adjusted to 8.0 with ammonium 
hydroxide.
Tris buffer, 0.01 M, pH8.0; A 2 M stock solution (121.14 g 
Tris-(hydroxymethyl)-methylamine in 500 ml) was prepared.
Fifty ml of this solution was diluted to 1 litre with 
distilled water and adjusted to pH8.0 using 1 M hydrochloric 
acid.
Sephadex G75 in Tris buffer; the Sephadex suspension was 
prepared according to the manufacturer's (Pharmacia Ltd.) 
directions.
Approximately 2 g of kidney tissue was washed with ammonium formate 
buffer, blotted dry and weighed. The samples were added to 10 ml ice- 
cold ammonium formate buffer and homogenised as described for liver 
(Section 3.4.2). The homogenate was transferred to a centrifuge tube and 
an aliquot (200 y£) removed for determination of total protein. The 
cytosol was separated from cell debris and formed elements by centrifuga­
tion at 120,000 g for 60 minutes in an 8x35 ml angle rotor using an MSE 
Super Speed 65 centrifuge. The supernatant was transferred to a 50 ml 
round bottomed flask and the aqueous phase removed by lyophilization.'
Tris buffer (10 ml) was added to the freeze-dried residue and the flask 
placed in an ice-bath for ten minutes with occasional mixing to dissolve 
the contents. This solution was decanted into a plastic tube and 
centrifuged at 600 g for 10 minutes. A sample (0.5 ml) of the supernatant 
was removed for protein determination and the remainder separated by gel 
filtration against gravity.
A column (870x2.6 cm) of Sephadex G75 in Tris buffer was set up and the 
sample applied. An elution rate of 17 ml per hour was established and 
fractions (2.8 ml) were collected every 10 minutes after elution of an 
initial volume of 68 ml. A total of 120 fractions were collected. 
Absorbance of the eluate at 254 nm was continuously monitored. Gold, 
copper, zinc and iron were measured by atomic absorption spectroscopy.
The samples were aspirated without any preparative procedure and readings.
were compared against those of standards diluted in Tris buffer. 
Quantitative measurements of protein concentrations were made using 
the Folin-Ciocalteu reagent of Lowry et at. (182)
Microscopy
Reagents. Buffered formalin; Sodium dihydrogen orthophosphate
dihydrate, (4.5 g) and anhydrous disodium hydrogen ortho­
phosphate, (6.5 g) were dissolved in distilled water.
Formalin (40% formaldehyde, 40 ml) was added and the total 
volume made to 1 litre with water.
Ethanol.
Toluene.
Parafin Wax.
Glutaraldehyde solution; E.M. grade stock solution, 25% 
w / v .
Cacodylate buffer, 0.2 M, pH7.4.
Sodium cacodylate (21.4 g) was dissolved in 400 ml distilled 
water. The pH was adjusted to 7.4 with dilute nitric acid 
and the total volume made to 500 ml.
Buffered glutaraldehyde. 16 ml stock glutaraldehyde was 
added to 50 ml cacodylate buffer and the volume made up 
to 100 ml with distilled water.
Osmic acid, 4 g/100 ml.
Buffered osmic acid. Cacodylate buffer and osmic acid 
were mixed together 1 + 1 .
Propylene oxide.
Epon 812.
Tissue samples removed when the animals were killed were cut into small 
blocks and placed into appropriate fixatives.
For light microscopy fixing was in buffered formalin. Preparation of the 
tissue i.e. dehydration, wax embedding, section cutting, staining and 
counter-staining with eosin and haematoxylin, was carried out by 
conventional procedures. (183)
Material for electron microscopy (tissue blocks less than 0.5 mm cubes) 
were placed in glass tubes containing buffered glutaraldehyde at 4°C for 
two hours. The glutaraldehyde was replaced with 0.1 M cacodylate buffer
and washed for two hours. The tissues were counter-fixed for a further 
two hours by removal of the buffer and addition of buffered osmic acid. 
Samples were progressively dehydrated by immersion in solutions of 
ethanol (25%, 50%, 75%, 90%, absolute, v/v). Each solution was left for 
at least 10 minutes and two changes of each solution were made. The 
samples were similarly taken through a mixture of ethanol/propylene 
oxide (1 + 1 v/v), propylene oxide and a mixture of propylene oxide/
Epon 812 resin ( 1 + 1  v/v), and were then transferred to capsules 
containing Epon 812. The resin was polymerised at 60°C for 48 hours.
Sections were cut and mounted for electron microscopy and stained with 
uranyl acetate and lead acetate.
A Jeol JEM 200 cx transmission electron microscope was used with additional 
facilities for scanning electron microscopy and electron microprobe analysis. 
(University of Surrey Micro Structural Studies Unit).
4.3 RESULTS
4.3.1 Evidence for Gold-induced Renal Changes
The structure of the kidney as observed by light microscopy is pictured 
in Figs. 4.1 and 4.2. Fig. 4.1 shows a section prepared from kidney taken 
from a control (saline-treated) rat and no pathological changes are evident. 
Fig. 4.2 shows the histology from a gold-treated (7.5 mg sodium aurothio­
malate, sub-cutaneously, twice a week for four weeks) rat. Changes to the 
glomerulus were not found using haematoxylin and eosin stain. However, 
certain of the tubular cells had large pink coloured vacuoles which were 
localised along the medullary-cortex margin suggesting a situation 
primarily within the proximal tubules. (These vacuoles were identified 
at microscopy by an experienced pathologist (Prof. P. Grasso) but 
unfortunately do not show very clearly in the photographs).
Greater clarity of ultra structural and cellular architecture was 
appreciable from the electron microscopy (Figs. 4.3 - 4.6). Unfortunately 
sample fixation was not perfectly achieved and there was therefore some 
breakdown of structure in sections prepared from tissues of both the 
control and gobd-exposed rats. Nevertheless it was possible to differen­
tiate between them and to observe gold-induced changes in cell appearance.
Detail of cells of the proximal tubular region of the kidney from the 
control rat is shown at low (3,000) and high (10,000) magnification in
1HPr M
Fig. 4.1 Photomicrograph of normal kidney from rat given 0.9% w/v saline 
by sub-cutaneous injection twice a. week for 5 weeks.
Fig. 4.2 Photomicrograph of a kidney from rat given sodium aurothiomalate 
(7.5 mg/kg) by sub-cutaneous injection twice a week for 5 weeks. 
The arrows indicate the densely staining vacuoles induced by 
treatment with gold.
Figures 4.3 to 4.6
Fig. 4.3 Electronphotomicrograph of normal kidney, 3,000 x magnification. 
Prepared from control rat given 0.9% w/v saline twice a week 
for 5 weeks. Relevant features are the villi (a) and the size 
and number of lysosomes (b).
Fig. 4.4 Electronphotomicrograph of normal rat kidney, 10,000 x
magnification. The section shows a proximal tubular area with 
membranous invagination and signs of discharge of cellular 
contents into the lumen of the kidney tubule (a).
Fig. 4.5 Electronphotomicrograph of kidney from rat given sodium auro­
thiomalate (7.5 mg/kg by sub-cutaneous injection twice a week 
for 5 weeks, 3,000 x magnification. The section shows break­
down of the villi (a) and enlarged lysosomes which contain 
deposits of electron-dense material (b).
Fig. 4.6 Electronphotomicrograph of kidney from rat given sodium auro­
thiomalate, 10,000 x magnification. The electron-dense 
deposits with characteristic feathery outline are seen within 
a lysosome (a).
Fig. 4.3
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Figs. 4.3 and 4.4 while Figs. 4.5 and 4.6 show similar zones from a rat 
treated with sodium aurothiomalate. The particular features noted in the 
specimen from a rat given sodium aurothiomalate compared with the controls 
are the increased size of the lysosomes (Figs. 4.3 and 4.5), a breakdown 
of the villus structures at the tubule cellular-lumen margin (Figs. 4.3 
and 4.5) and the presence of electron dense inclusions within the 
enlarged lysosomes (Figs. 4.4 but particularly 4.5).
These electron dense structures present in the renal tubule cells of the 
gold-treated rats were shown to contain gold by electron microprobe 
analysis. A spectrum obtained from one such analysis is given in Fig.
4.7. The spectrum shows the emissions characteristic of the fixing and 
staining metals - osmium (Ma, La, LB, LY) , uranium (Mot, La) and lead 
(Ma, La) and also of the copper supporting grid (Ka). In addition the 
presence of gold was revealed from the La and L$ emissions at 8.91 and 
11.58 KeV. Analyses were also conducted at areas adjacent to, but 
distinct from the electron-dense bodies, and which had a similar visual 
background appearance. Gold emissions were not detected from these areas. 
It was noted (Table 4.1) that when the intensity of the copper Ka emissions 
at 8.04 KeV were compared at gold-rich or gold-free sites, greater amounts 
of copper were present in conjunction with the gold. Since a large 
proportion of the copper emission will have been derived from the support­
ing grid the increases represent a considerable enhancement of the in situ 
biological copper in association with gold.
Urine proteins v
The excretion of protein in the urine (Table 4.2a) by the rats who received 
the higher dose of gold (Group III) was significantly increased (19.4 mg/
24 hrs) compared with the controls (14.6 mg/24 hrs). On examination of 
unconcentrated urine samples by electrophoresis on cellulose acetate 
membranes, protein was detected only in urine samples from this same 
group. When compared with the separation pattern obtained for a sample 
of serum, the urine proteins were located between the a2 and 3 globulins. 
There was no albumin detected by this procedure.
The data obtained from the rats treated with sodium aurothiomalate for 
5 weeks allowed the calculation of creatinine clearance rates (Table 4.2). 
The clearance for the control animals (1.99 ml/min) was not significantly 
different from that found for the rats who had received sodium aurothio­
malate (1.58 ml/min).
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Table 4.2 Excretion of protein in urine and the creatinine clearance
of rats given sodium aurothiomalate by sub-cutaneous injection 
for four or five weeks.
(a) Protein (5 animals per group)
Group I II III
Dose (mg/kg) twice per v/eek 
for 4 weeks
0 1.5 7.5
Urine protein mean 14.6 13.6 19.4
mg/24 hrs SD 2.9 5.06 3.38
a, significant difference from control group p = <0.05
(b) Creatinine clearance (6 animals per group)
Group Control Test
Dose (mg/kg) twice per week
0 7.5
for 5 weeks
Creatinine clearance mean 1.99 1.58
ml/min . SD 0.86 0.30
4.3.2 Biochemical Features of Gold and the Kidney
The 254 nm absorbance and trace metal elution profiles for the kidney
cytosolic preparations are shown in Fig. 4.8. The protein (0D_ _ )
254 nm
resolved into high molecular weight material (albumin, haemoglobin etc.)
which eluted at or soon after the void volume - peaks Pr-1 and Pr-2 and
low molecular weight compounds which appeared close to the total column
volume - peaks Pr-4 and Pr-5. With the test sample from the gold-treated
animals there was a small additional peak - Pr-3 which was found in the
trough between the two extremes. This peak corresponded to an elution
volume of 214 ml. (In other experiments with the same column using
cytosolic preparations from cadmium-treated rats the 0Drt„. showed a
254 nm
large peak at this position. Cadmium-thionein, but not other metallo- 
thioneins, has an absorption maximum at 250 nm). The elution profiles 
for gold, copper, iron and zinc are also shown in Fig. 4.8.
Gold separated into two components Au-1 which appeared with the void 
volume and presumably corresponded to albumin bound metal and Au-2 which 
was coincidental with the Pr-3 peak at an elution volume of 214 m l . Most 
of the iron was associated with haemoglobin with smaller amounts co­
eluting with the albumin (Pr-1) and low molecular weight compounds (Pr-4). 
Identical patterns were obtained for the test and control samples. With 
zinc and copper however there were different elution profiles for the 
two samples. With the material from the controls, zinc eluted in two 
positions, Zn-1 with albumin and Zn-3 together with Pr-4. The test 
sample had these two components but also a third, Zn-2 which coincided 
with Pr-3. The copper elution profile was also characterised . by three 
components, Cu-1 with albumin, Cu-2 which eluted just after the haemo­
globin (Pr-2) and Cu-3 which like Au-2 and Zn~2 was coincidental with the 
peak, Pr-3. The copper concentrations in the eluate from the
254 nm
test sample were greater than in the control by a factor of about two in 
peaks Cu-1 and Cu-2 but about eight times in Cu-3.
The metal concentrations in the kidneys from the control and gold-treated 
rats are shown in Table 4.3. Chronic parenteral administration of sodium, 
aurothiomalate produced changes in the total concentrations of copper and 
zinc, which reflected the results obtained from the separation of cytosolic 
components. The effects upon renal copper were dose related with increases 
of 350% and 550% compared with the controls. Increased zinc concentrations 
were also found but these were less dramatic and not dose dependent. No 
significant effect upon renal iron,, calcium or magnesium were obtained.
Fig. 4.8 Gold, iron, zinc and copper (yg/ml) and absorbance (0D„„, )
254 nm
profiles of eluate from G75 Sephadex column (870x 2.6 cm) 
after application of kidney cytosolic preparations from a 
rat given sodium aurothiomalate (7.5 mg/kg).. —  ..—  or a
rat given 0.1 ml saline (0.9% w/v).......... , sub-cutaneously,
twice a week for 5 weeks.
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Table 4.3 Trace metal composition of kidneys from rats given sodium
aurothiomalate and their controls. (5 animals in each group).
Group Cu
Metal
Zn
yg/g wet 
Fe
weight
Ca Mg
control mean 7.95 28.53 92.55 61.38 241.25
SD 1.28 0.56 5.82 8.46 15.76
1.5 mg/kg mean 28.38** 35.73 89.38 56.50 298.25
SD 3.53 2.74 6.39 2.78 156.6
7.5 rag/kg mean
a c
44.55 33.68b 83.10 59.35 219.75
SD 2.95 2.52 14.50 2.46 13.84
Sodium aurothiomalate 1.5 mg/kg or 7.5 mg/kg given by sub-cutaneous 
injection twice a week for four weeks. Controls similarly given
0.9% w/v sodium chloride.
a, significant difference compared with control group p = <0.001
b, significant difference compared with cpntrol group p = <0.01
c, significant difference between the gold treated groups p = <0.001
4.3.3 Metal Interactions in Body Fluids and Tissues
Weights
The body and organ weights of the control and gold-treated rats after 
administration of sodium aurothiomalate for 5 weeks, are shown in 
Table 4.4. No significant differences were found in any parameter 
between the two groups.
Serum and excreta
The serum and urinary metal and creatinine concentrations and the excretion 
of metals into the faeces are given in Table 4.5. The mean serum copper 
concentration (15.28 ymol/£) was significantly lower in the gold-treated 
rats than In the controls (17.53 yinol/X) . After the administration of 
gold for three weeks, the urinary excretion of magnesium and the faecal 
elimination of copper, zinc and iron were significantly decreased compared 
with the control animals. There were no significant differences in any of 
the other analytes measured in these samples nor in those collected after 
five weeks although consistent trends could be observed. At five weeks 
after the start of the experiment most of the mean faecal measurements 
were lower in the gold-treated animals than in the controls but as a 
consequence of one sample with a very large weight (possibly representing 
more than 24 hours) the standard deviation concentrations were larger 
(Table 4.5c).
Tissues
The most dramatic change in metal concentrations (Table 4.6) were found 
in the kidney where copper and zinc concentrations were increased (as was 
found in the previous experiment - Table 4.3) by 560% and 124% respectively. 
Increased copper concentrations were also found in muscle tissue and in the 
samples Of bone. Other significant changes in elemental composition were 
the increased iron content of testis and muscle and an increase in the 
calcium in spleen. In all these tissues the effect of gold upon metal 
concentration was accumulative. "
4.3.4 Biliary Metals
The secretion of copper, iron and zinc into the bile in control rats and 
in animals given gold by intravenous injection are shown in Figs. 4.9 ■
4.11 respectively. , <
Table 4.4 Effect of chronic gold administration upon body and organ 
weights in rats given sodium aurothiomalate.
Parameter
Weight
Control
(mean
g
± SD)
Test
Total body weight 386 ± 34 374 ± 25
Liver 14.7 ± 1 . 9 13.4 ± 1.2
Kidney (both) ■ 2,3 ± 0.16 2.4 ± 0.15
Heart 1.01± 0.08 1.14+ 0.13
Spleen 0.90 ± 0.15 0.89 ± 0.08
Testis (one) 1.68 ± 0.15 1.78 ± 0.14
Lung 1.47± 0.18 1.54 ± 0.08
Test group given sodium aurothiomalate, 7.5 mg/kg by sub-cutaneous 
injection, tv/ice a week for 5 weeks. '
Controls given 0.9% w/v sodium chloride (0.1 ml) by sub-cutaneous 
injection, twice a week for 5 weeks.
Each group contained 6 animals.
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As is shown with the control rats there are time-related changes in the 
rate of excretion of copper and iron with a gradual decrease in the 
amount of copper appearing in bile whereas the secretion of iron 
increased during the period of collection. Concentrations at the start 
of an experiment (controls or pre-intravenous injection) were; copper
0.63 ± 0.09 yg/ml, iron 0.48 ± 0.07 lig/ml and zinc 0.068 ± 0.01 ]ig/ml 
(results are mean ± standard deviations).
4.4 DISCUSSION
In this series of experiments sodium aurothiomalate was chronically 
administered to rats at doses of 1.5 to 7.5 mg/kg for periods of 4 or 5 
weeks or given acutely by intravenous injection at a dose of 2.5 mg/kg.
The results from the chronic exposure experiments confirmed that the gold 
compound has an effect upon renal structure and function and for the first 
time have demonstrated an influence upon trace metal disposition in a 
range of body tissues and fluids.
When compared with the control animals, the urinary excretion of protein 
was significantly increased in the animals given 1.5 mg/kg of the gold . 
compound. The proteins present in the urine were not identified but on 
cellulose acetate electrophoresis the main components (qualitatively) 
were found in the a2 to B region (when compared against a diluted sample 
of serum). This proteinuria was very similar to that described following 
administration of cadmium (184,185) which is known to be caused by ‘ 
tubular dysfunction and is also similar to the tubular type proteinuria 
described in man.
Furthermore, the absence of albumin on the electrophoretograms and the 
normal creatinine clearance in the gold-treated rats suggests that there 
was no disturbance of renal glomerular function.
Evidence obtained by microscopy was also consistent with the occurrence 
of renal tubular rather than glomerular damage. The picture suggests the 
passage of a toxic agent through the glomerulus into the filtrate, with 
re-absorption into the cells of the proximal tubule. The features which 
support this mechanism are the degeneration of villi and the enlarged lyso- 
somes observed with the electron microscope (Fig. 4.5) and the appearance 
of large vacuoles within the cells when seen by light microscopy (Fig. 4.2). 
These signs are also observed with other tubular nephrotoxic compounds such
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as cadmium which are believed to be transported through the kidney in 
this way. At the same time there were no ultra-structural changes found 
in the glomerulus, either by light or electron microscopy which were 
indicative of membranous glomerulonephritis. In addition, the large 
electron dense inclusion bodies (Fig. 4.6) shown by microprobe analysis 
to contain gold (Fig. 4.7), were found only within the tubular region of 
the kidney.
Vacuolization observed in proximal tubular cells by light microscopy was 
remarked upon by Antonovych (107) although in this report the species 
exposed, the gold compound administered and the conditions of exposure 
were not stated. This author also claimed that the primary site of gold 
deposition was within- the mitochondria which eventually show signs of 
degeneration. (107) While not readily apparent in Figs. 4.5 and 4.6 the 
sections of kidney from rats treated with sodium aurothiomalate contained 
mitochondria of normal appearance and gold was not detected in them by 
electron microprobe analysis when a series were examined. Antonovych 
therefore possibly used a more extreme course of administration to induce 
such changes.
The gold-containing electron dense bodies found within lysosomes of the 
proximal tubular tissue (Figs. 4.5 and 4.6) were identical in appearance 
with those described by Ghadially (157) and others. These dense granules 
with a feathery outline have been found at many sites in several species 
and, with the exception of those formed on exposure to colloidal gold, 
assume a consistent morphology. Since gold at high concentrations is 
known to inhibit lysosomal enzymes (Chapter 1) accumulation of the metal 
within these organelles gives support to the hypothesis that chrysotherapy 
is effective by an action upon the activity of lytic enzymes. The micro­
scopy also revealed that in animals where a specific disturbance in renal 
function was demonstrated (Section 4.3.1) a coincidental localisation of 
gold also occurred.
From this series of experiments there emerged a consistent pattern with an 
association between gold and trace metal concentrations, particularly with 
copper (Fig. 4.12).
In his lecture at the 1977 Symposium on the Clinical Chemistry and Chemical 
Toxicology of Metals, Schwarz (186) illustrated a point relating to trace
Fig. 4.12 Interactions found to occur between gold (sodium aurothiomalate) 
and other metals in the rat. (All effects were significant at 
levels of 5% or less).
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metal interactions using a chart prepared in 1953. He noted that such a 
chart similarly prepared in 1977 to demonstrate the interactions then known 
to exist would be far too complex to comprehend. In the five years since 
that observation was made by Schwarz, examples of the importance of 
biological interactions between metals have continued to be described with 
increasing frequency.
Interactions between metals are important in the metabolism and distribution 
of essential elements at various sites throughout the body. Intestinal 
transport of iron is inhibited by cadmium (187) and similar, reciprocal 
effects have been described among other elements e.g. copper, zinc, mercury 
and lead. (188-192) Other sites where competition between metals is a 
feature of normal metabolism include excretion into the faeces (193) and 
uptake into cells, e.g. of the liver. (194) Metal interactions are also 
important in toxicity. Excessive exposure to copper interferes with iron 
metabolism, decreasing tissue concentrations and producing a situation of 
iron deficiency anaemia. (195) Cadmium alters not only the tissue 
concentrations of trace elements but also major elements such as calcium. 
(196) Changes in the serum concentrations of trace elements, apparently 
unrelated to the aetiology of the disease, have been noted in many patho­
logical conditions and may be measured in order to monitor the progress of 
the patient. (197)
In addition to changes in tissue metal concentrations which are consequent 
upon metal interactions at the intestine, modulation of tissue metal 
composition has been found in animals treated with e.g. mercury (198,199), 
bismuth (199) and cadmium (199-202). In these reports, changes in the 
renal metal concentration has been a regular response with an increase in 
copper the most significant finding. Recently it has been demonstrated 
that aurothioglucose administered to mice on 10 occasions during three 
weeks also produced increases in kidney copper and in renal and hepatic 
zinc concentrations. (203) These animals received very large doses of the 
gold compound (50, 200 and 400 mg/kg) compared with the doses of aurothio­
malate given in the experiments reported above. With the mice, the changes 
in tissue zinc were only found in animals which received the highest dose . 
of aurothioglucose whereas the increases in renal copper were also dose 
related and occurred in all three groups.
Types of metal interactions and possible mechanisms whereby they may be 
effected were considered by a Task Group on Metal Interaction at a meeting
concerning Factors Influencing Metabolism and Toxicity of Metals. (204)
The Group concluded that metals may react to produce synergistic, antagon­
istic or entirely new types of effects. Possible mechanisms of these 
interactions were summarised as:
(a) formation of metal complexes which reduce bio-availability,
(b) interchange of metals bound to proteins such as carrier proteins,
plasma albumin, enzymes and metallothionein,
(c) attenuate cellular reactivity to a subsequent exposure,
(d) induction of metal-binding proteins.
Some reactions however do not fit into a situation with just one
mechanism (205) and it is necessary to propose interactions occurring at 
different sites and involving more than one of the above mechanisms.
In seeking to explain how exposure to metals such as mercury, cadmium etc. 
produce an increase in renal and hepatic concentrations of copper and other 
metals authors (196,198,202,203) have presumed a mechanism involving 
metallothionein. The proteins isolated from tissues of cadmium or mercury-
treated animals have been shown also to bind zinc and copper. (179) It has
been argued therefore that the alterations in tissue metal content are 
secondary to the synthesis of and sequestration by, metallothionein. 
Evidence to substantiate this hypothesis (which invokes mechanisms (b) and 
(d) above) by examining cytosolic metal binding protein and total tissue 
concentrations at the same time, has however been singularly lacking.
The results presented here from rats treated with sodium aurothiomalate
(Figs. 4.8 - 4.11, Tables 4.3 - 4.6) indicate changes in trace metal 
disposition which are similar to those realised in animals exposed to other 
metals and also to aurothioglucose. Changes in zinc, copper, iron, 
manganese, calcium and magnesium concentrations have been described in 
liver, spleen, thymus, lung, heart and bone. (196,203,206,207) Alterations 
in metal concentrations in these studies were variable in amplitude and 
direction depending upon size, route and length of exposure, species and 
organ examined. Furthermore, increases in renal copper were also produced 
in a range of species (rat, mice, sheep) with varying routes of admini­
stration. (198-200,203,208) In some of these studies the renal concentra­
tion of other metals was also determined with increases in zinc, iron,
magnesium, calcium and manganese noted. (203,207,208) The increase in 
renal copper was always the most sensitive phenomenon. In the experiments 
reported here it has been shown that aurothiomalate produced increased 
renal copper and zinc concentrations and at the same time, in the same 
animals, there was induction of the synthesis of metal-binding protein. 
This represents one of the few experiments in which a close association 
has been shown between these two independently observed responses to the 
administration of any metal.
Low molecular weight gold binding proteins have been isolated from liver 
and kidney of experimental animals treated with aurothiomalate (209-211) 
or with chloroauric: acid (212,213) although not all attempts have been 
successful. (214) In addition it has been demonstrated that aurothio­
malate will bind in "Ovtvo to thionein synthesised in response to 
cadmium (211) and zinc. (214)
Two possibilities must therefore be borne in mind in any consideration of 
the results obtained for the cytosolic binding protein experiments. The 
protein may have been a true gold-thionein, synthesised in response to the 
challenge of the aurothiomalate. Alternatively, there may have been bind­
ing of gold to a pre-existing or simultaneously produced thionein which 
was present in response to some other stimulation. For two reasons the 
latter mechanism can probably be discounted.
1. There were quite distinct differences between the results in the' 
control and test animals. The copper and zinc elution profiles and the
„ readings showed evidence for a low molecular weight binding 
254 nm
protein only in the test samples and not in those from the control. If 
the induction of metallothionein synthesis had been consequent upon some 
extraneous stimulus e.g. handling, receiving injections etc. which have 
been demonstrated to promote zinc thionein production (215-217) or upon 
contamination of the diet by another metal, similar results would have 
been obtained in both groups.
2. The metal which had the greatest binding to the low molecular weight 
protein was copper. Effective isolation and demonstration of copper- 
thioneiii requires anaerobic conditions to avoid loss of the metal from 
the ligand. (158) The copper remained in association with this particular 
protein even though an anaerobic environment was not established. It can 
be inferred therefore that the protein was not copper-thionein to which 
the gold also became bound. The relatively low levels of zinc compared
with copper and gold which were found together with the protein and the 
minimal 0I>254 readinSs also suggest that the protein was not a zinc- 
thionein nor a cadmium-thionein.
It is improbable therefore that the low molecular weight protein induced 
in the rats given sodium aurothiomalate is anything other than gold- 
thionein. It can then be argued that induction of gold-thionein synthesis 
and the binding to it of copper and zinc (two of the mechanisms for metal 
interactions which were proposed by the Task Group (204)) operated to effect 
the accumulation of gold, copper and zinc in the kidney and liver of these 
animals.
Synthesis of cadmium-thionein has been shown to occur in several other 
organs also (e.g. spleen, thymus, heart, brain, testis). (207,218) Thus 
the increased metal concentrations observed in most of the rat tissues 
(Table 4.6) could be a consequence of gold-thionein formation at a similar 
wide range of sites. Sequestration of copper and zinc into gold-thionein 
could be further responsible for the reduced concentrations of metals 
measured in serum and urine (Table 4.5).
It was of particular interest to find that the electron dense deposits 
which contained gold also appeared to contain increased amounts of copper 
(Table 4.1). While this observation requires the examination of many more 
animals and measurements in additional numbers of deposits within each 
section to confirm a relationship between these metals, it was a consistent 
feature of all those which were analysed.,' ...
Microprobe analysis of these gold bodies has been attempted by Ghadially 
(156,157) and Tubbs et at. (177) The latter workers examined tissue 
removed on renal biopsy from a patient with gold induced glomerulonephritis 
and detected copper (when using a nylon support grid) and calcium.
Ghadially has performed more extensive analyses with synovial membrane, 
articular cartilage, liver, kidney, spleen, bone marrow and skin of rabbits 
and rats. Gold inclusion bodies were found at all these sites and he was 
able to find phosphorus in all cases, usually sulphur also and sometimes 
traces of calcium. Ghadially also reported that the composition of bodies 
did not alter over the course of several months.
Such deposits imply that the gold has undergone considerable transformation 
since gold(l) thiol and phosphine complexes are very soluble (Chapter 1).
The presence of sulphur and phosphorus may represent other lysosomal contents
but could also suggest that an insoluble sulphide or phosphate complex is 
formed with gold. Alternatively, the incorporation of cations such as 
copper may be instrumental in the production of an insoluble mixed metal 
cluster. Thionein aggregation in the presence of copper has been reported 
(219) and if copper and cadmium are administered simultaneously, incorpora­
tion of cadmium is reduced with resultant enhanced toxicity. (220)
Aggregated thionein would have a reduced capacity for metal binding which 
could explain this finding. (220) An altered protein-metal complex, 
particularly where aggregation also occurs would be expected to be 
removed to lysosomes.
It is evident that gold distributes among several components within cytosol. 
The elution profiles obtained from the rat kidney high speed supernatant 
(Fig. 4.8) and the data from liver and kidney separations (153,210,211) 
demonstrated that gold binds to high and low molecular weight compounds 
with approximately 20-30% of cytosolic metal associated with the thionein- 
like protein. Other metals e.g. copper and zinc similarly bind to more 
than one cytosolic component. Metal interactions could therefore be 
expected to involve other proteins in addition to metallothionein.
Following intravenous injection of sodium aurothiomalate the interaction 
between gold and copper in the liver cell, which influences the secretion 
of copper into bile, occurs within too short a time to be consequent upon 
sequestration into newly synthesised metallothionein (Fig. 4.9). The 
results are more consistent with a mechanism involving competition between 
the metals for a shared binding site. Copper entering the liver cell 
becomes incorporated.into several proteins including the plasma transport­
ing protein caeruloplasmin. Radiolabelling experiments show that once 
synthesised, caeruloplasmin is very rapidly removed from the hepatocyte 
into the circulation and that very little enters the bile. (221)
Cytosolic cuproproteins occur with molecular weights of about 150,000 
(caeruloplasmin), 31,000 and 11,000. Injected radioactive copper enters 
the low molecular weight fraction (probably a thionein) but is soon trans­
ferred to the molecular weight 31,000 compound (superoxidedismutase) which 
coincides with "the position of most of the stable copper in liver cytosol.
In gel chromatography experiments, copper in bile was found in two components 
(221,222) but Frommer (222) suggested that the high molecular weight peak 
(greater than 800,000) was an artefact v/hich was abolished when bile salts
were included in the eluting solution. It is suggested therefore that 
biliary copper occurs attached to one molecule (or molecular aggregate) 
of about 5,000 molecular weight. (222) This protein does not appear to 
have been characterised.
The proposition that copper could be easily displaced from a binding site 
is supported by the following data.
1. Cytoplasmic copper-metallothionein concentrations are increased in 
primary biliary cirrhosis. At least during the early stages of the disease 
the copper is very labile and can be removed using penicillamine. (223)
This is in contrast to e.g. cadmium-thionein where the metal is resistant 
to mobilization.
2. The transfer of hepatic copper from thionein to superoxide dismutase 
(221) presents an opportunity for displacement.
3. Copper added to bile in vitro distributes with the same pattern as is 
found for the endogenous metal. (222) This suggests that the copper is 
added onto the protein and is not incorporated as an integral part of the 
molecule as is found with caeruloplasmin.
Gold could be envisaged as competing for or displacing copper from the 
protein at any of these sites and influence the transport of copper into 
the bile.
Whether there exists an association between toxicity and the changes in 
trace metal disposition which follow from the administration of gold will . 
be considered in the final chapter.
C H A P T E R  F I V E
DISCUSSION AND CONCLUSIONS
It is evident from the introductory discussion that the possible mechanisms 
of action of gold are extremely complex with the involvement of several 
different sites (Fig. 1.4). The overall aim of this project was to investi­
gate some of the biochemical responses to the administration of sodium auro­
thiomalate in order that mechanisms responsible for the beneficial and toxic 
sequelae of chrysotherapy might be identified. With an awareness of the 
metabolic reaction involved, improved techniques for the management of 
patients receiving chrysotherapy could then be anticipated. To this end, 
investigations were made in patients and experimental animals, of acute and 
chronic effects of gold with particular emphasis on the concentration of the 
metal in body fluids, the tissue and subcellular disposition, the routes of 
elimination and interactions with essential trace-metals.
The first objectives studied were the serum and urine gold concentrations 
in patients with rheumatoid arthritis undergoing chrysotherapy. Preliminary 
reports demonstrated that a wide range of serum gold concentrations are 
produced following administration of a standard dose of a gold drug.
Different body size is one parameter which will influence the plasma 
responses but the spread of concentrations, e.g. 2.54-14.8 ]imol/& (Table 
2.12) suggests that other factors are also involved.
The results in the retrospective and prospective studies shewed that there 
was no association between serum or urinary gold concentrations and the 
therapeutic response. Patients whose rheumatoid condition remained 
unaltered had serum gold levels within the same range as did those who 
showed moderate or marked improvement (Table 2.3). Similarly, during the 
investigation of maintenance chrysotherapy, differences in clinical response 
were not found between patients with different concentrations of serum gold 
as a consequence of receiving gold at 2-weekly or 4-weekly intervals (Tables 
2.9-2.11).
These results, which are in agreement with those recently published by other 
authors (80,81,100,131,132,140,141) are disappointing in that contrary to the 
hypothesis of Lorber (86) it is not possible to adopt the concept of a 
therapeutic bloody concentration and to improve therapy by manipulation of the 
dose so that this level is maintained. It is appropriate therefore to look 
closely at the features involved in gold metabolism (as demonstrated by the 
experiments with animals) and assess the importance of these vis a vis 
response. The points to be considered include the rate of absorption from
the site of injection, compartmentalization of plasma gold, rates of tissue 
uptake and excretion, transfer of ’active’ gold species to sites of action 
and the sensitivity of target sites, (Fig. 5.1).
Recovery of almost 100% of administered carbon-14 from rats given sodium 
14
(1,4- C)aurothiomalate (Figs. 3.7, 3.8) and the retention of very little 
radioactivity in muscle 24 hours after injection demonstrates that there 
is complete absorption of the administered drug into the circulation. 
Assuming that assimilation occurs to the same extent from subsequent 
injections it cannot be argued that variable rates of absorption account 
for the spectrum of clinical response.
Within the plasma there are an abundance of compounds shown to be relevant 
to further metabolism of sodium aurothiomalate. Therefore it is the 
circulating gold compound which is particularly vulnerable to individual, 
patient differences. The in vitro binding experiments demonstrated that 
several gold species will exist in plasma. The most abundant of these 
was an albumin-Au complex (Fig. 3.26) which is consistent with the measure­
ments made on serum from gold-treated patients. (76,90,91) These experi­
ments also showed that not all the gold was lost from thiomalate and that 
some aurothiomalate continues to exist, both as albumin bound and non-bound 
compound. Since binding of the metal to albumin is particularly avid 
(Table 3.7) (162,163), it is not unreasonable to presume that the non­
protein bound fraction will represent, or include, the ’active’ gold pool. 
Hypoalbuminaemia and low plasma albumin-globulin ratios are well recognised 
features of rheumatoid arthritis (64,65,224) and the size of the non-bound 
gold pool will therefore be greater in patients than in normal subjects. 
Moreover, concentrations of albumin will not be identical in all patients 
(e.g. 30.6-38.9 g/& quoted in reference 64) with an effect therefore upon 
the size of the free pool. A consequence of such an inference is that gold- 
albumin ratios may correlate more significantly with clinical response than 
does just the total gold concentration.
Albumin was shown to be responsible for separation of the gold drug also into 
aurothiomalate and R-Au species, i.e. for the removal of gold from the thio­
malate (Figs. S ^ l  - 3.26). This transformation however will probably be 
further influenced by thiol compounds within the plasma. Reactions of metals 
and thiol compounds have been recognised for a number of years. The toxicity 
of lead and-mercury for example has been attributed to the binding with -SH 
groups of enzymes and an inhibitory effect upon catalytic activity. (225)
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Binding of metals to smaller molecular weight thiol compounds has also been 
recognised with the special role of thioneins in metal metabolism referred 
to in earlier chapters. A proportion of circulating zinc (and other trace- 
metals) is made up of complexes with amino-acids and small peptides. This 
pool assumes special significance in circumstances where the concentration 
of these metals is increased e.g. muscle catabolism, since urinary excret­
ion is then considerably increased. (226)
More recently, small molecular weight thiol compounds have been shown to be 
involved in cellular uptake, organ distribution and excretion of metals. 
Alterations to the cellular concentration of non-protein sulphydryl groups 
e.g. by diethylmaleate, have significant effects upon the uptake of mercury 
and subsequent development of toxicity, in rats. (227,228) The finding of 
urinary metabolites from rats given carbon-14 labelled aurothiomalate or 
thiomalic acid which may have included complexes of aurothiomalate with 
cysteine and thiomalate with glutathione (Table 3.2) is consistent with an 
hypothesis that such reactions are general to many metals. Thus, as was 
speculated upon in the preliminary discussion of the biological chemistry of 
gold (Section 1.2), there is some evidence that thiol compounds influence 
the metabolism of gold and therefore changes in the concentrations of 
cysteine, glutathione and other small sulphydryl containing molecules in 
plasma may, like albumin,* be associated with the size of an 'active* gold 
pool and hence with clinical response to chrysotherapy.
Hemovai of aurothiomalate from the circulation and uptake into tissues would 
involve mechanisms of thiol association a n d vexchange but at the same time, 
as has been noted above for mercury, interactions of . gold with the intra­
cellular thiol compounds, particularly metallothionein, will further influence 
movements of the metal. This was observed following a single dose of auro­
thiomalate to rats when gold was found in many tissues (Table 3.3) but 
particularly in the organs which have an abundance of thiol compounds - 
kidney and liver. Gold also accumulates in these organs when repeated 
administration of aurothiomalate was provided (Table 4.6) although in 
patients receiving chrysotherapy it was found that gold was present in all
body tissues. The subcellular distribution experiments and also the studies 
*
with rheumatoid arthritis patients gave evidence of considerable relocation 
of gold. Intracellularly this was seen as movement from cytosol into the 
lysosomes. A reflection of this shift was observed on a larger scale at the 
region of the arthritic joint. Increased gold accumulation occurred during 
chrysotherapy but when treatment ceased there was a differential loss from
the synovium (i.e. from the tissue which attracts a large but transient 
population of lysosome-rich macrophages).
The relevance of these results to the different response observed clinically 
is not obvious, particularly since no data are available whereby tissue gold 
concentrations could be related to the outcome of treatment.
Mechanisms of action of the gold which arrives at the active site(s) also 
require consideration. The experiments performed to examine interrelation­
ships between the metal and other trace-elements were of particular interest. 
As was noted in the first Chapter, in rheumatoid arthritis the serum 
concentrations of copper and zinc are increased and decreased respectively. 
(72) As the patient progresses towards remission as a consequence of 
successful treatment, the concentrations revert towards normal. Copper 
complexes have occasionally been used as therapeutic agents to control 
rheumatoid arthritis but gold compounds have proven to have greater efficacy 
in producing remission. These observations suggest (together with the bio­
chemical hypothesis of Gerber - Section 1.4.3) that some aspects of 
rheumatoid arthritis are related to alterations in metal metabolism and that 
by influencing metal concentrations the course of the disease may be modi­
fied. Furthermore, gold administered therapeutically distributes to all 
organs and some patients receiving chrysotherapy develop symptoms of gold 
toxicity which involve several sites in the body; skin, bone-marrow, kidney 
etc. (106) Therefore if gold is effective as an anti-arthritic agent by 
interacting with other metals and if gold toxicity also involves metal inter­
actions, the changes in metal concentrations in a wide range of body tissues 
(Fig. 4.12) following chronic administration of gold, should not be unexpected
From the biochemical changes associated with rheumatoid arthritis and from 
the benefit in some patients following therapeutic administration, copper 
metabolism is one important area where gold may exert an effect. Further 
evidence that copper and gold interactions are important is derived from the 
signs and symptoms of gold toxicity. Many of the toxic effects of gold are 
similar to those observed in humans with abnormal metabolism of copper, e.g. 
Wilson’s disease or exposed to high chronic levels of copper, e.g. workers 
in the plating industry. (229). Similarly, the toxic effects of gold in 
animals resemble closely those of copper toxicity (e.g. renal tubular damage, 
hepato-biliary dysfunction, deposition of metal in the eye). This is not 
surprising for copper and gold have similar physico-chemical properties and 
are in the same sub-group (IB) of the Periodic Table (Table 1.1).
The results presented in Chapter 4 (Figs. 4.9 - 4 . 1 2  and Tables 4.3-4.6) 
provide the first report of what is a dramatic and diverse effect of auro­
thiomalate upon the metal content of body tissues and fluids (other than 
serum). The changes found in the concentrations of the essential elements 
were similar to those which have been found in animals exposed to other 
metals e.g. mercury (198,199), bismuth (199) and cadmium. (199-202) In 
such studies it was the increase in renal copper which was the most sensi­
tive phenomenon with an increase of 560% in the aurothiomalate treated rats 
(Table 4.3). This copper was shown by gel filtration to be associated with 
a low molecular weight protein, gold and zinc in the cytosol and by electron
microprobe analysis to be coupled with copper in lysosomes.
The liver plays a fundamental role in the physiology of copper (230,231) 
and, as was shown in the work reported in the previous Chapters, is also 
important in the metabolism of gold. Copper entering hepatocytes passes to 
a low molecular weight protein (221) and. is then incorporated into other 
proteins (caeruloplasmin, superoxide dismutase). Furthermore, bile is the
principle excretory route for copper and hepatic lysosomes, into which the
copper is known to be concentrated, discharge into the bile. Non-protein 
bound copper is highly toxic so that any displacement of copper from proteins 
might be expected to have profound effects.
A mechanism of gold toxicity could therefore be envisaged whereby; (i) gold 
enters cells e.g. hepatocytes and displaces copper from lysosomal metal 
binding proteins, (ii) free copper has a direct cytotoxic effect which would 
be manifested if (a) the liver already contained a large copper load or
(b) there was a prior deficiency or poor ability to synthesise copper binding 
protein(s), (iii) displaced copper induces the formation of additional metal 
binding protein which spills into the circulation, is filtered at the 
glomerulus and is reabsorbed by renal proximal tubular cells. This protein 
also sequesters other metals producing deficiencies elsewhere (e.g. skin).
This mechanism then introduces other parameters into cellular reactions 
involving gold. The effect of this is to provide further points at which 
individual patient variation can be envisaged. The validity of the mechanism 
could be tested^by investigating the details of copper and metallothionein 
metabolism in patients and experimental animals receiving gold.
It is recognised however that neither this nor any other single mechanism 
can account for all of the variation in response to gold which is encountered
during chrysotherapy. Furthermore, factors such as the activity of the 
humoral or cellular immune mechanisms (232-234), which feature in the 
aetiology of rheumatoid arthritis, will be superimposed upon the direct 
effects of gold.
Conclusions
The main conclusions derived from these clinical and experimental studies 
with sodium aurothiomalate are:
1. Routine measurements of total gold concentrations in serum and/or 
urine of patients receiving chrysotherapy are of no value in predicting 
the response to gold. Attempts to manipulate treatment to maintain a 
’therapeutic blood level’ do not result in more patients showing improve­
ment and fewer patients with gold toxicity.
2. Previous assertions that gold and its carrier molecule rapidly 
dissociate are not correct and some aurothiomalate remains as the intact 
drug. Compartmentalization of the plasma gold is achieved by albumin and 
by thiol compounds in the blood.
3. Gold is removed from the circulation into all tissues but particularly 
the kidney and liver. Further localisation of gold into tissues which 
contain or attract macrophages, e.g. the rheumatoid synovial membrane, 
also occurs. It was shown that the kidney and liver gold is associated 
intracellularly with a cytosolic low molecular -weight protein which also 
contains copper and zinc but that much of this gold is subsequently 
relocated within lysosomes.
4. Administration of sodium aurothiomalate has a diverse effect upon trace 
metals at many sites within the bodjr. Interactions with copper and metallo­
thionein metabolism may represent a mechanism of action of gold and of
gold toxicity.
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